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Abstract 
 
Glaucoma is a leading cause of blindness.   As a progressive condit ion, it  is 
important  t o monitor how the visual f ield (VF) changes over t ime with perimet ry in 
prevent ing vision from deteriorat ing to a stage where quality of life is affected.   
However, there is lit t le evidence of how clinical measurements correlate with 
meaningful quality of life landmarks for the pat ient  or, by extension, the proport ion 
of pat ients in danger of progressing to these landmarks.   Further, measurement  
variability associated with visual fields make it  dif ficult  to monitor t rue change over 
t ime.   The purpose of this thesis was to use large-scale clinical data (almost  
500,000 VFs) to address some of these issues. 
The first  study at tempted to relate clinical measurements of glaucoma severity to 
UK legal fitness to drive status.   Legal fitness to drive (LFTD) was est imated using 
the integrated visual field as a surrogate of the Esterman test , which is the 
approved method by the UK DVLA of defining LFTD, while the mean deviat ion (M D) 
was used to represent  defect  severity.   An M D of -14dB or worse in the bet ter eye 
was found to be associated with a 92% (95% Confidence Interval [CI]: 87-95%) 
probability of being legally unfit  to drive. 
The second study used a stat ist ical model to est imate the number of pat ients 
progressing at  rates that  could lead to this landmark of significant  visual 
impairment  or blindness in their predicted remaining lifet ime.   A significant  
minority of pat ients were progressing at  rat es that  could lead to statutory 
blindness, as defined by the US Social Security Administ rat ion, in their predicted 
remaining lifet ime (5.2% [CI: 4.5-6.0%]) with a further 10% in danger of becoming 
legally unf it  to drive (10.4% [CI: 9.4-11.4%]).   M ore than 90% (CI: 85.7-94.3%) of 
pat ients predicted t o progress to statutory blindness had an M D worse than -6dB in 
at  least  one eye at  presentat ion, suggest ing an associat ion between baseline VF 
damage and risk of future impairment . 
The next  sect ion invest igated whether choice of test ing algorithm, SITA Standard or 
SITA Fast , affected the t ime taken to detect  progression in VF follow-up.   The 
precision of the tests was measured using linear modelling techniques and the 
impact  of these differences was analysed using simulat ions.   Though SITA Fast  was 
found to be slight ly less precise, no evidence was found to suggest  that  this resulted 
in progression being detected later. 
The f inal study evaluated a validated and published risk calculator, which ut ilised 
baseline risk factors to prof ile risk of fast  progression.   A simpler model using 
baseline VF data was developed to have similar stat ist ical propert ies for comparison 
(including equivalent  R2 stat ist ics).   The results suggested that  risk calculators with 
low R2 stat ist ics had lit t le ut ilit y for predict ing future progression rate in clinical 
pract ice. 
Together these results cont ribute a variety of novel findings and demonst rate the 
benefit  of using large quant it ies of data collected from the everyday clinical milieu 
to extend clinical know ledge.  
15 
 
List of Abbreviations and Terms 
 
ACG  Angle closure glaucoma 
ADREV  Assessment  of Disability Related to Vision 
AGIS  Advanced Glaucoma Intervent ion Study 
AIGS  Advanced Imaging in Glaucoma Study 
ANSWERS Analysis with Non-Stat ionary Weibull Error Regression with spat ial 
enhancement  
AUC  Area Under the curve 
Beta-PPA Beta-zone Parapapillary At rophy 
BEM D  Bet ter Eye M ean Deviat ion 
CCT  Cent ral Corneal Thickness 
CGS  Canadian Glaucoma Study 
CI  Confidence Interval 
CIGTS  Collaborat ive Init ial Glaucoma Treatment  Study 
CNTGS  Collaborat ive Normal Tension Glaucoma Study 
CPSD  Corrected Pat tern Standard Deviat ion 
DH  Disc Haemorrhage 
DVLA  Driving and Vehicle Licensing Agency 
EM GT  Early M anifest  Glaucoma Trial 
ERF  Error Related Factor 
FDP  Frequency Doubling Perimet ry 
FDT  Frequency Doubling Technology 
FL  Fixat ion losses 
FN  False negat ive 
FP  False posit ive 
GCP  Glaucoma Change Probability 
GSS  Glaucoma Staging System 
H-P-A  Hodapp-Parrish-Anderson 
16 
 
HFA  Humphrey Field Analyzer 
IOP  Int raocular Pressure 
IVF  Integrated Visual Field 
IQR  Interquart ile Range 
LFTD  Legal Fitness to Drive 
LFTDP  Legally Fit  to Drive Pat ients 
LUTDP  Legally Unfit  to Drive Pat ients 
M D  M ean Deviat ion 
NICE  Nat ional Inst itute for Health and Clinical Excellence 
NPV  Negat ive Predict ive Value 
NTG  Normal Tension Glaucoma 
NY-GAPS New York Glaucoma Progression Study 
OHT  Ocular Hypertension 
OHTS  Ocular Hypertension Treatment  Study 
OLSR  Ordinary Least  Squares Regression 
ONH  Opt ic Nerve Head 
ONS  Office of Nat ional Stat ist ics 
OPP  Ocular Perfusion Pressure 
PoF  Probability of failure (the posit ive predict ive value) 
PD  Pat tern deviat ion 
PLR  Pointwise Linear Regression 
POAG  Primary open angle glaucoma 
PSD  Pat tern Standard deviat ion 
POAG  Primary Open Angle Glaucoma 
PROM   Pat ient  Reported Outcome M easure 
QoL  Quality of Life 
ROC  Receiver Operat ing Characterist ic 
SAP  Standard Automated Perimet ry 
17 
 
SITA  Swedish Interact ive Thresholding Algorithm 
SSI  Severely Sight  Impaired 
SWAP  Short -wavelength automated perimet ry 
TD  Total deviat ion 
UKGTS  United Kingdom Glaucoma Treatment  Study 
USP-GVFSS University of Sao Paulo Glaucoma Visual Field Staging System 
VF  Visual Field 
VFI  Visual Field Index 
WEM D  Worse Eye M ean Deviat ion 
ZATA  Zippy Adapt ive Threshold Algorithm 
  
18 
 
Chapter One: Background and Aims 
 
This int roductory chapter sets out  to briefly go over the important  background 
informat ion underpinning my topic and defining the research quest ions that  I have 
set  out  to answer in this thesis.   It  begins by briefly describing what  glaucoma is, 
the risk factors associated with its incidence and progression and the way that  a 
pat ient  visual f ield (VF; this refers to the full extent  of what  an eye can see) is 
measured.   The importance of monitoring loss effect ively over t ime, the means of  
doing so and the problems associated with this VF loss will also be looked at , thus, 
set t ing the groundwork necessary to int roduce how the work in this thesis 
cont ributes to current  clinical understanding. 
1.1 Glaucoma 
 
Glaucoma is a group of opt ic neuropathies in which the opt ic nerve head and ret inal 
ganglion cells are damaged potent ially causing blindness.   The eye disease is the 
second leading cause of blindness globally (Figure 1.1) and the leading cause of 
irreversible blindness worldw ide affect ing an est imated 60.5 million people 
worldwide with 8.4 million blind from the disease (Quigley &  Broman 2006, World 
Health Organisat ion 2007, Nat ional Eye Inst itute 2010).   In the UK, glaucoma is the 
main at t ributed cause of 10% of the cases of blindness (Nat ional Inst itute for Health 
and Clinical Excellence 2009).   Treatment  and monitoring of the condit ion is behind 
over one million hospital visits each year (Nat ional Inst itute for Health and Clinical 
Excellence 2009) and, due to the fact  that  the condit ion becomes more prevalent  in 
elderly populat ions (Khawaja et  al. 2013), it  represents an even larger challenge to 
resources and healthcare in the future as global life expectancies increase (Quigley 
&  Broman 2006, Nat ional Eye Inst itute 2010). 
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Figure 1.1 – Global causes of blindness due to eye disease; glaucoma is the second 
leading cause of blindness worldwide.   The figure was reproduced from 
http:/ / www.who.int/ whr2001/ 2001/ archives/ 2000/ en/ pdf/ StatisticalAnnex.pdf 
accessed in June 2014. 
There are various types of glaucoma (Figure 1.2), generally classif ied according to 
features of the disease, although increased int raocular pressure (IOP) is a common 
characterist ic in most  types.   Glaucoma is commonly referred to as either primary 
or secondary; this refers to naturally occurring disease and disease caused by or 
through t reat ing another exist ing condit ion.   Primary glaucoma is further sub-
classified through checking the angle formed between the ir is and cornea of the eye 
using a method called gonioscopy (Nat ional Inst itute for Health and Clinical 
Excellence 2009).    Angle closure glaucoma (ACG) is associated with a narrow angle 
between the iris and the cornea.   When the angle is closed, the ir is can block the 
t rabecular meshwork, blocking the drainage canals and causing a build-up of fluid 
inside the eye, increasing the IOP (Figure 1.3).   The onset  can be quick and painful, 
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as in acute ACG, or it  can be slow and asymptomat ic as chronic ACG usually is.   
However, the most  common form of glaucoma is when the angle to be wide, as in 
primary open angle glaucoma (POAG), which is thought  to arise due to impeded 
aqueous out f low through the t rabecular meshwork, causing a rise in IOP.    Open 
angle glaucoma is an incurable progressive condit ion that  requires cont inual 
monitoring after diagnosis and is managed through various medical intervent ions 
such as eye-drops or surgery to reduce the IOP.   The progression of POAG tends to 
be gradual and symptomless in its early stages.   Though most  glaucoma is 
associated with increased IOP, glaucoma can occur when pressures inside the eye 
are at  populat ion normal levels (normal tension glaucoma; NTG).   Another primary 
glaucoma is congenital glaucoma, a life-long condit ion cont racted from birth.   
However, as this form of glaucoma is relat ively rare, congenital glaucoma will not  
be a focus of the thesis.   Common variet ies of less prevalent  secondary glaucoma 
include pseudoexfoliat ive and pigmentary glaucoma.   Pseudoexfoliat ive glaucoma 
can be seen in eyes with pseudoexfoliat ion syndrome, which is characterised by 
deposit ion of microscopic granular protein fibers (which are like dandruff) in the 
anterior segment  (the area between the cornea and iris) of the eye.   Glaucoma 
occurs in this case where this pseudoexfoliat ive material blocks the drainage canals.   
Pigmentary glaucoma can occur in individuals wit h pigment  dispersion syndrome in 
which pigment  is shed from the back of the iris, which can then block drainage 
canals for ocular aqueous humour. 
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Figure 1.2 – A flow-chart showing the prevalence of different classifications of glaucoma.   
Pseudoexfoliative and pigmentary glaucoma are classed as secondary glaucomas.   
Diagram recreated based on figure 7.1 from Henson 2000 
Regardless of the mechanisms behind the condit ion, and much remains unknown 
about  the cause of glaucomatous symptoms, the product  of the condit ion is 
invariably the death of ganglion cell axons in t he ret ina at  the back of the eye.   
With the death of these cells, the signal from photosensit ive rod and cone cells on 
the back of the eye cannot  be t ransmit ted along t he opt ic nerve to the brain.   This 
results in patches in the field of view where vision is impaired otherwise known as 
scotomas.   The rate at  which vision is lost  as a result  is known as the rate of 
progression of the disease.   Due to the fact that  the brain tends to fill in 
informat ion based upon the surrounding st imuli, pat ients often do not  not ice their  
scotomata unt il later stages of disease (Crabb et  al. 2013).   Added to the fact  that  
glaucoma is usually characterised by gradual progression (Heijl et  al. 2012a), does 
not  tend to affect  cent ral vision later stages of the disease and the fields from both 
eyes cover the same cent ral area (binocular summat ion) pat ients often do not  
not ice they are losing their vision unt il late in the disease (Shaw 2005).   As a result , 
pat ients can be diagnosed with visual impairment  that  can seriously undermine 
their quality of life (Ang &  Eke 2007, Kotecha et  al. 2012a), hence the condit ion’s 
nickname as “ the silent  thief of sight ” .   The severity of this condit ion, as well as the 
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fact  that  there is not  yet any cure for the blindness caused by it , makes finding ways 
of detect ing and prevent ing the disease progression imperat ive. 
 
 
Figure 1.3 - The fluid pathway in the eye.   Glaucoma is often related to the partial or 
complete blockage of the outflow of aqueous fluid through the trabecular meshwork 
(labelled “meshwork”).   The “angle” refers to the angle between the iris and cornea.   In 
open-angle glaucoma this is wide, whereas in angle-closure glaucoma this is narrow such 
that the iris presses against the cornea.  Image taken from the National Eye Institute: 
http:/ / www.nei.nih.gov/ health/ glaucoma/ glaucoma_facts.asp accessed in June 2014. 
 
1.1.1 Risk factors in glaucoma 
 
There are various risk factors in glaucoma, yet  the only modif iable one of these is 
an eye’s IOP.   Although not  all individuals with high IOP have glaucoma (individuals 
with IOP over 21 mm Hg but  no other signs of glaucoma are diagnosed as having 
ocular hypertension [OHT]) and not  all glaucoma pat ients have high IOP (as is the 
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case in pat ients with NTG), it  has been shown repeatedly to not  only be a major risk 
factor for glaucomatous disease incidence and progression (Sommer et  al. 1991, 
Gordon et  al. 2002, Chauhan et  al. 2008a, Kim et  al. 2011, Jiang et  al. 2012), but  
also a factor in the rate of progression of the disease (Heijl et  al. 2012a, M edeiros et  
al. 2012, Chauhan et  al. 2014).   Large fluctuat ions in IOP have also been 
demonst rated to be a risk factor for glaucoma (Asrani et  al. 2000, De M oraes et  al. 
2011a).   How pressure relates to the death of ganglion cells is not  fully understood, 
but  its effects, along with the fact  it  can be changed, makes it  an essent ial risk 
factor to consider.    
There are various other factors associated w ith glaucoma that  can be used to help 
ident ify at  risk groups of the disease.   Old age is very consistent ly linked with 
developing glaucoma, with over 50s a part icularly at  risk group (M ukesh et  al. 2002, 
Gordon et  al. 2002, Leske et  al. 2007, Chauhan et  al. 2008a, Nat ional Eye Inst itute 
2010).   Similarly,  other non-modifiable risk factors such as family history of 
glaucoma (Leske et  al. 2008) and ethnicity (Nat ional Eye Inst itute 2010) are also 
often found to be risk factors in disease incidence, with individuals of African 
descent  part icularly vulnerable.   For instance, while populat ion studies est imate 
incidences of def inite OAG at  around 0.1% per year in largely Caucasian Europe (de 
Voogd et  al. 2005) and Aust ralia (M ukesh et  al. 2002) populat ions, these est imates 
were as high as 0.6% in the predominant ly Afro-Caribbean Barbados Eye Study 
(Leske et  al. 2001).   Features of the eye such as exfoliat ion syndrome (Heijl et  al. 
2009) are also linked to development  of glaucoma.   Finally, there are various 
st ructural features of the eye that  have often been linked to glaucoma, such as thin 
cent ral corneal thickness (CCT) (Gordon et  al. 2002, M edeiros et  al. 2003, European 
Glaucoma Prevent ion Study Group 2007, De M oraes et  al. 2011a, M edieros et  al. 
2012) and large axial length (which causes myopia or short -sightedness) (Jiang et  al. 
2012, M arcus et  al. 2011) though the lat ter factor has not  consistent ly been shown 
to be a reliable risk factor (Sohn et  al. 2010).   Interest ingly, despite studies showing 
that  individuals with OHT tend to have high CCT compared to those with glaucoma 
(Sobot tka Ventura et  al. 2001), at tempts to correct  IOP for CCT in predict ion models 
have not  yet been found to have great  ut ilit y (Brandt  et  al. 2012).   One possible 
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explanat ion is down to the fact  that  thicker corneas tend to give higher IOP 
readings using tonometry than individuals with thinner corneas. 
There are various other suspected factors that  are not  universally acknowledged as 
risk factors for disease.   For instance, increased systolic blood pressure has been 
linked to disease incidence (Jiang et  al. 2012) whilst  other morbidit ies such as 
diabetes (M itchell et  al. 1997, Gordon et  al. 2002), vasospast ic disease (Broadway & 
Drance 1998) and even sleep apnoea (M ojon et  al. 2000) have all previously been 
linked, although their relat ionships with the disease is by no means proven 
(Chauhan et  al. 2008a, European Glaucoma Prevent ion Study Group 2007).   Ocular 
perfusion pressure (OPP) is another clinical characterist ic that  has previously been 
linked to developing glaucoma (Leske et  al. 2008, Zheng et  al. 2010), largely in an 
at tempt  to explain why not  every glaucoma pat ient  has high IOP.   However, ocular 
blood flow is diff icult  to measure and has largely been est imated using a funct ion of 
the blood pressure and IOP.   Unfortunately, this measurement  does not  give any 
more informat ion than blood pressure where IOP is also being accounted for 
(Khawaja et  al. 2013).   As a result , the status of OPP as an independent  risk factor is 
st ill quest ionable. 
1.1.2 Diagnosis of glaucoma 
 
Glaucoma is diagnosed through using a bat tery of dif ferent  tests: Nat ional Inst itute 
for Health and Clinical Excellence (NICE) Guidelines st ipulate that  all people 
suspected of having POAG or who even have OHT should have Goldmann 
applanat ion tonometry performed, CCT measured using pachymetry, gonioscopy 
performed, VF measurements using standard automated perimet ry (SAP) and opt ic 
nerve head (ONH) assessment  using stereoscopic slit  lamp biomicroscopy (Nat ional 
Inst itute for Health and Clinical Excellence 2009). 
Tonometry is the method used in measuring the main risk-factor of glaucoma, the 
IOP, so is understandably important  in determining pressure targets for t reatment .   
Though not  necessarily direct ly related to glaucoma itself, in conjunct ion with high 
IOP, thin CCT can be linked to greater likelihood and speed of progression in 
glaucoma and is therefore required to be taken into account  when determining 
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t reatment  severity (Nat ional Inst itute for Health and Clinical Excellence 2009).   The 
ONH assessment  allows clinicians to look at  the health of the opt ic nerve, but  SAP is 
the only means of direct ly invest igat ing the actual visual health in terms of its 
impact  on the pat ient .   Due to its importance in assessing disease status and its 
relevance to the pat ient , it  is measurements from SAP that  will be predominant ly 
looked at  over the course of this thesis. 
 
1.1.3 Treatment for glaucoma 
Whilst , these risk factors are all related to glaucoma and could be useful for 
considerat ion in screening purposes, cont rolling t he IOP remains the only means of 
t reat ing the disease.   Various clinical t rials, including the Ocular Hypertension 
Treatment  study (OHTS) (Gordon et  al. 2002), the Early M anifest  Glaucoma Trial 
(EM GT) (Heijl et  al. 2002, Leske et al. 2003) and the Canadian Glaucoma Study (CGS) 
(Chauhan et  al. 2010) have all demonst rated the ut ilit y of lowering the IOP to 
reduce the incidence and progression of glaucoma. 
M anagement  of IOP is performed either through medicat ion (normally eye drops), 
laser t reatment  or surgery.   Eye drops are certainly preferable, but  can have 
various side-effects ranging from eye irritat ion to nausea.   Non-adherence to 
t reatment  is a large issue in glaucoma (Gurw itz et  al. 1993, Shaw 2005) for various 
reasons, including the fact  that pat ients do not  realise their vision is get t ing worse 
and therefore the importance of adherence.   In addit ion, t reatments can also be 
diff icult  to administer, part icularly for elderly pat ients, who are unfortunately also 
the main demographic affected by glaucoma. 
It  is important  to ensure that  pat ient  vision does not  deteriorate to blindness or 
even visual disability within their remaining lifet ime, so it  is important  not  to under-
t reat  pat ients.   However, there is a significant  risk of overt reatment  in glaucoma 
too, which wastes limited clinical resources; a part icularly pert inent  issue given that  
the growing numbers of pat ients will increasingly st retch nat ional health resources 
(Tuulonen 2013) and that  the condit ion may not  necessarily lead to visual 
impairment  (Heijl et  al. 2009).   In addit ion, although pat ients would rather have 
26 
 
surgery than lose vision (Bhargava et  al. 2006), it  must  be taken into considerat ion 
that  t reatment  tends to become more unpleasant  as severity increases.   For 
instance, t rabeculectomy can potent ially result  in increased risk of cataract , 
infect ion, blurred vision, bleeding, sudden, permanent  loss of cent ral vision and 
even secondary glaucoma if  fluid drainage is prevented by scarring.    
1.2 Monitoring glaucomatous vision loss 
 
It  is clearly highly important  to monitor pat ient  visual deteriorat ion over t ime in 
order to evaluate whether or not  t reatment  is required or needs to be escalated 
(Heijl 2013).   The next  sect ion will brief ly look at  ways of doing so in clinical 
pract ice. 
1.2.1 Structural measurements 
 
One method of monitoring loss is to measure the changing st ructural characterist ics 
of the eye as they change with disease.   For example, examinat ion of the opt ic disc 
and measurement  of ret inal nerve fibre layer thickness can be used.   New, high-
resolut ion imaging inst ruments such as Spect ral-Domain Opt ical Coherence 
Tomography are start ing to emerge from research laboratories in the hope of more 
accurately ident ifying disease progression (Figure 1.4).   The ult imate advantage of 
st ructural methods is that  they are object ive, as they are not  reliant  on pat ient  
response.   However, current  imaging devices, though useful, are not  a replacement  
for funct ional measurements in measuring glaucomatous progression (St routhidis &  
Garway-Heath 2008, Gabriele et  al. 2011).   The largest  issue is that  it  is difficult  to 
reconcile st ructural measures to clinical outcomes that are meaningful to the 
pat ient , as they do not  port ray what  the pat ient  can actually see and therefore the 
impact  of the disease.   M oreover, there can be large discrepancies between 
st ructural and funct ional measurements of progression in glaucoma to the point  of 
being largely independent  of one another (Artes &  Chauhan 2005).   In addit ion, 
despite appearing precise, st ructural measurements are st ill subject  to variability 
(Owen et  al. 2006).   St ructural measurements are not  present ly acceptable for the 
evaluat ion of medical products for the t reatment  of glaucoma (Weinreb & Kaufman 
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2011).   They are, nonetheless, useful tools in glaucoma diagnosis and monitoring 
when used alongside more funct ional means of measuring glaucomatous loss.   
However, this thesis will not  focus on the use of t hese measurements. 
 
Figure 1.4 – Output from an OCT showing the Retinal Nerve Fibre Layer of my own right 
eye. 
1.2.2 Perimetry 
 
M easuring the funct ional progression of the glaucoma (that  is, what  the pat ient  can 
actually see) is important  in diagnosing glaucoma and monitoring its progression.   
Perimet ry is the means by which the VF; of a pat ient  is mapped (Henson 2000), and 
the only means of measuring funct ional progression.   Other than reduct ion in IOP 
(which is the basis by which most  new therapies are evaluated), VF measurements 
are the only accepted endpoints in the evaluat ion of new t reatments for glaucoma; 
the Advanced Glaucoma Intervent ion Study (AGIS), Collaborat ive Init ial Glaucoma 
Treatment  Study (CIGTS) and EM GT being examples of major t rials in which VF 
progression was the chief endpoint . 
M easuring an individual’s VF is simple in principle; the subject  must  f irst  fix their 
eyes on a part icular point  and light  st imuli of varying intensit ies are then displayed 
around the individual’s field of vision.   The subject  must  then communicate to the 
examiner whether they can see the light  or not .   Tradit ionally, manual methods of 
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doing this were performed including the Goldmann perimeter, but  these 
approaches have largely been superseded by automated perimet ry due to the fact  
that  Goldmann perimet ry is highly dependent  on the examiner in terms of accuracy 
and bias.   Given Goldman perimet ry involves a moving st imulus, pat ients 
undertaking this test  tend to lose fixat ion to a greater extent  than those using 
automated perimet ry where the pseudo-randomised locat ion of the st imulus is less 
predictable (Heijl &  Krakau 1977).   Thus, stat ic automated perimet ry  is a clinical 
gold standard in clinical pract ice as the more reliable and more reproducible opt ion 
(Fankhauser et  al. 1977), although Goldmann perimet ry can somet imes st ill be used 
in cases where pat ients st ruggle to interface w ith automated perimet ry. 
 
1.3 Standard Automated Perimetry 
 
There are various automated perimet ric methods, but  of these standard automated 
perimet ry (SAP) is most  commonly used in clinical pract ice and regarded as the 
clinical standard.   SAP uses white lights as st imuli presented on a white 
background.   Tests typically use stat ic st imuli, which are flashed sequent ially in a 
pre-defined grid of locat ions.   The dist ribut ion of test  locat ions can vary, but the 
two common VF test ing pat terns are at  6-degree even intervals in a 30-2 pat tern 
(with 38 points in each hemisphere spanning the cent ral 30 degrees) or a 24-2 
pat tern (27 points in each hemisphere spanning the cent ral 24 degrees).   The 
durat ion and size of st imulus is also fixed in stat ic perimet ry (commonly at  0.2 
seconds and 0.43˚ of visual angle in diameter [Goldmann Size III] respect ively).   
However, though SAP has been available from the 1970s, there have nonetheless 
been a number of other automated perimet ry methods that  have been developed, 
including Short  Wavelength Automated Perimet ry (SWAP), Pulsar (or Flicker 
Perimet ry) and Frequency Doubling Perimet ry (FDP or FDT) (Giangiacomo et  al. 
2006, Turalba & Grosskreutz 2010).   However, research is st ill ongoing on the ut ilit y 
of these newer techniques so, for the moment , SAP remains the primary method 
for detect ing VF progression and is hence the subject  of this research.   As with 
st ructural methods, alternat ive funct ional methods may possibly be helpful 
alongside rather than instead of SAP (Chauhan et  al. 2008b). 
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There are three main machines used for SAP in the UK at  present : the Humphrey 
Visual Field Analyzer (HFA; Carl Zeiss M editec, Dublin, CA), the Octopus (Haag-
St reit , Köniz, Switzerland) and the Henson (Elekt ron technology, Cambridge, UK).   
These three devices produce slight ly different  outputs, but  generally perform the 
same funct ion, to similar standards.   The HFA is most  commonly used in many large 
clinical cent res in t he UK, especially in a tert iary or referral set t ing where the goal is 
to monitor VFs in pat ients with glaucoma or who are at  risk of developing 
glaucoma. 
 
1.3.1 Measuring the Visual Field using Standard Automated Perimetry 
 
SAP derives an est imate of the ret inal sensit ivit y at  various equally-spaced point  
locat ions in a pat ient ’s VF.   There are two common types of test ing: threshold and 
supra-threshold test ing.   In case-finding, supra-threshold test ing is often used 
because it  is quick; this mode of test ing uses one or more light  intensit ies and 
simply tests whether these st imuli can be seen in each test  locat ion.   However, in 
glaucoma monitoring, where measuring changes in severity at each locat ion is 
important , threshold test ing is more commonly used.   The aim of threshold test ing 
is to t ry and f ind, for each tested locat ion, the lowest  level of light  that  it  is possible 
for a pat ient  to ident ify.   In order to determine the thresholds of each test  locat ion, 
it  is important  to test  at  each locat ion repeatedly. 
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Figure 1.5 – A colleague performing Standard Automated Perimetry on an Octopus Visual 
Field device 
In SAP, the subject  fixates on a cent ral st imulus and indicates whether or not  they 
are able to see other lights flashed in randomised locat ions around their gaze at 
varying intensit ies by pressing a but ton (Figure 1.5).   The result  is a series of 
measurements at each tested locat ion called sensit ivit ies (or thresholds), measured 
in decibels, an inverse measure of the st rength of the st imulus (measured in 
candelas per met res2).   The VF threshold measurement  ranges from 50 to 0dB w ith 
0 dB represent ing perimet ric blindness in that  part icular point  of the eye (around 
30dB is usually considered healthy).   Generally, the results will be output  in the 
form of a grid of numbers and a greyscale represent ing what  parts of the VF are 
missing in black (Figure 1.6). 
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Figure 1.6 – Output from a Visual Field (VF) examination from a patient’s right eye.   The 
left grid shows the measured threshold sensitivities at 52 locations (excluding the blind 
spot), whereas the right grid is a greyscale with darker areas representing less sensitive 
parts of the VF. 
In theory, pat ients will always see st imuli brighter than a test  locat ion’s threshold, 
but  fail to see a st imulus dimmer than a locat ion’s threshold.   However, in reality, 
when a light  brightness is presented at  a level close to an individual’s t rue 
threshold, there is a chance the pat ient  may not  respond as expected.   In other 
words, there is a probability of a pat ient  failing t o register the st imulus even if  it  is 
visible to detect .   The probability of a pat ient  seeing or not  seeing a given st imulus 
is therefore somet imes referred to as the frequency of seeing.   The aim of test ing is 
to t ry and find a light  threshold at  which a st imulus is seen 50% of the t ime. 
1.3.2 Perimetric Testing algorithms 
 
There are different  methods for establishing VF sensit ivit ies at  each locat ion.   The 
earliest  to be widely used in perimet ry was full-t hreshold test ing.   In this method, 
an init ial st imulus is presented at  a test  locat ion.   If a pat ient  sees this presentat ion, 
the st imulus brightness is decreased by 4dB, whereas if it  cannot  be seen then the 
brightness is increased by the same amount .   This cont inues unt il the status of 
whether the point  can or cannot  be seen changes (the first  reversal).    The st imulus 
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intensity is then decreased or increased back in steps of 2dB unt il the pat ient  
response changes once more (the second reversal).   An average of the f inal and 
penult imate test  sensit ivit ies is recorded as the threshold for that  test  locat ion.   
The order of the VF locat ions tested is randomised automat ically in order to aid 
fixat ion (Heijl &  Krakau 1975).   Ult imately, this method is thorough, but  it  can also 
take a relat ively long t ime to complete (about  10 to 15 minutes for each eye for a 
24-2 test  pat tern) (Bengtsson & Heijl 1998a, Bengtsson & Heijl 1998b, Nordmann et  
al. 1998, Wild et  al. 1999) during which it  can be difficult  for the pat ient  to maintain 
their at tent ion.   As a result , it  is not  suitable for all pat ients. 
Though, in theory, the increased amount  of test ing is supposed to improve test  
precision, some researchers speculate that  the result ing fat igue from the length of 
a full threshold test ing could exaggerate defects or even result  in the finding of 
defects that  do not  exist  (Bengtsson & Heijl 1998b, Turpin &  M cKendrick 2011).   
Thus, faster methods have been devised in order to reduce test  t ime.   The most 
successful and most  widely adopted of these techniques is known as the Swedish 
Interact ive Thresholding Algorithm (or SITA as it  is commonly known) for the HFA.   
This Bayesian technique relies on a similar principle to the full threshold methods, 
but  seeks to cut  out  the unnecessary test ing t ime by reducing the number of 
presentat ions (Bengtsson et  al. 1997a). 
SITA Standard begins with prior informat ion about  the sensit ivity of each locat ion 
before the test  starts, using age-corrected normal values, ant icipated frequency-of-
seeing curves and correlat ions between sensit ivit ies at  each test  locat ion 
(Bengtsson et  al. 1997a).   However, the test  begins present ing st imuli in the same 
way as full threshold test ing, measuring the first  four “ primary”  points (or seed 
points) in a stepwise manner; one in each quadrant  of the VF 9 degrees away from 
fixat ion in both axes.   As with full threshold test ing, after present ing an init ial 
st imulus the test  simply seeks the threshold sensit ivity of each test  locat ion in the 
eye through increasing or decreasing the light  sensit ivity presented in steps of 4dB 
unt il the pat ient  response changes.   Once the first  four points are est imated, the 
sensit ivit ies of the other test  locat ions can be est imated and these est imat ions are 
amended as the test ing proceeds.   In other words, the threshold of one point  acts 
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to “ predict ”  the probability of seeing a threshold for the others, so each test  is 
act ively changing the predicted threshold of the other points.   A second reversal 
only occurs if the difference between adjacent  point  thresholds is larger than a pre-
calculated value based on the pat ient ’s demographic known as the error related 
factor (ERF) (Bengtsson et  al. 1997a).   The exact details of how the ERF is calculated 
have not  been disclosed, but  it  is calculated automat ically by most  perimet ry 
machines.   During the test , response t imes are cont inually recorded and used to 
adjust  the durat ion of test  presentat ions.   At the end of the test , thresholds may be 
adjusted slight ly in post-processing according to thresholds of adjacent  test  
locat ions and changes in react ion t imes during the test . 
The large advantage of the SITA Standard is that  it  can halve the durat ion of test ing 
for many pat ients (Bengtsson & Heijl 1998a, Nordmann et  al. 1998, Wild et  al. 
1999).   However, there is a consistent  discrepancy between the SITA Standard and 
full threshold methods in that  the former algorit hm is consistent ly more opt imist ic 
in terms of threshold measurement  by around 1dB (Figure 1.7) (Artes et  al. 2002, 
Bengtsson & Heijl 1999).   As a result  of the t ime saved using it  and the fact  that  it  
has similar repeatability to full threshold test ing (Artes et  al. 2002, Bengtsson &  
Heijl 1999), SITA Standard is now the most  commonly used threshold detect ion 
method. 
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Figure 1.7 – The mean sensitivities for Full threshold, SITA Standard and SITA Fast tests 
taken on the same patients in a study by Artes et al. 2002.   SITA Fast and Standard tests 
tended to yield higher, more optimistic thresholds than full threshold testing.   Image 
taken from Artes et al. 2002. 
Other even faster methods have been devised by researchers in order t o enhance 
the speed of test ing further.   SITA Fast , in part icular, is commonly reported to 
reduce test ing t imes to below 5 minutes (Bengtsson & Heijl 1998b, Nordmann et  al. 
1998, Wild et  al. 1999, Pierre-Filho et  al. 2006), which could potent ially have clinical 
ut ilit y in terms of saving t ime in clinical pract ice.   SITA Fast  was designed to be 
equivalent  in terms of accuracy to Fast -threshold st rategies, such as Fastpac (Glass 
et  al. 1995), which uses 3dB steps and one reversal instead of two reversals in full 
threshold test ing, but  it  is signif icant ly faster (Bengtsson & Heijl 1998b).   However, 
the test  algorithm itself is similar to SITA Standard, the main difference being fewer 
reversals.   Only one reversal is used (as opposed to two) unless the difference 
between the est imated and expected thresholds is greater than more than 12dB.   
In addit ion, the algorithm can terminate test ing of any test  locat ion even earlier 
provided there is at  least  one posit ive response at  a test  locat ion and the 
measurement  error is below the ERF (Bengtsson & Heijl 1998b).   Unsurprisingly 
given the nature of its design, there is a suspicion that  SITA Fast may have less 
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sensit ivity in ident ifying VF defects than full threshold test ing and SITA Standard 
and there is some evidence that  the results from this test  are less repeatable (Artes 
et  al. 2002) (Figure 1.8).   It  is uncertain whether the potent ial for increased test ing 
and the impact  on fat igue compensate for the natural reduct ion in precision as a 
result  of less test ing. 
 
Figure 1.8 – The test-retest variability about full-threshold measured thresholds using Full 
threshold, SITA Standard and SITA Fast VF testing.   The variability is greater for SITA Fast 
than Full threshold, but SITA Standard performs relatively well by comparison.   This 
image is taken from Artes et al. 2002. 
1.3.3 Reliability Indices 
 
In an ideal world, perimet ry should produce accurate results on every occasion, but  
results that  are not  ref lect ive of a pat ient ’s actual VF can be produced, due to loss 
of at tent iveness, inexperience, overenthusiasm or not  fixat ing on the cent ral point  
well enough.   It  is therefore important  to evaluate the reliability of the VFs 
measured before using them to inform clinical decision making. 
Every test ing algorithm described above have methods of evaluat ing the reliability 
of the test  itself through looking for false negat ives (FN), false posit ives (FP) and 
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fixat ion losses (FL).   False posit ives are a measure of how ‘t rigger-happy’ the 
pat ient  is, measuring how likely they are to indicate observat ion of a st imulus 
without  seeing it .   In full threshold test ing they are tested through simply having 
occasions where the device pretends to change the st imulus locat ion, but  shows no 
light .   To cut  test ing t imes, the SITA algorithms do not  use catch t rials, but  judge 
false posit ives by the react ion speed of the pat ients, such as when a subject  
responds before they have had t ime to see and react  to the st imulus.   False 
negat ives are a measure of inat tent iveness of the pat ient  – the devices show a light  
in an area where test ing has already confirmed t he threshold and give a brightness 
that  the pat ient  should be able to detect .   Fixat ion losses meanwhile test  how 
accurately the subject  is fixat ing at  the fixat ion target  by present ing st imuli at  the 
locat ion of their physiological blindspot; this is the area corresponding to their opt ic 
disc, which has no photoreceptors. 
The major clinical t r ials, such as AGIS, CIGTS and EM GT have used all these 
measures to assess field reliability (The Advanced Glaucoma Intervent ion Study 
Invest igators 1994, Gillespie et  al. 2003, Heijl et  al. 2008), yet  the criteria applied to 
them remain arbit rary and vary between t rials.   For instance, for the AGIS and 
CIGTS t rials, a scoring system was used which meant  that  pat ients could 
theoret ically pass with false posit ive or negat ive rates in excess of 33% (The 
Advanced Glaucoma Intervent ion Study Invest igators 1994, Gillespie et  al. 2003), 
whilst  EM GT t rials did not  look at  the FN rate at  all (Heijl, Bengtsson et  al. 2008).   In 
addit ion, other reliability criteria such as the total number of quest ions asked (The 
Advanced Glaucoma Intervent ion Study Invest igators 1994) (longer tests imply 
greater uncertainty in measuring the threshold) and short  term f luctuat ion values 
have been used (The Advanced Glaucoma Intervent ion Study Invest igators 1994, 
Gillespie et  al. 2003). 
There is evidence to suggest  that  none of the reliability indices provide an accurate 
insight  into a pat ient ’s performance.   For instance, Bengtsson found that  none of 
the main three met rics for reliability cont ributed significant ly more informat ion to 
test  reproducibilit y than the level of VF loss itself (see Sect ion 1.3.4).   The only 
met ric that  linked to test  reproducibilit y at  all were FNs (Bengtsson 2000).   
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However, there were indicat ions in the same study that  this relat ionship was most  
likely to be due to a signif icant  associat ion between FNs and VF loss (Bengtsson 
2000).   Similarly, Shao et  al. found FNs to be the best  index for predict ing test  
reproducibilit y account ing for severity of VF loss, but  also found that  none of the 
reliability indices are good predictors of overall test -retest  variability (Shao et  al. 
2011).   M ontolio et  al. meanwhile, found false posit ives to be the most  crucial 
index, w ith each 10% increase in FPs being est imated to increase threshold 
est imates by 1dB (Junoy M ontolio et  al. 2012).   Fixat ion losses have been shown to 
cont ribute to test  variability without  being a major cont ributor (Henson et  al. 1996, 
Junoy M ontolio et  al. 2012). 
Overall, there is likely no single “ best ”  reliability index in assessing progression; if a 
VF is unreliable in any way then this has the potent ial of hindering the ability to 
detect  progression, whether it  gives the impression that  the pat ient ’s VF is bet ter or  
worse than in reality, thereby leading to impaired clinical judgement .   For this 
reason, clinicians should be aware reliability indices when taking VFs.   Addit ionally, 
the inst ruct ions given to the pat ient , the correct ion of spherical ammetropia and 
pat ient  at tent ion may also have a significant  bearing on the result  and these indices 
should not  be relied upon exclusively (Chauhan et  al. 2008b). 
 
1.3.4. Problems in monitoring Visual Field deter ioration in perimetry 
 
The output  produced from SAP can be confusing as it  contains a huge amount  of 
data and informat ion, and it  is not  always part icularly obvious how large changes 
are from one VF assessment  to the next .   In spite of all the efforts in perimet ry to 
accurately detect  the threshold of a pat ient  accurately, there is st ill a lot  of “ noise”  
in the measurements of thresholds, which is what  makes measuring the rate of 
progression non-t rivial, part icularly in areas of the VF where vision is worse and this 
variability is greater (Henson et al. 2000, Artes et al. 2002, Russell et  al. 2012a).   As 
a result , there exists test re-test variability between VF tests that  needs to be taken 
into account  when analysing results. 
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M easuring a threshold where a pat ient  can only see 50% of presentat ions can often 
be hard to f ind explicit ly.   Using a technique called method of constant  st imuli to 
measure st imuli accurately (Laming &  Laming 1992), Gardiner and colleagues found 
that  some locat ions with measured thresholds using SAP did not  have a st imulus 
intensity associated with them that  could be seen 50% of the t ime, which led them 
to conclude the probability of seeing a st imulus did not  increase appreciably 
regardless of how bright  the st imulus was at measured ‘thresholds’ of below 19dB 
(Gardiner et  al. 2014).   In other words, they concluded that  the likelihood of 
response at  19dB or brighter is governed by chance rather than giving any 
informat ion on the ret inal sensit ivity at  that  locat ion.   If this is t rue, then perhaps 
there is an argument  for incorporat ing a new lower limit  for sensit ivit ies in VF 
test ing (e.g. set t ing 20dB as the lowest  possible measurement ), which would 
perhaps reduce variability in the calculat ion of progression indices.   In the studies 
included in this thesis, however, it  is assumed that  there is st ill some informat ion to 
be gained from lower threshold values in VF test ing. 
Furthermore, the psychophysical nature of the tests means that  learning effects 
need to be taken into considerat ion, as pat ients often improve in their ability to 
part icipate in perimet ric test ing with experience (Wild et  al. 1989, Heijl et  al. 1989, 
Heijl &  Bengtsson 1996).   As a result , measured thresholds tend to increase over 
t ime, somet imes persist ing long after the f irst  three tests (Wild et  al. 1989).   As the 
first  test  is often part icularly deflated (one previous study reported an average 
increase of as much as 2.6dB in M D between the first  two tests in perimet ry naïve 
glaucoma pat ients [Heijl &  Bengtsson 1996]), discount ing the first  VFs remains good 
pract ice when assessing glaucoma progression. 
In spite of all the problems associated with judging progression, many clinicians 
nonetheless assess progression ‘manually’ using their experience through 
comparing SAP printouts.   However, decision-making, even among expert  
clinicians, can be inconsistent (Viswanathan et  al. 2003, Tanna et  al. 2011) and 
concordance between clinicians has been shown to increase substant ially when 
Progressor software is used (Viswanathan et  al. 2003).   As a result , it  is clear that  
clinical decision-making in evaluat ing progression status can be improved with the 
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thorough understanding and ut ilisat ion of the available software and analysis 
methods to facilitate this task (Figure 1.9). 
 
 
Figure 1.9 – A range of analytical tools available for use in clinical practice a) Statpac 2’s 
Glaucoma Probability Analysis for the HFA, b) Eyesuite Analysis software for the Octopus 
perimeter, c) Progressor and d) Peridata’s boxplot trend analysis 
 
1.4. Global indices 
 
Given the difficulty of thinking about  54 points simultaneously, it  is often desirable 
to have a single global index to summarise the amount  of vision loss in an eye.   As a 
result , there are a range of global summary indices that  have been developed for 
the purpose of measuring levels of VF damage. 
1.4.1 The Mean Sensitivity, Mean Defect and Mean Deviation 
 
The simplest  way of summarising all of the VF sensit ivit ies into one single index is to 
simply take their arithmet ic mean.   This is called the mean sensit ivity (Flammer 
1986).   However, the disadvantage of using the mean sensit ivity is that  it  is unclear 
whether a pat ient  sensit ivity is normal or not .   Without  a reference value, it  is 
impossible to tell what  is meant  by a mean sensit ivity of 26dB for a part icular eye.   
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This is especially pert inent  given the fact  that  the ret inal sensit ivity decreases 
naturally with age (Heijl et  al. 1987). 
As a result , every type of perimeter  has a normat ive database of VF thresholds to 
compare measured VF thresholds against  at  a given locat ion and for a given age.   
M easured thresholds are then compared with these average thresholds of the rest  
of the populat ion and the differences between these for each locat ion are known as 
total deviat ions (TD).   Taking the arithmet ic mean of these TD values gives the 
mean defect  (Flammer 1986).   However, it  is well known that  the variability in the 
periphery of the VF tends to be higher than in the cent re around the point  of 
fixat ion (Heijl et  al. 1987) and the mean defect  does not  take into account  these 
differences.   In addit ion, it  could be argued that  t he more cent ral test  locat ions are 
more important  in the context  of pat ient  life and therefore require greater 
weight ing. 
The most  commonly used and widely understood met ric for summarising damage 
in an individual’s VF is the M ean Deviat ion (M D) index (Artes et  al. 2011).   The M D 
is much like the mean defect except  weighted to give more prominence to the less 
variable cent ral test  locat ions (Heijl et  al. 1987).   This allows for a more accurate 
summary of the eye’s overall visual capabilit ies and it  is therefore commonly 
ut ilised over the mean defect . 
These stat ist ics give a crude, yet  understandable, single stat ist ic to give an 
indicat ion of how an individual’s global VF sensit ivity is compared with that  of a 
“ normal”  person of that  individual’s age.   However, the problem with using the M D 
(as well as the mean defect  and sensit ivity) and summary measures in general is 
that  they are only useful in terms of summarising the defect iveness of the whole 
VF, when, in glaucoma, it  is often the size and posit ion of localised damage that are 
of most  interest  (Figure 1.10). 
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Figure 1.10 - HFA greyscale representations of six different eyes.   Clearly all the VF 
defects are different and might impact on the patient’s day-to-day function differently.   
Yet all of these VFs have the same M D value of -5dB. This illustrates the limitation of 
using a global index, or a single number like M D to summarise the VF, because all spatial 
information about the defect is lost.   For instance, the visual function of a patient with a 
central defect (such as patients e and f) is likely to be more compromised than that of a 
patient whose VF is affected more peripherally (such as patients a to d). 
 
1.4.2 Total Deviation Map 
 
Humphrey print -outs have two TD maps which show where defects in the VF are 
located.   One is a map of measured TDs at  dif ferent  locat ions in the VF.   The 
second is a probability map where the measured TDs are compared to t he 
dist ribut ion of thresholds in healthy eyes (the normat ive database), which are 
annotated according to the percent ile below which they fall.   Thresholds measured 
in the bot tom 5% of the sample populat ion flagged visually with dif ferent  symbols 
for the sub 5, 2, 1 and 0.5 percent iles (Figure 1.11).   This is an effect ive visual way 
of communicat ing the VF of one eye when used in conjunct ion with the summary 
stat ist ics described previously. 
fed
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Figure 1.11 - The above distribution represents the variation in the total deviation 
value (TD) of a given point in a monocular VF.   If a measured TD value falls within 
the green area (i.e. below the fifth percentile), then there is a significant 
probability of damage and the location will be flagged in the TD plot.   This figure 
was previous published in the European Ophthalmic Review (Saunders et al. 
2013). 
1.4.3 The Pattern Deviation and Pattern Standard Deviation 
 
There is a notable flaw with the methods of measuring VF loss discussed so far.   
Cataracts are a common eye condit ion in old age that  causes a loss in sensit ivity 
throughout  the VF and using these methods exclusively it  is hard to different iate 
the effects of cataract  and open-angle glaucoma.   Addit ionally, a pat ient  may 
simply have thresholds that  are unusually low for someone of their age.   As a 
result , the pat tern deviat ion (PD) plot  has also been devised and is commonly 
consulted by clinicians in order to assess whether defects are likely to be localised 
glaucomatous ones or a result  of general VF worsening (Figure 1.12).   To this end, 
it  references each TD value against  the 7th highest  TD value and checks what 
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percent ile the difference between these two values are.   In other words, the PD 
at tempts to compare focal VF loss with diffuse VF loss.   As with the TD plot , any 
readings in the bot tom 10% of the populat ion are flagged.  
 
Figure 1.12 – Total and Pattern Deviation plots.   The top grids show the number of 
decibels that each threshold deviates from the expected threshold, whereas the bottom 
grids show the percentiles of the estimated distribution of a normal population the 
thresholds reside below.   Pattern deviation plots correct for diffuse loss in the eye that 
often results from cataract; a common co-morbidity in old age. 
The pat tern standard deviat ion (PSD) measures the amount  of variability within the 
VF, meaning that  it  can be useful for different iat ing glaucomatous focal loss from 
diffuse cataract  loss.   Specifically, it  sums the absolute difference between the 
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sensit ivity at  each field locat ion and the normal age-normal sensit ivity corrected for 
the pat ient ’s M D.   A high PSD thus implies that  there is a great  deal of variat ion 
between points measured in the VF, which is more indicat ive of typical 
glaucomatous f ield loss, whilst  if  each locat ion is uniformly depressed (as in dif fuse 
loss) the PSD is low.   However, this measure is ineffect ive at  the end-stage of 
glaucoma, because it  w ill decrease as defects become more homogenous across the 
VF.   Thus, the PSD not  a good indicator of overall damage, though it  can st ill be 
helpful when used alongside the M D (Brusini &  Filacorda 2006). 
 
1.4.4 The Visual Field Index 
 
The Visual Field Index (VFI) is a relat ively new summary measure that  seeks to 
quant ify glaucomatous damage, in later software upgrades of the HFA (Bengtsson &  
Heijl 2008).   It  is similar to the M D, though there are various notable differences.   
The VFI seeks to be user friendly to clinician and t herefore at tempts to est imate the 
percentage of vision the pat ient  has left .   Vision with no discernable defect  is 
categorised at  100% with 0% signifying perimet ric blindness.   The VFI is weighted 
more towards the cent ral VF than the M D, operat ing on the principle that  the 
cent ral part  of the vision is of highest  importance in terms of quality of life.   Finally, 
the PD is ut ilised rather than the TD to calculate this stat ist ic. 
There are therefore two main benefits of using the VFI to monitor VF loss over 
other measures such as M D: first ly, it  measures only damage that  is related to 
localised VF defects, thus giving it  relat ive immunity to the confounding effects of 
cataract , and, second, it  priorit ises the cent ral VF more, therefore giving a bet ter 
representat ion of how visual loss is likely to impact  on visual funct ion.   Bengtsson 
and Heijl point  out  that  using a percentage scale makes the result  more relevant  to 
pat ients than t radit ional decibel measurements (Bengtsson & Heijl 2008).   
However, Artes et  al. have pointed out  a number of flaws with the stat ist ic (Artes et  
al. 2011).   One key issue is that  there is evidence that  the VFI is overly-opt imist ic in 
est imat ing the proport ion of vision left  when compared with expert  opinion, which 
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suggests that  the stat ist ic can be somewhat  misleading in represent ing how well a 
pat ient  can see (Artes et  al. 2011).   A possible reason behind this is that  the 
reliance of the VFI stat ist ic on pat tern deviat ion is thought  to fail to take into 
account  the fact  that  glaucoma does also cause diffuse loss (Henson et  al. 1999), 
which is ignored using this stat ist ic.   Thus, the VFI can risk underest imat ing the 
overall effect  that  glaucoma has on the eye (Artes et  al. 2010) a fault  also 
acknowledged by Bengtsson and Heijl (Bengtsson & Heijl 2008).   Thus, though the 
VFI may potent ially be useful, the M D is st ill a gold-standard in summarising VF loss 
into a single stat ist ic. 
 
1.4.5 Issues with global indices 
 
Overall, though summary measures are useful in t erms of having a singular measure 
represent ing how badly an individual’s vision has been degraded by glaucoma, a 
universal problem for all of these measures is that  they waste data and ignore 
important  spat ial informat ion.   Furthermore, it  is difficult  to tell how changes in 
these measures relate to visual disability.   For example, what  exact ly does a drop in 
VFI from 100 percent  to 97 percent  mean?   Thus, criteria must  be devised in order 
to indicate whether glaucomatous progression is t aking place at  a dangerous rate or 
not .   It  is also accepted that  summary measures are relat ively insensit ive to change 
when subject  to analysis due to the fact  that  it  averages the healthy parts of the VF 
as well as the unhealthy sectors to calculate the measure deteriorat ion (Smith et  al. 
1996, Wild et  al. 1993). 
 
1.5 Event and Trend-based analyses 
 
Whatever measure is ut ilised to summarise damage, it  is important to be able t o 
have some analysis method for establishing the difference between VF progression 
and differences in VF measurements due to variability.   The analysis methods for 
doing this can generally be divided into two categories: event  and t rend-based 
analyses.   There is often much debate between which type are bet ter to use.   
Overall, there are clear dif ferences between these two families of methods as a 
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result  of how they t reat  measurements taken between the first  and last  VF.   This 
gives them unique propert ies that  have to be considered before evaluat ing which 
set  of methods have the best  ut ilit y in detect ing glaucomatous progression. 
Event  based analysis involves taking a baseline and comparing every subsequent  
test against this reading.   Any significant  difference between the baseline and 
latest  reading is considered to be due to progression.   On the other hand, t rend 
based analyses are an evolving process in which all VFs are analysed using linear 
regression to assess the rate and significance at  which the measurement  is 
changing. 
 
1.5.1 Staging glaucoma patients 
 
One means of marking progression is through using some staging system to mark 
when glaucomatous eyes have progressed beyond a certain level.   Although useful 
for categorising glaucomatous eyes at  diagnosis and for categorising damage in 
various studies, they are generally too insensit ive to change to be pract ical in terms 
of monitoring progression.   These methods are described in depth by Susanna Jr 
and Vessani (Susanna Jr. &  Vessani 2009). 
The most  commonly used method of staging glaucoma is the Hodapp-Parrish-
Anderson (H-P-A) index, which categorises defect  severity into three stages (Early, 
M oderate and Severe) based upon M D, numbers of points below the 5% in the 
pat tern deviat ion and health of points specifically in the cent ral 5˚ (Hodapp et  al. 
1993).   Though over 20 years old, this method of categorisat ion remains useful for  
roughly categorising VF loss and is st ill popular for use as a standard for VF defect  
severity (Elbozan Cumurcu et  al. 2010, Labiris et  al. 2010). 
However, the fact  that  there are only three stages means that  this method is not  
always helpful in the context  of monitoring disease.   In order to deal with this, 
some have adapted the H-P-A criteria, to contain more categories (M ills et  al. 2006, 
Kobelt  et  al. 2006).   Others have created newer more complex methods of 
categorising loss.   For instance, Brusini &  Filacorda devised the Glaucoma Staging 
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System (GSS), which incorporates M D and PSD to determine the stage of the defect  
(Brusini &  Filacorda 2006).   One very recent  categorisat ion method is the University 
of Sao Paulo Glaucoma Visual Field Staging System (USP-GVFSS), which incorporates 
the VFI, the proximity of damage to fixat ion, the number of hemif ields affected and 
whether the damage is connected to the blindspot  into one st ring of code (Susanna 
Jr. &  Vessani 2009).   However, the increase in ut ilit y that  has come in increasing 
the number of categories come at  a cost  of making the categorisat ion criteria more 
complex and as a result  none of these methods have made a large impact  in clinical 
pract ice. 
 
1.5.2 Pointwise scoring criteria 
 
Pointwise scoring criteria (examining each VF locat ion separately) are somet imes 
used for determining progression though usually only in clinical t rials, as they have 
good diagnost ic specif icity (probability of diagnosing healthy eyes as non-
progressing) (The Advanced Glaucoma Intervent ion Study Invest igators 1994, Heijl 
et  al. 2008, M usch et  al. 1999, Heijl et  al. 2003, Ernest  et  al. 2011, Vest i et  al. 2003).   
Two of the most  famous criteria for detect ing glaucoma progression were 
developed in order to analyse the results of two large scale clinical t r ials, AGIS and 
CIGTS, and hence are named after those t rials. 
However, both of the AGIS and CIGTS scoring methods, though specific in terms of 
their criteria of progression, both suffer from similar flaws to those of the summary 
methods described earlier.   Specif ically, these scoring systems can be affected and 
lowered by cataract , whilst  there is also a fundamental loss of detail that  occurs 
when summarising disease severity by using a single number in a disease that 
fundamentally affects the VF in a localised manner.   As a result , in clinical pract ice, 
more sensit ive event and t rend based analyses tend to be ut ilised in order to 
est imate VF progression. 
1.5.3 Glaucoma Change Probability Analysis 
 
Perhaps the most  useful form of event  analysis to date is the Glaucoma Change 
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Probability method (GCP), which is somet imes called Glaucoma Probability Analysis 
or Guided Progression Analysis and is available from Statpac 2 GPA software for the 
HFA.   This method takes the first  three VFs and t hen averages the thresholds from 
the two most  reliable VFs to at tain a baseline reading for each test  locat ion.   This 
baseline is compared with all subsequent  VF tests and the difference between them 
is assessed using the GCP map, which designates the amount  of variability from the 
average threshold one would expect  from the baseline value, calculated from 
typical populat ion variability.   Any signif icant  difference between the baseline and 
latest  reading that  is confirmed in two subsequent  tests is considered to be due to 
progression and a new baseline is taken.   Typically with this type of analysis, three 
points or more being shown as consistent ly defect ive in three tests are required to 
mark progression.   An adapted version of the GCP map known as the pat tern 
deviat ion GCP map has been used for the EM GT, which accounts for cataract  based 
defects similarly to how the pat tern deviat ion isolates localised effects from TD 
plots (Bengtsson et  al. 1997b, Heijl et  al. 2003). 
The GCP method is one of the most  sensit ive methods for detect ing glaucomatous 
progression (Vest i et  al. 2003) and is in good agreement  with expert  opinion on 
progression status (Heijl et  al. 2008).   The test ’s specificity (its ability to correct ly 
diagnose non-progressors) has been found to be slight ly worse than less sensit ive 
methods such as the CIGTS and AGIS methods, but  FP rates are nonetheless good, 
with one study est imat ing FP rates of progression of just  2.6% (Artes et  al. 2014).   
Furthermore, the GCP method has substant ially higher sensit ivity in detect ing 
change than these scoring methods (Vest i et  al. 2003, Heijl et  al. 2008, Ernest  et  al. 
2011).   Important ly, given the context of want ing to diagnose VF progression as 
quickly as possible to prevent  future impairment , GCP analysis is also much quicker 
in diagnosing progressive change than the CIGTS and AGIS scoring methods (Heijl et  
al. 2008), though only under the condit ion of frequent  test ing (Vest i et  al. 2003).   It  
is important  to further note that  the use of the GCP map is based upon the 
populat ion variability; some pat ients are more consistent  VF test  takers than others 
(Heijl et  al. 1987) and using a populat ion based measure ignores this.   As a result , 
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pat ients that  are exhibit ing signs of progression but  are consistent  test-takers may 
not  get  flagged as early as they should. 
 
1.5.4 Trend-based analyses 
 
Event  analyses are useful in determining whether progressive change is occurring, 
but  cannot  be used to predict  future outcomes, which may be important  in 
informing t reatment  decisions.   In addit ion, they only tend to look at  two VF 
observat ions in determining whether progression has occurred and this seems 
wasteful of the large amount  of data collected in long term monitoring.   As a result , 
incorporat ing t rend-based analyses that  can be used to ant icipate future VF status 
are popular. 
The simplest  type of t rend analysis is to monitor how summary measures change 
linearly over t ime using ordinary least  squares regression (OLSR) and this is easily 
accessible for clinicians using software such as Statpac 2 and EyeSuite Progression 
Analysis software for the Octopus (Figure 1.9).   Recent ly, this approach has been 
specifically advocated with the VFI in part icular (Bengtsson et  al. 2009), but  
regression of summary measures has been occasionally crit icised for being 
relat ively insensit ive to measuring progression (Smith et  al. 1996, Wild et  al. 1993).   
Furthermore, summarising all of the points in the VF will tend to result  in equally 
weight ing the damaged and undamaged parts, which will inevitably not  be as 
sensit ive as concent rat ing on the faster progressing sect ions of the field.   However, 
this approach can be nonetheless useful in giving an impression of the future status 
of an individual’s VF. 
A more sensit ive commonly ut ilised approach is Pointwise Linear Regression (PLR), 
available from PROGRESSOR (Progressor M edisoft , London, UK), EyeSuite (Haag-
St reit , Köniz, Switzerland) or Peridata (Peridata Software GmbH, Huerth, Germany) 
software (Figure 1.9), which detects the rate of progression of each point  in the VF 
(Fitzke et al. 1996).   As the name implies, PLR carries out  OLSR on the individual 
thresholds to assess how each test  locat ion sensit ivity is changing over t ime.   In 
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PROGRESSOR software, the results are presented in the form of a series of 
histograms for each point  tested in the eye.   Large bars represent  large defects, 
whilst  small ones represent  normal vision with colours ranging from white/ red 
(signifying signif icant  deteriorat ion in threshold levels) to grey (indicat ing no 
change) to green (signifying signif icant  improvement  in threshold levels).   A 
common criterion used to assess whether progression is significant  for a single 
point  is a rate less than -1dB/ year with a p-value of less than 0.01. 
However, the assumpt ion that  progression at  each test locat ion is linear, and 
therefore the use of OLSR, has recent ly been called into quest ion, with pointwise 
exponent ial models being proposed instead (Caprioli et  al. 2011, Azarbod et  al. 
2012).   Crit ics of linear regression point  to the fact  that  necessary assumpt ions of 
constant  variance, normality of residuals (due to f loor effects) and independence of  
measurements are all violated (Pathak et  al. 2013).   Although, account ing for the 
lat ter issue of temporal autocorrelat ion through mixed modelling has not  led to 
greater model ut ilit y (Pathak et  al. 2013), two different  exponent ial models have 
nonetheless been suggested to account for the other two issues: the decay and the 
non-decay exponent ial model.   The non-decay exponent ial model is based on the 
principle that  linear measurements of ret inal sensit ivity (decibels are a logarithmic 
measure) are proport ional to the percentage of ganglion cells lost .   This implies 
that , under the assumpt ion of constant  progression, one would theoret ically expect  
rates of loss to appear to increase on the logarithmic decibel scale.   The ut ilit y of  
this approach over linear regression appeared t o be demonst rated in a study by 
Pathak et al. (Pathak et  al. 2013).   Other groups have promoted a cont radictory 
model (the decay exponent ial model) whereby one would expect  rates of decay to 
decrease over t ime (Caprioli et  al. 2011).   One expects that  the ut ilit y of this 
measurement  is due to floor effects in VF measurements.   Tobit  linear regression, 
which is a form of linear modelling that  incorporates floor effects, has also been 
suggested in order to deal with this (Russell &  Crabb 2011).   Overall, there is not  
much consistent  evidence point ing to one opt imal modelling st rategy, despite 
various limitat ions associated with OLSR.   In fact , a recent  study comparing various 
regression methods had OLSR as the best  performing in terms of predict ive ut ilit y in 
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spite of the fact  that  assumpt ions of homoscedast icity (constant  variability across 
sensit ivit ies), normality and independence are violated (Bryan et  al. 2013).   Overall, 
linear regression is an undoubtedly imperfect , but  overall an adequate compromise 
of f it  and predict ive ut ilit y in monitoring long-term VF deteriorat ion. 
1.5.5 Advantages and Disadvantages of Event and Trend-based analyses 
 
 
Figure 1.13 - A demonstration of the differences between (a) event and (b) trend based 
analyses for one point in consecutive visual fields (VF). 
In (a), each threshold is compared to the initial baseline derived from averaging two VF 
measurements (the first two points).   If the point is significantly less than the baseline 
for a stable glaucomatous eye (i.e. below the dotted blue line) for three consecutive VF 
that point is determined as highly likely to be progressing.   Only the baseline and last VFs 
are used to determine whether progression has occurred. 
In (b), for every new VF taken, a regression line is fitted and the significance of it is 
assessed.   If the rate of change is less than 1 dB/ year and is significant (p<0.05) then that 
point is deemed to be progressing (solid red line).   As can be seen, it is possible for a 
point to be deemed stable (dotted black line) having been diagnosed as progressing in an 
earlier field.   All VFs are considered in calculating the rate of progression.   A version of 
this figure was published previously in the European Ophthalmic Review (Saunders et al. 
2013). 
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As a result  of using all the previous fields in its diagnosis, t rend analysis has dist inct  
advantages and disadvantages compared with event  based analyses.   First  of all, 
event  based analyses generally require fewer VFs and less t ime to produce 
definit ive results, so may detect  rapid deteriorat ion in the VF more quickly than this 
technique.   As a result , t rend analyses tend to hold a much higher risk of init ially 
falsely diagnosing stable VFs as progressing.   For example, in the scenario shown in 
Figure 1.13b, progression would be diagnosed after 3-and-a-half  years, but  this 
prognosis would change to not  progressing after 4 years (though six months later 
progression is once again diagnosed).   Conversely, t rend analysis can also be slower 
at  detect ing actual glaucomatous progression t han methods such as glaucoma 
change probability analysis (Nouri-M ahdavi et  al. 2007).   However, this technique 
est imates the rate of VF progression, which can be ext remely helpful in the context  
of following pat ients cont inuously over a long period of t ime in clinical pract ice.   
Furthermore, w ith enough f ields, t rend analyses generally have higher diagnost ic 
sensit ivity than event  analyses over the same t ime period (Vest i et  al. 2003). 
There have been successful at tempts to create criteria to help correct ly reduce FPs 
in PLR by imposing limitat ions on the number of points required to detect  
progression (Gardiner &  Crabb 2002a), yet  even these ignore the fact  that  test  
locat ions that  are near one another are more likely to be of a similar sensit ivity than 
ones that  are further away.   Ut ilising this informat ion could be a big step in 
improving t ime to detect  progression for analyt ical methods. 
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Table 1.1 on page 54 summarises the difference between various methods 
described here.   However, for a more comprehensive review summarising the 
evidence base on the different  methods for assessing glaucomatous VF progression 
readers are directed t o a review by Ernest  et  al (Ernest  et  al. 2011).   Recent ly, 
Nouri-M ahdavi &  Caprioli have also reviewed various methods for measuring 
changes in VF measurements and offer a further explorat ion of the posit ives and 
negat ives of approaches to est imat ing funct ional, as well as st ructural, loss (Nouri-
M ahdavi &  Caprioli 2014).   Overall, though flawed in various ways, t rend analysis 
using summary indices or each test  locat ion remain the most  feasible pract ical way 
of monitoring VF progression over t ime and ext rapolat ing the future VF status of 
pat ients.
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Table 1.1 – M ethods of detecting glaucomatous progression.   Acronyms described in Abbreviations Section.   This table has been previously published by Saunders et 
al. (Saunders et al. 2013) 
M et hod M et hod of  at taining 
baseline 
M et hod of  defining progression Advantages Disadvantages Correct ion 
for 
cataract? 
M et hod 
Type 
Rate of  
progression 
calculable? 
Linear 
Regression 
of M D 
values 
No consensus, but  
at  the very least  3 
VFs are required 
No consensus, but  EyeSuite for 
the Oct opus perimet er defines 
progression if t he previous six 
M Ds are significant ly progressing 
(p<0.5%) (Haag-Streit  
Int ernat ional 2009) 
- Simple 
 
- No spat ial considerat ion of t he data 
- Assumes progression is linear  
- Long t ime period required (Smith et  al. 1996) 
- Low  sensit ivity (Smith et  al. 1996) 
- Affect ed by cataract  
No Global 
Summary 
Trend 
Analysis 
Yes 
Linear 
Regression 
of VFI values 
5 VFs over  3 years 
required for init ial 
t rend in Humphrey 
Field Analyzer  
software (Carl Zeiss 
M editec 2008) 
Assesses significance of  slope, 
and relates rate of  progression to 
how much VFI pat ients w ill lose 
in the next  5 years (Carl Zeiss 
M editec 2008) 
- Simple 
- Gives an est imate of t he % vision an 
individual may lose in fut ure 
- No spat ial considerat ion of data 
- Assumes  progression is linear  
- Quite a long t ime period required 
- At  least  5 VF t ests required 
-  Discounts diffuse loss, so may 
underest imate overall glaucomatous loss 
Yes Global 
Summary 
Trend 
Analysis 
Yes 
AGIS 
M et hod 
One VF A decline in score from baseline 
equal to 4 “ AGIS units”  in 3 
consecut ive tests (AGIS 
Invest igators 1994, Heijl et  al. 
2008) 
- High specificity (Vest i et  al. 2003, Heijl et  
al. 2008, Ernest  et  al. 2011) 
- Score test ing based on real pat ient  data 
- Poor sensit ivity (Vest i et  al. 2003, Heijl et  al. 
2008, Ernest  et  al. 2011) 
- Cannot  det ermine spat ial charact erist ics of  
progression 
- Long t ime required (Vest i et  al. 2003) 
- Cannot  det ect  progression rat e 
- Can be affect ed by cataract  
No Pointw ise/  
scoring 
event  
analysis 
No 
CIGTS 
M et hod 
Two VFs (M usch et  
al. 1999, Gillespie et  
al. 2003) 
A decline in score from baseline 
equal to 3 ‘CIGTS units’  in 3 
consecut ive tests (Heijl et  al. 
2008) 
- Fast  (Vest i et  al. 2003) 
- High specificity (Vest i et  al. 2003, Heijl et  
al. 2008, Ernest  et  al. 2011) 
- Score test ing based on real pat ient  data 
- Low  sensit ivity (Vest i et  al. 2003, Heijl et  al. 
2008, Ernest  et  al. 2011) 
- Cannot  det ermine spat ial charact erist ics of  
progression 
- Cannot  det ect  progression rat e 
- Can be affect ed by cataract  
No Pointw ise/  
scoring 
event  
analysis 
No 
GCP Analysis Two VFs “ Likely progression”  defined as a 
reduct ion in sensit ivity (below 
normal limits) from baseline for 
≥3 separate VF points in 3 
consecut ive tests(Vest i et  al. 
2003, Heijl et  al. 2008) 
- Fast  (Vest i et  al. 2003, Nouri-M ahdavi et  al. 
2007) 
- High sensit ivity and specificity (Vest i et  al. 
2003, Heijl et  al. 2008, Ernest  et  al. 2011) 
- Normal limits defined using real (stable) 
pat ient  data 
- Cannot  det ect  progression rat e 
- Cannot  take t he diffuse effects of  
glaucomat ous loss int o account   
 
Yes Pointw ise 
event  
analysis 
No 
PLR Analysis No consensus, but  
at  the very least  3 
VFs are required 
No consensus, but  usually a 
stat ist ically significant  (p<5%) 
decrease of  1dB per year for at  
least  3 separat e VF point s 
- High sensit ivity (Vest i et  al. 2003, Ernest  et  
al. 2011) 
- High specificity (Vest i et  al. 2003, Ernest  et  
al. 2011) 
- Long t ime period required (Vest i et  al. 2003, 
Nouri-M ahdavi et  al. 2007) 
- Assumes progression is linear  
- Can be affect ed by cataract  
No Pointw ise 
t rend 
analysis 
Yes 
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1.6 Factors affecting time-to-detect progression 
 
The most  crucial aim in the monitoring of glaucoma is to diagnose VF progression as 
quickly as possible.   Bearing this in mind, aside from criteria for flagging 
progression, there are three further factors that  affect  how quickly quality of life 
(QoL) threatening deteriorat ion of the VF can be detected: the rate of VF loss, the 
variability in the VF series (otherwise known as the ‘noise’) and the frequency at  
which VF measurements are taken (Chauhan et  al. 2008b). 
 
1.6.1 Rate of loss 
 
The rate at  which VF is lost  is clearly a highly important  factor in the ease of 
detect ing progression.   The principle behind this is simple: if  the magnitude of 
change in the VF from baseline is higher, then there will simply be greater power t o 
detect  a difference whatever method is used to analyse the results.   However, 
obviously in the context  of glaucoma, a more rapid rate of loss needs to be 
detected earlier.   It  is therefore important  to detect  deteriorat ion in eyes 
progressing at  a rate, which could very quickly cause visual impairment  (Chauhan et  
al. 2008b). 
 
1.6.2 Noise 
 
Higher variability, or higher levels of noise, in a series makes it  more diff icult  to 
dist inguish actual glaucomatous progression from fluctuat ions in measurements 
according to uncont rollable factors.   The inevit able result  of this is that  there is 
greater uncertainty about  progression status lengthening the t ime required to 
establish VF loss.   Finding ways to minimise or bet ter account  for noise  is therefore 
the subject  of a lot  of research in VFs, although research suggests a 20% reduct ion 
in noise is required to make any clinical dif ference (Turpin &  M cKendrick 2011). 
There are various causes for noise such as technician effect , algorithm, seasonal 
effects, t ime of day and pat ient  experience and reliability (Junoy M ontolio et  al. 
2012, Gardiner et  al. 2013).   However, one major diff iculty  in measuring VF loss 
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glaucoma is that  levels of noise increase with decreased sensit ivity (Figure 1.14) 
(Henson et  al. 2000, Artes et  al. 2002, Russell et  al. 2012a).   Progression is 
therefore easier to detect  in test  locat ions with good sensit ivity than locat ions 
exhibit ing glaucomatous damage.   Noise reaches a peak at  around 10-15dB and 
decreases towards 0dB due to the fact  that  sensit ivit ies reach the measurement ’s 
lower limit . 
 
Figure 1.14 – An illustration of how variability changes with sensitivity levels in various 
clinical studies.   The blue background is a density plot of all absolute residuals taken 
from fitting models to retrospective visual field series in a study by Russell et al 2012a.   
The blue and green lines represent using least-squares linear regression and tobit 
regression for these field series respectively.   The red and yellow lines reflect the 
findings of Artes et al 2002 and Henson et al. 2000 respectively.   This figure was taken 
from Russell et al. 2012a. 
1.6.3 The Frequency of Visual Field Measurements 
 
A more accurate est imate of the rate of progression is obtained by taking more 
readings because the underlying signal is more likely to be detected amidst  the 
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variability.   Gardiner and Crabb found, using simulated eyes with thresholds 
decreasing by 2dB per year, that  undergoing three VF tests per year was opt imal in 
terms of sensit ivity and specif icity of detect ing progression (Gardiner &  Crabb 
2002b).    However, their est imate of the noise is perhaps too small as it  does not  
take into account  the fact  that visual thresholds are more variable in areas of lower 
sensit ivity (Heijl et  al. 1987, Henson et  al. 2000, Artes et  al. 2002, Russell et  al. 
2012a). 
One of the most  influent ial papers on this topic writ ten by Chauhan and associates 
makes suggest ions based on the power (the probability of correct ly diagnosing a 
progressing pat ient ) associated with the number of tests taken (Chauhan et  al. 
2008b).   Chauhan et  al. suggest , as a minimum, that  six VFs should be taken in the 
pat ient ’s first  two years of monitoring, before choosing the number of subsequent  
tests per year on the basis of progression rate and t ime-scale thereafter (Figure 
1.15).   However, these figures are based on theoret ical power calculat ions (using 
est imated M D variability of pat ients in OHTS [Art es &  Chauhan 2005]) rather than 
through the analysis of clinical pat ient  data, so one could argue that  this advice is 
st ill to be substant iated.   In addit ion, taking more VFs in a period of t ime will 
increase the number of FP diagnoses, i.e. decrease specificity (Gardiner &  Crabb 
2002b). 
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Figure 1.15 – Based on Table 2 in the paper by Chauhan et al. 2008b, this graph shows an 
estimate of the number of visual fields per year required to have an 80% probability of 
successfully detecting a progressive change in mean deviation in a given number of years.   
This figure was first published in the European Ophthalmic Review (Saunders et al. 2013). 
Nouri-M ahdavi and his associates conducted a study using clinical t rial data 
confirming Chauhan’s basic hypothesis that  taking more tests will increase 
sensit ivity of glaucoma progression detect ion methods and lead to earlier glaucoma 
diagnosis (Nouri-M ahdavi et  al. 2011).   They did this by comparing pat ient  
progression w ith all VFs included against  that  with half  of their fields omit ted, which 
roughly t ranslates to comparing bi-annual and annual test ing.   However, the 
differences in amount  of progression detected between the high and low  test  
frequency groups were less profound than one would theorise based on the 
findings of Chauhan et  al.; the lat ter publicat ion ant icipated that  having two instead 
of one VF test  a year would result  in a halving of the t ime required to detect  
progression (Chauhan et  al. 2008b), which is substant ially more than differences 
reported by Nouri-M ahdavi et  al. (Nouri-M ahdavi et  al. 2011).   Part  of the 
conservat ism found in Nouri-M ahdavi’s study was probably due in part  to the fact  
that  many pat ients had more frequent  follow-ups than the 6 month average - the 
length of t ime unt il diagnosis is theoret ically halved as the frequency of tests is 
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doubled, which means that  as tests become more frequent  the dif ferences in speed 
of diagnosis become less profound.   As a result , taking into account  the pract ical 
const raints in clinics, Nouri-M ahdavi et  al. recommended measuring VFs for 
pat ients once every six months. 
Perhaps the best  recommendat ion for clinical pract ice, however, is to vary the 
intervals between VF tests to opt imise detect ion of progression (Jansonius 2006).   
One novel approach is to adopt  an approach that  varies the length of the interval 
between subsequent  tests depending on the outcome of previous test results 
(Jansonius 2007).   It  has further been suggested that  clustering tests to the 
beginning and end of a follow-up period (for instance the init ial two-year period 
suggested by Chauhan et  al.) rather than spacing tests out  evenly can help 
determine rates of VF deteriorat ion with higher precision (De M oraes et  al. 2011b, 
Crabb & Garway-Heath 2012). 
However, in spite of the evidence support ing the importance of performing plenty 
of tests on pat ients, in pract ice, recommended clinical guidelines on frequency of 
VF test ing are largely not  followed in clinical pract ice (Fung et  al. 2013, M alik et  al. 
2013).   A key reason for this is likely to be that  it  is simply not  possible given limited 
resources or capacity (M alik et  al. 2013).   The inability to achieve this goal, 
however, represents a serious obstacle to sufficient ly monitoring VF progression in 
clinical pract ice.   Perhaps the key is to st rat ify pat ients into those that  will benefit  
from more frequent  test ing, yet  accurate risk prof iling of progression awaits further 
research. 
 
1.7 Visual fields and Visual function 
 
Detect ing progression is important , but  it  is really the impact  of VF loss on visual 
funct ion in everyday life that  makes glaucoma an important  condit ion to 
understand.   In fact  it  has even been suggested that  QoL be rout inely invest igated 
in clinical pract ice such is the importance of relat ing clinical measurements to 
impact  on the pat ient  visual funct ion (Skalicky &  Goldberg 2010).   Given the fact  
that  the aim of glaucoma care is to ensure that  no individual suffers avoidable 
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visual impairment  in their lifet ime, it  is important  to have some idea about  what  
daily act ivit ies are affected by glaucoma and the stages of disease at  which this 
happens. 
 
1.7.1 Evaluating patient visual function 
 
Unfortunately, lit t le is known about  how VF defects, at  different  stages of 
glaucoma, affect  pat ients’ abilit ies to perform everyday visual tasks.   This is not  
only due to the direct ion of research into this topic being limited (Glen et  al. 2011), 
but  also due to the challenges of measuring impairment  due to vision specifically in 
a variety of tasks.   Quest ionnaires (or Pat ient  Reported Outcome M easures 
[PROM s]) are occasionally used as a measure of QoL, but  responses tend to be 
insensit ive and heavily affected by the pat ient  (Bozzani et  al. 2012).   While 
prospect ive performance-based measures, such as the Assessment  of Disability 
Related to Vision (ADREV) (Altangerel et  al. 2006), are an object ive alternat ive and 
have been shown to be more correlated to VF measurements (Richman et  al. 2010), 
it  can be difficult  to obtain a good quant ity of data and there is no guarantee 
experimental condit ions can replicate real-life situat ions.   M eanwhile, analysing 
ret rospect ive data affords none of the detail of collect ing informat ion in an 
experimental study.   A common f law across methodology is that  it  is diff icult  to tell 
whether performance is just  due t o glaucoma or affected by other co-morbidit ies; 
this is part icularly t rue in the context  of the fact  that  glaucoma is a disease that  
affects the elderly populat ion.   Nonetheless, being able to link the measurements 
taken in the clinic t o what  pat ients visually ‘can’ and ‘cannot  do’ would be 
enormously helpful.   The best  approach is likely to evaluat ing links between visual 
funct ion and f ield loss is to draw evidence from studies using a variety of different  
methods. 
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1.7.2 Monocular and Binocular fields 
 
Another large issue when considering pat ient  visual funct ion is that  often VF 
measures are monocular (take measurements from one eye at  a t ime), when it  is 
worth not ing when considering VF loss and the effect  of this on visual funct ion that  
pat ients have two eyes (Asaoka et  al. 2011).   In t he cent ral field in part icular there 
is a binocular summat ion effect  where the VFs of each eye crossover.   As a result , 
damage in the cent ral field of one eye may not  impact  on the QoL of the pat ient  so 
long as vision in the other eye is preserved. 
A binocular measure of a VF is likely the best  way to predict  the impact  of VF 
damage on a pat ient ’s QoL (Jampel et  al. 2002a) although an opt imal binocular test  
that  is sensit ive to different  degrees of VF loss does not  exist  (Jampel et  al. 2002a, 
Jampel et  al. 2002b, Noe et  al. 2003).   At  present , clinicians tend to measure 
monocular VFs only and binocular VF test ing is rarely performed.   Therefore, QoL 
studies often correlate quest ionnaire responses and task proficiency with the bet ter 
eye M D (BEM D) or the worse eye M D (WEM D).   However, ignoring the vision 
provided by the other eye can easily lead to overstat ing the impact  of a pat ient ’s VF 
loss on their visual funct ion (Asaoka et  al. 2011).   This is, in fact , especially 
important  given that  there is some evidence that  there is a natural tendency for the 
binocular VF to be preserved in bilateral glaucomatous VF deteriorat ion (i.e. 
glaucomatous loss in both eyes) (Sponsel et  al. 2014). 
Ideally, binocular tests should be carried out  in order to bet ter assess the impact  of 
disease on an individual’s visual funct ion.   The only established test  for this 
purpose, however, is the binocular Esterman test  (Esterman 1982).   This perimet ric 
test  procedure randomly presents lights of a fixed intensity of 10dB at  120 separate 
locat ions (Figure 1.16).   The subject  taking the t est  is simply required to indicate 
whether or not  they have seen each point .   Unlike SAP, the binocular Esterman test  
extends into the periphery evaluat ing the full 160° field in the horizontal (24-2 
test ing only tests points within 30° of fixat ion).   These locat ions are not  spread 
evenly; more points are tested in cent ral vision and also in the inferior f ield.   
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However, not  as many points are tested in the cent ral 30° of fixat ion as SAP.   In 
addit ion, although FNs and FPs are tested, FLs cannot  be measured using this 
technique.   However, the key disadvantage with this binocular test  is that  
thresholds are not  measured.   Given the very bright  level st imulus presented, the 
several met rics using this test  are not  sensit ive to change (Harris &  Jacobs 1994) 
and do not  tend to correlate well w ith pat ient  assessment  of visual funct ion (Jampel 
2001).   In fact , the binocular Esterman does not  even seem to perform as well as 
monocular test ing at  evaluat ing pat ient  funct ion (Jampel et  al. 2002a)   Despite 
these limitat ions, the Esterman test  is nonetheless ut ilised in the UK in evaluat ing 
fitness to drive (Drivers M edical Group 2013). 
 
Figure 1.16 – The print-out from an Esterman Test taken from Viswanathan et al. 1999. 
 
Binocular tests can also be taken using 24-2 perimet ry and have occasionally 
performed for some studies (Tabret t  &  Lathan 2012), but  t hese often are not  
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ut ilised in clinical pract ice as they require a separate test .   One simple method of 
evaluat ing binocular loss for the cent ral 21° of th e VF is to combine VFs from each 
eye into one binocular VF.   The theory behind this is that there are locat ions of the 
VF in each eye that  correspond the same parts of the binocular VF.   There are three 
main approaches that  have been suggested for combining monocular f ields.   The 
first  such approach, taking the average of corresponding test  locat ions has been 
shown to have poor correspondence with t rue binocular test ing, so there is lit t le 
need to ment ion it  further (Nelson-Quigg et  al. 2000).   The second is known as 
quadrat ic summat ion, which has previously performed well when compared with 
binocular test ing (Nelson-Quigg et  al. 2000).   It  is calculated using the following 
formula: 	ܤ݅݊݋ܿݑ݈ܽݎ	ܵ݁݊ݏ݅ݐ݅ݒ݅ݐݕ = 	ඥܮ݂݁ݐ	ܵ݁݊ݏ݅ݐ݅ݒ݅ݐݕଶ + ܴ݅݃ℎݐ	ܵ݁݊ݏ݅ݐ݅ݒ݅ݐݕଶ 
However, the most  commonly used method combining VF results is the Integrated 
Visual Field (IVF), also known as the best  locat ion method.   This approach takes 
each corresponding locat ion in the VF and compares their sensit ivit ies, taking the 
highest  one at  each locat ion (Figure 1.17).   Although not  perfect , a study by 
Nelson-Quigg and colleagues indicated that  this test  was closest  on average to 
binocular VF test ing, although tended to vary more from Esterman measurements 
when compared with the quadrat ic summat ion method (Nelson-Quigg et  al. 2000).   
Crucially, IVF measurements compare favourably with self-reported pat ient  
diff iculty (Jampel et  al. 2002a, Crabb & Viswanathan 2005, Bozzani et  al. 2012) and 
are also in good agreement  with t he Esterman in terms of categorising pat ient  legal 
fitness to drive (Crabb et  al. 1998, Crabb et  al. 2004, Crabb & Viswanathan 2005, 
Chisholm et  al. 2008).   An important  limitat ion of ut ilising the IVF is that  it  would 
not  detect  pat ients unfit  to drive if they had damage outside of the cent ral 24˚ that 
caused them to be legally unfit  t o drive (see Chapter 2).   However, evidence 
suggests it  is relat ively uncommon for pat ients to fail the Esterman test  on this 
criterion alone.   In fact , it  is more common for pat ients classified as fit  to drive to 
be classified as legally unfit  by the IVF surrogate, even account ing for the fact  that 
the IVF tests more points in the cent ral 20˚ (Crabb et  al. 1998, Crabb et  al. 2004, 
Chisholm et  al. 2008).   When there is a large discrepancy between the bet ter eye 
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and the worse eye, the IVF is often very similar to the bet ter eye (Arora et  al. 2013), 
yet  the IVF is nonetheless helpful in a number of cases when evaluat ing pat ient  QoL 
in bilateral glaucoma. 
 
 
Figure 1.17 - This figure illustrates how the integrated visual field (IVF) is calculated.   
Corresponding points in the left and right visual fields (VF) are compared and the one 
with the higher sensitivity is chosen to represent the IVF for that point.   The nasal steps 
are unique to each eye so these are not used in the IVF.   The mean deviation (M D) from 
the better eye can be very similar to the IVF M D in many cases as for Patient A, but can 
overestimate the severity of binocular damage in cases where damage between the eyes 
are asymmetric as it is for Patient B. 
 
1.7.3 The effect of glaucomatous loss on visual function 
 
Whatever method has been used to demonstrate VF loss, there is plenty of 
evidence to suggest that  VF deteriorat ion has a profound effect  on pat ient  QoL and 
visual funct ion (Altangerel et  al. 2003).   Quest ionnaire responses have not  only 
been able to discriminate well between pat ients and cont rols (Goldberg et  al. 
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2009), but  have also been able to link visual funct ion and QoL to BEM D (Jampel et  
al. 2002a), WEM D (Hirneiss et  al. 2011, Chan et  al. 2013) and binocular measures of 
VF loss (Parrish, Gedde et  al. 1997).   This dist inct ion is moreover clearer w ith 
greater defect  severity (Goldberg et  al. 2009, Chan et  al. 2013, M cKean-Cowdin et  
al. 2008, van Gestel et  al. 2010) although severity is often erroneously based on 
monocular f ields, which do not  ref lect  visual health as well as measures using both 
eyes.   There is evidence that  depression score indices are linked to both VF loss and 
self-reported quest ionnaire responses (Skalicky &  Goldberg 2008). 
In addit ion there is evidence through experimental means that  glaucoma affects 
various tasks that  impact  on day-to-day QoL.   For instance, face recognit ion (Glen 
et  al. 2012), reaching and grasping speed (Kotecha et  al. 2009) and visual search 
(Smith et  al. 2012) have all been experimentally demonst rated to be affected by 
glaucoma.   Richman et  al. found st ronger links between various experimental tasks 
as part  of the ADREV set  of tests, than through PROM s (Richman et  al. 2010). 
Three act ivit ies that  have been shown to be important  to pat ients in part icular are 
driving, mobility and reading (M angione et  al. 1998, Aspinall et  al. 2008) and there 
are a number of studies that  show these are affected in glaucoma.   For instance, 
not  only has VF loss been linked to quest ionnaire responses on mobility (Noe et  al. 
2003), but  recorded data on the number of falls have also been linked (Black et  al. 
2011).   The issues surrounding mobility for pat ients are supported by experimental 
data; Kotecha et  al. found that  balance could be affected in glaucoma (Kotecha et  
al. 2012b), whilst  speed and success in navigat ing obstacle courses have also been 
reportedly impacted in the ADREV tests (Altangerel et  al. 2006). 
There have also been many studies that  have suggested a link between self-
reported reading diff icult ies and glaucoma (Parrish et  al. 1997, Gut ierrez et  al. 
1997, M angione et  al. 1998, Lee et  al. 1998, Nelson et  al. 1999, Janz et  al. 2001, 
Altangerel et  al. 2003, Spaeth et  al. 2006, Freeman et  al. 2008).   This has been 
supported by a number of performance-based studies.   The reading of small print  
task on the ADREV has been shown to be among the most  visually demanding tasks 
in glaucoma pat ients (Altangerel et  al. 2006).   Associat ions between both the speed 
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of reading out -loud (Ramulu et  al. 2009a) and silent ly (Ramulu et  al. 2012) and 
glaucomatous VF loss have also been shown, even under condit ions where 
differences in acuity should not  impact  on f indings (Ramulu et  al. 2009a).   These 
associat ions do, however, tend to be weak due to the large variability in observed 
reading speed in pat ients with glaucoma (Roberts et  al. 2005). 
Fitness to drive, however, is perhaps one of the most  important  landmarks to 
blindness for pat ients, due to the fact  that  it  can affect  an individual’s 
independence and self-suff iciency, something ref lected in the fact  that  studies have 
linked changes in driving pat terns to depression (Fonda et  al. 2001).   Visual f ield 
health is a key component  in fitness to drive in the UK (Drivers M edical Group 
2013), although the legal criteria behind regulat ions are based on sparse evidence 
(West lake 2000).   Although the consensus is that  impairment  in VF does affect  
driving (Johnson & Keltner 1983, Owsley et  al. 1998a), there are few studies that  
have found the link between VF loss and risk of accident  to be negligible (Burg 
1971, M cCloskey et  al. 1994, Owsley et  al. 1998b).   However, due to a number of 
studies being out-of-date and having methodological problems, this is st ill an area 
that  requires further research.   Driving simulat ions suggest  that  it  is perhaps only 
when driving tasks become more complex and there is a greater need t o 
concent rate that  there is a significant  dif ference in driving ability between 
glaucoma pat ients and visually healthy individuals (Vega et  al. 2013).   Nonetheless, 
legal f itness to drive notwithstanding, pat ients with bilateral loss tend to rest rict  
their own driving (Freeman et  al. 2006, Ramulu et  al. 2009b, van Landingham et  al. 
2012). 
Although it  is clear that  severity of condit ion is linked to impact  on visual funct ion, 
at  present , it  is not  obvious for driving or many other tasks at what  stage an 
individual becomes unsafe or unable to part icipate in a given task. In part icular, 
some associat ion between M D and visual disability would be ext remely helpful to 
give clinicians a general idea of what  levels of damage are associated with visual 
impairment  in different  day-to-day act ivit ies. 
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1.7.4 Areas of VF and visual function 
 
Assessing pat ient  QoL can be more complicated than simply assessing progression, 
as the dif ferent  spat ial configurat ions of defect s have different  effects when it  
comes to affect ing pat ient  visual funct ion.   However, ident ifying the areas of the VF 
that  correspond with deteriorat ion in QoL can be problemat ic, generally due to the 
fact  that , in addit ion to it  being very diff icult  to assess pat ient  performance, it  is a 
substant ial challenge to get  a good sample of pat ients with specific damage 
configurat ions.   Nonetheless, there have been various studies that  have at tempted 
to look in more detail at  how various defect  types affect  visual funct ion and it  is 
clear that  different  parts of the VF are important  for different  daily act ivit ies. 
Certainly defects close to fixat ion are debilitat ing, being consistent ly linked to more 
negat ive quest ionnaire responses (M cKean-Cowdin et  al. 2008, van Gestel et  al. 
2010).   This is especially t rue in reading, which has been shown to be part icularly 
dependent  on the cent ral field (Whit taker &  Lovie-Kitchin 1993, Tabret t  &  Lathan 
2012).   However, research observing visually healthy people w ith simulated VF loss 
suggests that  individuals have more diff iculty adapt ing to inferior field loss in terms 
of slowed reading speed than superior, nasal or temporal defects (Cummings, Rubin 
1993). 
A recent  UK study aiming to explore what  parts of the binocular VF may correspond 
most  closely with day-to-day difficult ies for pat ients with visual impairment , 
including a small number of glaucomatous pat ients, suggested that  whilst  the 
cent ral 5 degrees of the VF was part icularly important  in reading, the periphery of  
the cent ral field (10-30° from fixat ion) was most  a ssociated with mobility (Tabret t  &  
Lathan 2012).   A study from Black et  al based in Queensland further suggest  that  it  
is inferior defects rather than superior ones that are most  closely linked to risk of 
falling (Black et  al. 2011).   The inferior paracent ral part  of the VF has addit ionally 
been linked with reaching and grasping tasks (Kotecha et  al. 2009), whilst  face 
recognit ion, like reading, predominant ly seems to be dependent  on the health of 
the cent ralmost  VF (Glen et  al. 2012). 
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An act ivity such as driving is more complex, with any loss potent ially related to 
some facet  of the act ivity.   There is some evidence that  cent ral field loss does seem 
to be more crit ical than loss in the peripheral f ield (Kooijman et  al. 2004), while, in 
addit ion, the superior hemif ield seems to be more important than the inferior 
(Vega et  al. 2013, Glen et  al. 2014).   However, it  is unclear whether or not  there is a 
difference between defects being in the left  or right  side of the field.   A Canadian 
study (driving on the right ) noted that  diffuse loss in the right  hemifield, as well as 
focal loss in the left  hemifield were both associated with inadequate performance 
in on-road assessments (Racet te &  Casson 2005), whilst  a London-based study 
(driving on the left ) simulat ing damaged VFs onto the UK hazard percept ion test  did 
not  note any clear difference in performance regarding the left  or r ight  locat ion of  
the VF defect  (Glen et  al. 2014).   However, due to large int ra-individual variability 
in terms of how defects impact  on driving, being able to assess driving ability based 
on configurat ion of the defect  is st ill a long way away and it  would perhaps st ill be 
best  to base driving ability on assessed pract ical performance (Racet te &  Casson 
2005).   
One of the reasons for the difficulty of relat ing VF health to driving proficiency is 
not  only the complexity of eye movements involved in driving and the difficulty 
involved in measuring f itness to drive, but  also t he fact  that  pat ients can adapt  to 
their defects.   For instance, Crabb et  al. note that  pat ients taking the hazard 
percept ion test  at tempt  to compensate for VF losses by making more saccades 
(Crabb et  al. 2010), although this was not  observed in another study that used a 
driving simulator (Vega et  al. 2013).   A study by Coeckelbergh et  al. also at tempted 
to look at  the relat ionship between eye movements and driving in the hope that  
pat ients could adapt  to their VF loss and become safer drivers with t raining.   Whilst  
they found correspondence between search tasks and numbers of f ixat ions, no eye 
movement  parameters were found to correspond closely with a pract ical driving 
exam (Coeckelbergh et  al. 2002).   It  was further shown that  many of this cohort  
could not  be made fit  to drive even after t raining (Kooijman, Brouwer et  al. 2004). 
One of the most  interest ing studies on the subject , from M urata et  al., at tempted 
to use the machine learning orientated Random Forest  method to look at  which 
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areas of the VF are linked to various daily act ivit ies, linking VF locat ions to 
quest ionnaire responses (M urata et  al. 2013).   Although, the worse eye acuity was 
st ill the most  important  predictor of funct ional loss, the study found the peripheral 
superior left  and inferior left  hemifields were important  for reading, with the 
peripheral, mid-peripheral and para-cent ral inferior regions important  in walking, 
whilst  the superior peripheral was most  important  in the  set  of quest ions related 
to taking public t ransport .   Broad scat tered areas of the VF are related to dining 
(Figure 1.18).   This study is perhaps the most  interest ing illust rat ion of how VF 
defects of various types can impact  on the lives of pat ients suffering them in such 
differing ways. 
 
Figure 1.18 – Findings taken from the M urata et al. 2013 study showing the different 
parts of the visual field (VF) important in A) Reading, B) Walking, C) Dining and D) Going 
out.   Darker colours correspond with more important locations in the VF.   Image was 
taken from M urata et al. 2013.   
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1.7.5 Visual fields and life expectancy 
 
Evaluat ing the level of VF loss is important  in determining the current  status of an 
individual and determining progression rates are highly important  in calculat ing risk 
of future blindness or visual impairment .   However, progression rates are 
context less without  taking into account  how long the pat ient  is likely to live.   It  is 
thus important  to use informat ion on VF progression to assess whether a pat ient  
requires further intervent ion or not  dependent  on whether the condit ion is 
progressing quickly enough to have a tangible effect  in their expected lifet ime, thus 
determining whether t reatment  is saving sight  years (Heijl 2013).   One intuit ive 
means of doing this is to use pat ient  life expectancies as Wesselink and colleagues 
recommend (Wesselink et  al. 2011).   However, although life expectancies can give 
us a good idea, the length of t ime pat ients will live for is always uncertain and what  
severity of damage corresponds to different  daily act ivit ies is yet  unknown (Figure 
1.19) (European Glaucoma Society 2008). 
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Figure 1.19 – An illustration of the conundrum associated with monitoring visual field loss 
over time.   The aim of glaucoma management is to prevent patients from reaching a 
state of severe visual impairment within their lifetime, yet it is not clear when patients 
have progressed to blindness.   This figure is based on an image from the European 
Glaucoma Society Guidelines (European Glaucoma Society 2008). 
   
1.8 Objectives 
 
It  is clear that  there are st ill plenty of unknowns when it  comes to how the 
measured VF can impact  on QoL and furthermore how best  to monitor it  over t ime 
to prevent  pat ients from reaching a stage of visual impairment .   This thesis aims to 
explore a few of these quest ions. 
Chapter Two begins by exploring the impact  of VF loss on an act ivity that  has a large 
impact  on individual QoL, meet ing the legal requirements of being f it  to drive.   The 
aim of this chapter is to invest igate what levels of cent ral VF loss (24-2 pat tern) 
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corresponds to failure to the VF component  of legal fitness to drive in the UK 
measured using a surrogate of the Esterman VF test . 
Chapter Three then explores how many individuals with glaucoma are progressing 
at  a rate that  puts them at  risk of progressing to this level of visual impairment .   To 
do this, median life expectancies based on pat ient  age are taken from the Office of 
Nat ional Stat ist ics (ONS) and rates of VF loss are projected to predict  future visual 
funct ion.   In this modelling exercise, numbers of pat ients ant icipated to progress to 
visual impairment  and statutory blindness are analysed. 
Having established the number of pat ients at  risk of visual impairment  and the 
importance of monitoring pat ient  VF loss effect ively to f ind those likely to progress 
quickly, Chapter Four then looks at  whether there is a difference between using the 
two test ing algorithms SITA Standard and SITA Fast  in the context  of precision and 
the impact  on t ime needed to detect  VF progression. 
Finally, Chapter 5 invest igates whether risk factors at  baseline can be ut ilised to 
detect  those most  at  risk of reaching a state of visual impairment .   The ut ilit y of 
one current  proposed published risk calculator for predict ing future progression 
rates in part icular is described and est imated. 
The f inal chapter summarises the work in this thesis and looks brief ly at  other 
research current ly in the process of being undertaken along with future research 
projects. 
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1.9 Data 
 
 
Figure 1.20 - The locations of the four clinical centres in England where visual fields used 
in this thesis were collected 
In order to explore the topics out lined in this thesis above, a wealth of data has 
been ut ilised.   This research uses real-life clinical data from 473,252 anonymised 
VFs taken from four NHS glaucoma clinics across the UK.   These cent res include 
M oorf ields Eye Hospital in London (320,334 VFs), Cheltenham General Hospital 
Gloucestershire Eye Unit  (50,144 VFs), Queen Alexandra Hospital in Portsmouth 
(31,879 VFs) and the Calderdale and Huddersfield NHS Foundat ion Trust  (70,955 
VFs) (Figure 1.20).   The data was collected with pat ient  consent  and recorded onto 
a M edisoft  database.   Access to the data was granted by the Caldicot t  guardians at  
each cent re.   The study adhered to the Declarat ion of Helsinki, was approved by a 
research ethics commit tee of City University London and all anonymised data were 
t ransferred to a secure database.   The inclusion criteria varied from study to study 
and will be looked at  in more depth in the coming chapters. 
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Chapter Two: Visual field measurements and legal fitness to 
drive – deriving practical landmarks for visual field 
disability in glaucoma 
 
Visual f ield measurements are the only current  means of direct ly assessing what  a 
pat ient  with glaucoma can see and are therefore essent ial in monitoring funct ional 
disease progression to aid clinical decision making in prevent ing blindness.   Yet  
even in those pat ients where risk of blindness is averted, glaucoma can st ill cause 
‘visual disability’ that  impacts on QoL (Ramulu 2009).   For example, an associat ion 
has been demonst rated between VF loss and self-reported QoL among pat ients 
who were unaware of their glaucoma at  the t ime of QoL interview  (M cKean-Cowdin 
et  al. 2008).   There are many ways of summarising VF damage, but  how these 
measurements relate to visual impairment  remains largely unknown and requires 
further research (Glen et  al. 2011).   Though many at tempts have been made to 
categorise VF defect  severity and grading criteria (Susanna Jr. &  Vessani 2009), to 
date these criteria have not  been set  with stages of visual impairment  in mind.   For 
instance, none of these staging criteria can be linked to legal f itness to drive (LFTD) 
in the UK.   This is in spite of the fact  that  driving cessat ion has been shown to be 
one of the most  incapacitat ing consequences of glaucoma (Ramulu et  al. 2009b, 
van Landingham et  al. 2012) and has been shown to be a major negat ive QoL 
“ landmark”  for pat ients (Bhargava et  al. 2006) being linked to depression (Fonda et  
al. 2001). 
In the UK, the binocular Esterman VF test  (Esterman 1982) is used to assess LFTD by 
the Driving Vehicle and Licensing Agency (DVLA) (Drivers M edical Group 2014).   
The 120 point  Esterman tests a fixed st imulus threshold of 10dB at  120 test  
locat ions.   To sat isfy the VF component  of LFTD, current  regulat ions st ipulate that  
the person should have “ no signif icant  defect  in the binocular f ield which 
encroaches within 20˚ of fixation”, and the ability to use “ a f ield of at  least  120˚ on 
the horizontal”  meridian (Drivers M edical Group 2014).   The definit ion of a 
significant  defect  is debateable, but  the current  definit ion is: “ a cluster of four or 
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more adjoining [failed (missed)] points that  is either wholly or part ly within the 
cent ral 20 degree area”  or “ loss consist ing of both a single cluster of three adjoining 
missed points up to and including 20 degrees from f ixat ion, and any addit ional 
separate missed point (s) within the cent ral 20 degree area”  (Drivers M edical Group 
2014).   In other words, four cont iguous missed points or three plus an addit ional 
missed point  w ithin 20˚ of fixat ion.   The peripheral vision regulat ions are more 
vague, stat ing that  pat ients can pass with “ up to three adjoining missed 
points...lying on the horizontal meridian”  or a “ vert ical defect  of single point  width 
but  of any length, [that ] touches or cuts through the horizontal meridian”  (Drivers 
M edical Group 2014).   A clinician may only advise a sight  impaired pat ient  to 
inform the DVLA of their status with the onus being on the pat ient  to do so.   
However, clinicians are allowed to breach confident iality when their advice is 
ignored and the pat ient  is considered a danger t o himself and others in a vehicle 
(Royal College of Ophthalmologists 2013).   In pract ice, clinicians have been shown 
to be poor at  advising glaucomatous pat ients with binocular defects to contact  the 
DVLA (Puvanachandra et  al. 2008). 
The aim of this chapter is to provide a first  step towards relat ing VF summary 
indices from the 24-2 test  pat tern and LFTD.   Specifically, this sect ion analyses the 
relat ionship between the M Ds of pat ients’ monocular VFs and an IVF surrogate 
measure for the VF component  of legal fitness to drive in order to evaluate what 
levels of VF damage are associated with losing one’s license in the UK.   The work in 
this chapter has formed a paper published by the Brit ish Journal of Ophthalmology 
(Saunders et  al. 2012a).   Richard Russell (RR) and David Crabb (DC) were joint  
authors of the paper; RR cont ributed to the data analysis and the work was directed 
by RR and DC.   I prepared the data, performed all the analysis, wrote the paper and 
produced all results and figures; RR and DC edited and revised the paper.   This 
work was also presented as a read paper at  the United Kingdom and Eire Glaucoma 
Society M eet ing in Edinburgh, UK on 6-7t h December, 2012.   All data ut ilised for  
this chapter was from M oorfields Eye Hospital, as this was the only data available at  
the t ime of the study. 
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2.1 Methods 
 
This study ret rospect ively invest igated 68,099 anonymised VFs collected from 8,252 
pat ients visit ing the Glaucoma service at  M oorfields Eye Hospital between 1997 and 
2009.   The study adhered to the tenets of the Declarat ion of Helsinki and was 
approved by research ethics/ governance commit tees of the part icipat ing 
inst itut ions.   All data were anonymised and t ransferred to a secure computer 
database at  City University London.   In all cases VF test ing was carried out  with the 
HFA using the 24-2 test  pat tern with a Goldmann size III target  and the SITA 
Standard test ing algorithm.   VF tests with FP or FN rates above 30% or FLs greater 
than 20% were discarded.   Pat ients were only included if both eyes had VFs with an 
M D flagged as worse than -2.07dB (p<5%) in order to have a sample representat ive 
of pat ients who might  be referred for an Esterman test.   Finally, only a pat ient ’s 
most  recent  monocular right  and left  eye VF tests (performed on the same day) 
were included.   In total, 5,208 VFs from 2,604 pat ients were examined. 
2.1.1. Estimating legal fitness to drive using the IVF 
 
The IVF was ut ilised as a surrogate measure to assess whether a pat ient  would be at  
risk of passing or failing the Esterman test  criteria for LFTD.   This method has been 
shown to give very good agreement with the Esterman concerning the UK VF 
criteria for LFTD (Crabb et  al. 2004, Chisholm et  al. 2008).   The derived Binocular VF 
thresholds were dichotomised int o groups with thresholds ≥10 dB and thresholds 
<10dB represent ing whether a pat ient  would see or miss a point  in the Esterman 
test , respect ively.   The number and locat ion of these points were assessed and 
compared w ith current  DVLA standards to categorise pat ients as those that  would 
sat isfy the VF component  for LFTD (Crabb et  al. 2004).   Since the number of points 
tested in the inner 20° of the IVF is 32 instead of  24 in the Esterman, 6 or 4+1 (four 
aligned defect ive points within or part ly contained within 20˚ of fixation plus at 
least  one addit ional defect ive point  also within 20˚ of fixation) clustered points 
were required for a pat ient  to be deemed to legally unfit  to drive, as has been 
established by Crabb et  al. (Crabb et  al. 2004).   As the IVF using 24-2 
measurements only extend to a maximum of 21 degrees from f ixat ion, it  was not  
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possible to assess LFTD according to regulat ions applied to the peripheral VF.   This 
process was part -automated, using code purpose writ ten in the open-source 
stat ist ical environment  R (R Development  Core Team 2014) to f ilter out  pat ients 
having too few defects to fail, and then checked manually for cases where the 
definit ion required adjoining points.   M Ds were calculated using the PROGRESSOR 
software and the BEM D (i.e. the eye with the bet ter M D) and the WEM D were 
determined for each pat ient .   It  was assumed that  the prevalence of glaucoma 
pat ients who would fail the surrogate test  in this study was similar to the 
proport ion of the t otal populat ion of pat ients wit h exist ing bilateral funct ional loss 
who would do likewise. 
 
2.1.2. Analysis 
 
BEM D and WEM D were compared using Receiver Operat ing Characterist ic (ROC) 
curves, which represent  the specif icity and sensit ivity (Altman & Bland 1994a) of the 
variables to correct ly classify legally f it  to drive pat ients (LFTDP) and legally unf it  to 
drive pat ients (LUTDP) at  different  thresholds, respect ively (Altman & Bland 1994c).   
The area under the curve (AUC) represents a criterion-free measure of the curves’ 
comparat ive diagnost ic power.   Confidence intervals (CI) for the AUC were 
calculated using DeLong’s method, which is an asymptot ically exact  method of 
est imat ing CIs in this context  (DeLong et  al. 1988). 
It  was of interest  to see whether developing a model using data from both eyes 
would give an improved result , so a logist ic regression model was used to combine 
informat ion from both eyes and fit ted values were produced from which an ROC 
curve could be produced to test the hypothesis that  ut ilising informat ion from both 
eyes would improve diagnost ic ability. 
“ Probability of failure”  (PoF) was defined as the proport ion of LUTDP below a given 
M D threshold (this is also known as the posit ive predict ive value).   The PoF, as the 
main outcome measure of the study, was est imated for all M Ds alongside the 
sensit ivity and specificity to assess diagnost ic coverage, as well as the negat ive 
predict ive value (NPV), which is the probability of a pat ient  being legally fit  to drive 
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given an M D is above the threshold (Altman & Bland 1994b).   Stat ist ical analyses 
were carried out  in R and ROC curves were generated using the software package 
pROC (Robin et  al. 2011). 
2.2 Results 
Some demographic informat ion for the 2,604 pat ients invest igated is shown in 
Table 2.1.  Three-hundred and seventy pat ients were predicted to fail the Esterman 
test  based on their IVF (failure prevalence equal t o 14.2%). 
Table 2.1 - Patient information and M ean Deviations (M Ds) of the cohort LFTDP 
indicates those patients who are ‘legally fit to drive’ according to the surrogate 
IVF test while LUTDP indicates those patients who are ‘legally unfit to drive’ 
according to this test. 
 M edian Interquartile Range 
M onth of test December 04 January 02 to October 07 
Age (years) 69 58 to 76 
Better eye M D 
(dB) 
Overall -4.7 -3.1 to -7.8 
LFTDP -4.2 -3.0 to -6.2 
 LUTDP -14.0 -10.8 to -16.9 
Worse eye M D 
(dB) 
Overall -9.4 -5.5 to -15.3 
LFTDP -8.1 -5.1 to -12.7 
 LUTDP -19.4 -15.6 to -22.9 
 
2.2.1 ROC curve Analysis 
 
In Figure 2.1 an ROC curve is f it ted to the data for the BEM D; the area under curve 
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(AUC) stat ist ic is equal to 96.2% (95% DeLong CI: 95.4 to 97.1%).   The ROC curve for 
the WEM D is not  shown, but , as expected, this met ric had poorer diagnost ic ut ilit y 
(AUC: 89.2% [95% CI: 87.8-90.6%]).   This is reflected in the fact  that  the ROC curve 
for the WEM D in Figure 2.1 falls outside the 95% CI for the BEM D across 
specificit ies, suggest ing that  the BEM D is the bet ter diagnost ic of legal fitness to 
drive. 
 
 
Figure 2.1 - A receiver operating characteristic (ROC) plot for using different summary 
measures for predicting the IVF surrogate measure of legal fitness to drive.  The grey 
diagonal line represents the random-guess line (line of no discrimination), the solid 
line the ROC curve for the better eye mean deviation (M D) with the grey band is its 
95% CI generated using bootstrapping. The lower dotted line is the ROC curve for the 
worse eye M D, while the higher dashed black line is the ROC curve derived from the 
logistic model of worse and better eye M Ds.  
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The f it ted logist ic regression model and parameter est imat ion for the BEM D and 
WEM D can be summarised as: 
ߟ = ln ൬ ݌ݎ݋ܾܾ݈ܽ݅݅ݐݕ	݋݂	݂݈ܽ݅݅݊݃	ܫܸܨ	ݐ݁ݏݐ
1 − ݌ݎ݋ܾܾ݈ܽ݅݅ݐݕ	݋݂	݂݈ܽ݅݅݊݃	ܫܸܨ	ݐ݁ݏݐ൰ ߟ = −7.86 − 0.10(ܹܧܯܦ) − 	0.53(ܤܧܯܦ)  
This equat ion st rongly suggests that  the bet ter eye M D drives the model given that  
its effect  size is over f ive t imes that  of the worse eye M D (95% CIs: -8.60 to -7.18, -
0.14 to -0.06 and -0.59 to -0.47 for the intercept , WEM D and BEM D coefficients 
respect ively).   Fit ted probabilit ies were 
generated for each η value and an ROC 
curve for the model’s f it ted probabilit ies 
was produced (Figure 2.1); it  is clear from 
visual inspect ion that  there is no signif icant  
benefit  from using the logist ic model over 
the BEM D (AUC: 96.4% [95% CI: 95.6-
97.2%]). 
2.2.2 Calculating the Probability of Failure 
PoF is given for some BEM D values in Figure 
2.2.   A BEM D threshold of ≤-7.0dB serves 
as a promising referral stat ist ic with 
sensit ivit ies and specificit ies of 95% and 
82%, respect ively; these imply a good 
diagnost ic coverage rate but  the PoF is 
quite low (46%).   In other words, 46% of 
pat ients in this sample with a BEM D ≤-7dB 
would be legally unf it  to drive according to 
the surrogate Esterman test , which 
const itutes 95% of everyone in this study 
who would fail the test .   Nevertheless, less 
than 1% of pat ients with a BEM D ≥-7dB 
Figure 2.2 - A schematic showing the 
relationship between defect levels
(better eye mean deviation) and the 
probability of failure of the surrogate 
Esterman test with 95% confidence 
intervals (CI). 
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would fail the surrogate Esterman (NPV: 99%).   A BEM D threshold of ≤-10dB 
provided less diagnost ic coverage than the -7dB threshold (sensit ivity and 
specificity equal to 80% and 94%, respect ively), but  PoF was higher (70%), thereby 
offering a good compromise between coverage and accurate diagnosis.   In this 
case, 70% of the pat ients in this sample w ith a BEM D of -10dB or worse would fail 
the surrogate Esterman test , which const itutes 80% of all who would fail.   PoF was 
very high (over 90%) when a pat ient ’s BEM D was ≤-14dB. 
 
2.3 Discussion 
 
The aim of this study was to establish whether there is a meaningful relat ionship 
between VF M D and the IVF failure to drive threshold.   The stat ist ics given in Table 
2.1 suggest  that  BEM D was a good predictor of whether a pat ient  is legally fit  to 
drive and this is supported by Figure 1, which illust rates the diagnost ic performance 
of the BEM D to classify whether a pat ient  will pass or fail the surrogate Esterman 
test .   A BEM D value of -7dB appears to be a clinically useful landmark, and could 
serve as a reminder to refer a pat ient  for an Esterman test  if this has not  been 
advised already.   A BEM D of -14dB or worse could be a useful threshold as a clinical 
t rial endpoint  for “ visually disabling”  VF damage as it  suggests that a pat ient  is very 
likely to fail the DVLA criteria for the Esterman test.   Of course, no threshold is a 
perfect  diagnost ic as Figure 2.3 demonst rates but , interest ingly, many of the ‘false-
posit ive’ pat ients in the study (including the one shown in Figure 2.3) would have 
failed the surrogate Esterman test  if just  one more failed point  was present  in their 
IVF, raising important  quest ions about  the current  VF criteria for LFTD, discussed 
elsewhere (West lake 2000). 
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Figure 2.3 - Examples of ‘true-positive’ (A), ‘true-negative’ (B), ‘false-positive’ (C) 
and ‘false-negative’ (D) patients. Patient (C) has advanced visual field (VF) damage 
in both eyes; however, the damage is spatially asymmetric, and so the patient 
passes the surrogate Esterman test. Conversely, Patient D has less severe VF 
damage in both eyes, but the damage is spatially symmetric, and so the patient 
fails the surrogate Esterman test. Integrated VF and greyscales were generated in 
R. 
 
Unsurprisingly, this study has limitat ions; most  notably, the IVF is not  the same as 
the Esterman test .  In part icular, the possibilit y exists that  pat ients with healthy 
cent ral f ields may have binocular peripheral loss that  cont ravenes legal fitness to 
drive requirements, as no points beyond 21° from fi xat ion are ut ilised in the IVF.   
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However, previous research suggests that  the ‘bet ter sensit ivity’ method for 
generat ing the IVF represents a good measure of the ‘t rue’ binocular VF in pat ients 
with glaucoma (Jampel et  al. 2002a, Nelson-Quigg et al. 2000).   Furthermore, the 
IVF has already been demonst rated as pract ical for assessing LFTD compared to 
using monocular VFs (Owen et  al. 2008) and a st rong correspondence between IVF 
and Esterman test  results has been shown in glaucoma (Crabb et  al. 2004, Chisholm 
et  al. 2008, Crabb et  al. 1998) with a minimum level of agreement  equal to 88% in 
all cases.   Disagreements between the two tests can be at t ributed to the higher 
sensit ivity of the IVF due to its higher density of test  points in the cent ral and 
superior regions (Crabb et  al. 2004), including t he four points closest  to fixat ion, 
which the Esterman does not  test .   This suggests that  the sensit ivity and NPV of the 
bet ter eye M D to assess Esterman measured LFTD is even higher since there is 
evidence the IVF surrogate test  may be more stringent  than the actual Esterman 
test  (Crabb et  al. 2004).   Furthermore, the IVF offers advantages over the Esterman 
test  because it  is possible to measure a pat ient ’s fixat ion (Kotecha et  al. 2008) and it  
is based on a threshold test  rather than a supra-threshold test . 
Another limitat ion concerns the sample being representat ive of pat ients with 
binocular VF damage that  would be considered for referral to assess LFTD.   This is 
pert inent  given that  it  is possible to at tain almost  perfect  sensit ivity and specificity 
by supplement ing the sample with people without  significant  bilateral VF loss.   This 
bias has been minimised by only including pat ients with VF defects in both eyes, as 
measured by M D, thereby represent ing the populat ion of pat ients that  should be 
referred according to current  guidelines (Royal College of Ophthalmologists 2013).   
M ore than 2,500 pat ients with a range of VF defect  severit ies were analysed; a 
sizeable sample to allow important  conclusions to be drawn.   However, it  is 
important  to note that  the results are not  applicable to pat ients with VF defects 
from neurological condit ions (Chisholm et  al. 2008) and can only be related to 
glaucomatous pat ients with exist ing VF defects (i.e. not  glaucoma suspects or 
ocular hypertensives). 
The IVF test  results are not  direct ly equivalent  to the Esterman test , which is the 
means for test ing LFTD, and this paper does not  promote the usage of summary 
84 
 
stat ist ics over the Esterman test.   In part icular, M D discards important  spat ial 
informat ion about  a VF defect , which is an important  feature of glaucoma when 
assessing LFTD, but  the index is readily available to clinicians from their rout ine 
clinical follow-up of pat ients.   Perhaps, it  is worth echoing suggest ions that  
perimet ry analysis software could include analyses such as the IVF (Owen et  al. 
2008).   For now, results from this study can potent ially act  as a marker to aid 
clinicians in making t reatment  decisions that  will prevent  the QoL of a pat ient  from 
being affected in their lifet ime, as well as serving to remind the clinician to remind 
pat ients with binocular VF damage to not ify the DVLA.   This report  could be a step 
towards bridging the gap between a pat ient ’s real life disabilit ies and their VF 
damage, and such landmarks may prove part icularly useful as clinical t r ial endpoints 
or for audit  purposes. 
The results of this sect ion, thereby, provide clinicians, who only have access to 
monocular SAP measurements, evidence-based just ificat ion for assessing a 
pat ient ’s visual disability, aiding clinical decisions.   They do not  promote the use of 
summary measures as a replacement  for standards in measuring the VF component  
of LFTD, but  instead aim to encourage a framework for interpret ing VFs in the 
context  of a pat ient ’s visual disability rather than the current  precedent  which is 
devoid of a reference standard. 
Having some impression of what  severit ies of VF loss correspond to loss in QoL is 
useful in allowing clinicians to prevent  pat ient s with glaucoma from reaching 
impairment .   However, it  is also important  to take into account  that  glaucoma is a 
long-term progressive condit ion and pat ients can live for years with the condit ion, 
with VFs deteriorat ing over t ime.   It  is imperat ive to ensure that  disease 
progression is cont rolled so that  pat ients do not  reach a stage of visual impairment  
in their lives, whilst  not  burdening them with overt reatment .   In the next  chapter, I 
invest igate how many pat ients in clinical pract ice are progressing at  a rate of loss 
likely to lead to these levels of damage within their predicted remaining lifet ime. 
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Chapter Three: Examining visual field loss in patients with 
glaucoma during their  predicted remaining lifetime 
 
The previous chapter established the probability of being legally unfit  to drive (a 
major determinant  of pat ient  vision-related QoL) across a series of MD 
measurements.   In part icular, it  was established that  VF loss worse than -14dB in 
the bet ter eye was associated with an est imated 9 in 10 chance being legally unfit  
to drive in the UK.   Another key landmark for pat ients is becoming registered as 
legally blind or severely sight -impaired (SSI) in the UK.   The definit ion for becoming 
legally SSI is based upon both the visual acuity and VF; pat ients can be diagnosed as 
SSI with an corrected visual acuity of worse than 3/ 60 without  field loss or with a 
much reduced f ield of vision w ith healthy acuity.  In the US, statutory (legal) 
blindness is typically def ined as best  corrected visual acuity of 20/ 200 or worse, but  
also includes a definit ion based on VF limitat ion (US Social Security Administ rat ion 
2011).   In part icular, the widest  diameter of the cent ral VF, in the bet ter eye, must  
subtend an angle at  least  20 degrees (i.e. the width of the cent ral VF must  be 20 
degrees wide).   The US Social Security Administ rat ion (SSA) has recent ly 
determined that  automated perimet ry can be used for the lat ter, with an M D of -22 
dB in the bet ter eye corresponding to the VF definit ion of statutory blindness (a 
landmark ut ilised recent ly by another study) (Heijl et  al. 2011). 
 
A quest ion of major interest , however, is how many pat ients undergoing t reatment  
are progressing at  rates that  put  them in danger of experiencing significant  
impairment  of visual funct ion or legal blindness in their predicted remaining 
lifet ime.   This chapter uses more clinical data and cut-offs derived from the 
research in Chapter 2 of this dissertat ion and the US SSA to invest igate the 
proport ion of pat ients in clinical pract ice that  are in danger of progressing to levels 
of meaningful visual impairment  and statutory blindness. 
 
The work in this chapter has formed a paper published by Invest igat ive 
Ophthalmology and Visual Science (Saunders et  al. 2014).   Richard Russell (RR), Jim 
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Kirwan (JK), Andrew M cNaught  (AM ) and David Crabb (DC) were joint  authors of  
the paper; RR cont ributed to the data analysis and the work was directed by RR and 
DC.  I prepared the data, performed all the analysis, wrote the paper and produced 
all the results and figures; RR, DC, JK and AM  were all involved in edit ing and 
revising the paper.    This research was also presented as a read paper at  the Royal 
Stat ist ical Society’s Young Stat ist ician’s M eet ing in London, UK on the 4t h July, 2013.   
The data ut ilised for this chapter came from M oorf ields Eye Hospital, Cheltenham 
General Hospital Gloucestershire Eye Unit  and the Queen Alexandra Hospital in 
Portsmouth. 
 
3.1. Background 
 
Past  studies suggest that  many pat ients newly-diagnosed with glaucoma are not  at  
a high risk of blindness.   Studies based on ret rospect ive chart  reviews have found 
that  the proport ion of pat ients that  progressed to blindness during follow-up 
ranged from approximately 6% to 13% (Hat tenhauer et  al. 1998, Kwon et  al. 2001, 
Chen 2003).   However, these studies used data collected on manual perimet ry, 
were based on relat ively small numbers (all less than 300 pat ients) and were all 
carried out  more than 10 years ago. 
Other est imates for VF loss in predicted lifet ime can be ext rapolated from more 
recent ly conducted prospect ive studies.   The EM GT found that  the median 
progression rate of M D, even in pat ients without  t reatment , was slower than -0.5 
decibels (dB)/ year (Heijl et  al. 2009); as an example, a pat ient  with lit t le VF damage 
at  diagnosis (say -2dB) would take 40 years to reach an M D of -22dB at  this rate of 
decay, assuming a linear rate of VF deteriorat ion.   Of course, 40 years is likely to 
exceed most  pat ients’ expected lifet imes when it  is considered that  the onset  of 
glaucoma is usually towards the end of pat ient s’ lives.   For instance, the mean 
baseline age of pat ients in the database used in this thesis is 65 years (excluding 
pat ients under 40), although this can vary a large amount.   Obviously, there is large 
variat ion in rates of VF loss and faster progressing pat ients are at greatest  risk of 
visual impairment , yet  the prevalence of these ‘fast  progressors’ in clinical pract ice 
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is unclear.   Cohort  studies from Canada and California have indicated that  less than 
5% of pat ients progress at  a rate of -1.5dB/ year or worse (Chauhan et  al. 2010, Reis 
et  al. 2012, M edeiros et  al. 2012).   However, results from retrospect ive studies, 
which may reflect  clinical pract ice more closely but  are less well cont rolled, are less 
consistent ; results from the New York Progression Study suggest  that  the 
prevalence of fast  progressors ranges from 9% to over 25% (with the use of 
different  exclusion criteria) (De M oraes et  al. 2009b, Prata et  al. 2010, Teng et  al. 
2010)   In addit ion, a recent  review of clinical data from Sweden by Heijl and 
colleagues recorded over 15% of pat ients progressing at a rate faster than -
1.5dB/ year (Heijl et  al. 2012a). 
Taking t reatment  and monit oring costs into account , it  is ext remely important  that  
resources are priorit ised in favour of those pat ients that  are at  greater risk of 
suffering signif icant  visual disability in their lifet ime (Heijl 2013).   In this context , 
informat ion about  rate (speed) of VF loss over a period of follow-up is clinically 
useful.   Recent  research has emphasised the clinical importance of this approach 
by recommending frequency and pat tern of VF test ing required over t ime in order 
to establish reasonable est imates of these rates (Chauhan et  al. 2008b, European 
Glaucoma Society 2008, Jansonius 2010, Crabb & Garway-Heath 2012).   Once the 
rate of VF loss has been established, a natural next  step is to consider the likelihood 
of a pat ient  suffering visual disability within their expected lifet ime.   Incorporat ing 
est imates of life expectancy adjusted for age (residual life expectancy) in glaucoma 
care was suggested by Wesselink et  al. (Wesselink et  al. 2011), but  before now has 
not  been implemented.   Therefore, this study at tempted to combine informat ion 
about  speed of VF loss and residual life expectancy to est imate the proport ion of 
pat ients under clinical care in glaucoma clinics that  progress at  a rate quick enough 
to result  in serious visual impairment  in their expected lifet ime. 
 
3.2 Materials and Methods 
 
Three separate M edisoft  (M edisoft  Ltd., Leeds, UK) VF databases from glaucoma 
clinics in M oorf ields Eye Hospital in London, Cheltenham General Hospital 
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Gloucestershire Eye Unit  and Queen Alexandra Hospital in Portsmouth were 
available for this ret rospect ive study.   The databases contained a total of 402,357 
anonymised VFs from 75,857 pat ients recorded between 1989 and 2012.  The study 
adhered to the tenets of the Declarat ion of Helsinki, was approved by a research 
ethics commit tee of City University London and all anonymised data were 
t ransferred to a secure computer database.   Only VFs recorded on the HFA with 
the 24-2 test  pat tern, a Goldmann size III st imulus and the SITA (SITA Standard or 
SITA Fast ) test ing algorithm were included in the study.   Unreliable VFs, defined 
here to have a FP or FN score of 33% or more, or, a FL score of 20% or more were 
excluded; 29.6% of the SITA Standard and Fast  VF records were excluded from the 
study owing to these reliability criteria.    
This study cent red on VF progression, and, to be included in the study, one of each 
pat ient ’s eyes had to have a VF series that  was at  least  3 years long, with at  least  5 
VFs after discount ing the first  VF in order to at tempt  to obviate learning effects 
(improvements in results through the pat ient  becoming more pract iced at  taking 
the tests) (Wild et  al. 1989, Heijl et  al. 1989, Heijl &  Bengtsson 1996).   The first  
recorded M D, having excluded the init ial VF for learning effects, is subsequent ly 
referred t o as the baseline M D, whilst  the last  recorded M D in the follow-up is 
denoted as the final M D.   The study only considered VF data and no other clinical 
informat ion.   Therefore, it  was not  possible to confirm whether individuals in the 
database were clinically diagnosed with glaucoma or were glaucoma suspects.   
Thus, the baseline VF of each pat ient  had to have an HFA M D or HFA pat tern 
standard deviat ion value outside the established HFA 95% normal limits in at  least  
one eye.   Given that  individuals had measurable VF damage at  baseline and were 
followed regularly for at  least  3 years in these glaucoma clinics, it  is reasonable t o 
assume that  the vast  majority in this study had glaucoma.   Pat ients under 35 years 
of age were not  included in the study. 
  
3.2.1 Extrapolating Visual Field Status at Patient End of Expected Lifetime 
 
Rates of M D loss were calculated in decibels per year (dB/ y) using ordinary least  
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squares regression.   It  was assumed that  the rate of change in M D would remain 
constant  for the remainder of a pat ient ’s expected lifet ime.   Therefore, the M D at  
expected death was calculated as the observed rate of loss mult iplied by the 
pat ient ’s residual life expectancy (Figure 3.1).   It  is important  to use residual life 
expectancies to take into account  pat ient  age rather than use populat ion age 
stat ist ics, as the probability of dying at  a part icular age will not  remain constant  
across all ages.   For instance, the probability of a 10 year old living to 78 is very 
different  to an individual that  has already lived to 76.   M edian life expectancies, 
based upon age and gender, were collected from the UK ONS (Office of Nat ional 
Stat ist ics 2011); these were derived using the latest  available English census data 
(2001) and survey data to est imate expectancies valid for the 2008-2010 period. 
 
Figure 3.1 - A schematic illustrating the analysis conducted in this study.   Visual field (VF) 
series from the left and right eyes of a patient were used to estimate a linear rate of loss 
in each eye (dB/ y).   The patient’s median life expectancy was obtained from the UK 
Office of National Statistics (Office of National Statistics 2011), and was used to predict 
the mean deviation (M D) of each eye at expected time of death.   In this illustration, the 
right eye was anticipated to progress into the statutory blindness stage by the end of the 
patient’s life.   However, given that the left eye is progressing less quickly and has less VF 
damage at the outset, this patient would be unlikely to experience severe visual disability 
in their lifetime. 
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3.2.2 Characterising the Expected Visual Function of each Patient 
 
When assessing visual disability in a pat ient ’s lifet ime, it  is necessary to consider the 
VF loss in both eyes; a damaged VF in one eye will not  necessarily impact  on the 
overall QoL of a pat ient  if the other eye remains healthy (Jampel, Friedman et  al. 
2002).   M ethods for classifying overall VF damage into ‘moderate’ or ‘severe’ 
abound (Hodapp et  al. 1993, Brusini &  Filacorda 2006, Susanna Jr. & Vessani 2009), 
but  few offer thresholds that  have an evidence base underpinning their link t o 
visual impairment  or offer any pract ical meaning t o a pat ient .   Nevertheless, results 
from Chapter 2 suggested that  a pat ient  with an M D less than -14dB in their 
“ bet ter”  eye (the eye with the least  damaged VF) is highly unlikely to sat isfy the 
vision component  of legal f itness to drive in the UK.   Hence, this threshold was 
employed as a benchmark for “ visual impairment ”  in the current  study.   A second 
M D benchmark for “ statutory blindness”  equal to -22 dB, as recommended by the 
US SSA (US Social Security Administ rat ion 2011), was also employed.   To be 
classified as having visual impairment  or statutory blindness both pat ient  eyes had 
to reach the necessary levels of VF loss.   If pat ients had less than 3 VFs performed 
in one of their eyes then their baseline M Ds were recorded and the eyes were 
either deemed to be stable (i.e. progressing at  a rate of 0 dB/ year) or progressing 
(at  a rate of -1.5 dB/ year) represent ing a ‘best ’ and ‘worst ’ case scenario 
respect ively.   In the event  of no recorded VF for the other eye, the eye was 
recorded as either visually healthy for the ‘best  case scenario’ or blind in the ‘worst  
case scenario’.   The open-source stat ist ical environment  R (R Development  Core 
Team 2014) was used for all stat ist ical analyses. 
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3.3 Results 
 
The characterist ics of the study sample of 3790 pat ients are given in Table 3.1.   
Figure 3.2 (A) and (B) show the dist ribut ion of pat ient  eye follow up t imes, pat ient  
residual life expectancies and progression rates in all eyes, respect ively.   It  is 
apparent  from Figure 3.2 (B) that  the vast  majority of eyes progressed at  a rate 
between ± 0.5dB/ year (74.0% - 95% binomial CI: 73.0 to 75.0%).   A small 
proport ion of pat ient  eyes progressed at  a rate worse than -1dB/ year (7.5% - CI: 6.9 
to 8.2%) and only 3.0% (CI: 2.7 to 3.4%) of eyes progressed at faster than -
1.5dB/ year.   It  is worth not ing that  a considerable number of eyes recorded 
posit ive M D rates (33.3% - CI: 32.2 to 34.4%). 
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Table 3.1 - The demographics of patients analysed in the study.   IQR denotes the 
interquartile range, whilst the better eye corresponds to the eye with the better 
mean deviation (M D) at the baseline VF examination 
M easure Patients with series in 
both eyes (n=3359) 
Patients with a series in 
one eye only (n=431) 
Number of patients with 
glaucoma (VF defects) in 
both eyes (%) 
2212 (65.9) N/ A 
Number of female 
patients (%) 
1684 (50.1) 228 (52.9) 
Number of patients from 
London (%) 
3124 (93.0) 413 (95.8) 
Number of patients from 
Cheltenham (%) 
183 (5.4) 10 (2.3) 
Number of patients from 
Portsmouth (%) 
52 (1.5) 8 (1.9) 
M edian number of VFs 
recorded (IQR) 
6 (5 t o 8) 6 (5 t o 8) 
M edian follow-up time 
(IQR) 
7.1 years (5.2 to 9.1) 7.2 years (5.5 to 8.9) 
M edian Baseline Age 
(IQR) 
65 years (56 to 72) 66 years (57 to 75) 
M edian Final Age (IQR) 71 years (62 to 78) 72 years (63 to 80) 
M edian Residual Life 
Expectancy from final age 
(IQR) 
16 years (11 to 22) 14 years (9 to 21) 
M edian Baseline M D in 
better eye (IQR) 
-2.6dB (-5.2 t o -1.1) -7.0dB (-11.9 to -3.7) 
M edian Baseline M D in 
worse eye (IQR) 
-6.9dB (-12.5 to -3.8) 
M edian Final M D in 
better eye (IQR) 
-3.4dB (-6.8 t o -1.3) -8.4dB (-14.6 to -4.7) 
M edian Final M D in 
worse eye (IQR) 
-8.7dB (-14.8 to -4.6) 
M edian Rates of Loss in 
better eye (IQR) 
-0.12dB/ year (-0.38 to 
0.07) 
-0.19dB/ year (-0.54 to 
0.05) 
M edian Rates of Loss in 
worse eye (IQR) 
-0.15dB/ year (-0.46 to 
0.08) 
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Figure 3.2 (A) Distribution of residual life expectancies for all 3790 patients included in the study and (B) the rate of progression of M ean 
Deviation (decibels per year) from all 7149 eyes.   The distribution of life expectancies is positively skewed as a result of the increased 
prevalence of glaucoma in older patients.   The red circles indicate the median (m) and other quantiles.
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Of the 3359 pat ients with a VF series from both eyes (Table 3.2 and Figure 3.3), 
only 5.2% progressed to statutory blindness (both eyes progressing to an M D worse 
than -22dB) with a further 10.4% progressing to visual impairment  (both eyes 
progressing to an M D level of worse than -14dB) in their expected residual lifet ime.   
The ‘best  case scenario’ produced similar results to those just  considering eyes with 
two series, but  under the ‘worst  case scenario’, the number of pat ients at  risk of 
statutory blindness increased to 7.1%, and a further 11.5% were at  risk of visual 
impairment  (Table 3.2).   Interest ingly, almost  half of the pat ients with both eyes 
followed had at  least  one eye with a posit ive rate of change (49.0% - CI:  47.3 – 
50.7). 
Table 3.2 - The proportion of patients likely to suffer visual field impairment in the 
course of their lifetime 
* 95% confidence intervals (CI) were calculated using the normal approximat ion of a 
binomial dist ribut ion 
When just  pat ients with series in both eyes tested were considered, 159 of the 175 
pat ients (90.9% - CI: 86.6 to 95.1%) who reached statutory blindness had an M D 
worse than -6dB in at  least  one eye at  baseline; t his M D level is equivalent  to what  
Visual impairment at 
death 
% No impairment 
(95% CI* ) 
% Visual 
impairment (95% 
CI* ) 
% Statutory 
Blindness 
(95% CI* ) 
Including patients with 
a series for each eye 
only (n=3359) 
 
84.4 (83.2 – 85.6) 10.4 (9.4 – 11.4) 5.2 (4.5 – 6.0) 
All patients best-case 
scenario (n=3790) 
 
84.9 (83.7 – 86.1) 10.0 (9.0 – 11.0) 5.1 (4.3 – 5.8) 
All patients worst case 
scenario (n=3790) 
 
81.5 (80.2 – 82.8) 11.5 (10.4 – 12.5) 7.1 (6.2 – 7.9) 
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is considered t o be at  least  a “ moderate defect ”  for one criterion of the Hodapp-
Parrish-Anderson index (Hodapp et  al. 1993).   Pat ients that  were predicted to 
progress to statutory blindness were around 70% more likely to have moderate 
damage (M D worse than -6dB) in at  least  one eye at  baseline than pat ients not  
predicted to progress to this stage (+ Likelihood Rat io: 1.7; 95% CI: 1.6 to 1.8).   Put  
different ly, only 1.1% (CI: 0.6 to 1.6%) of the pat ients that  were likely diagnosed 
with early VF defects, with an M D bet ter than -6dB in both eyes (44% of the study 
populat ion), progressed to statutory blindness.   St rikingly, almost  60% (CI: 52.0 – 
66.4%) of pat ients progressing to statutory blindness had one eye with an M D 
already worse than -14dB in at  least  one eye at  baseline. 
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Figure 3.3 - A series of scatterplots showing M ean Deviation (M D) in vertical (Y-axis) and 
horizontal (X-axis) eyes at baseline, at the end of follow-up and, through extrapolating 
current rates of M D deterioration, after 10, 20 and 30 years follow-up and at the end of 
expected lifetime.   Both eyes in the plot had to fulfil the original inclusion criteria.   The 
patients are coloured according to their visual disability status at expected time of death.   
Blue represents a patient where at least one of the eyes has a positive slope over time, 
green represents progression, but no significant impairment by the end of the patient’s 
lifetime, yellow represents degradation to visual impairment (-14dB or worse in both 
eyes), while red corresponds to statutory blindness in both eyes  (below -22dB). 
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3.4 Discussion 
 
This ret rospect ive study of a very large number of VFs collected in different  clinics 
over a 23 year period has provided a number of interest ing findings.   The modelling 
indicated that  a small proport ion of pat ients under clinical care in glaucoma clinics 
in the UK were est imated to be at  risk of progressing to a level of statutory 
blindness in both eyes during their predicted residual lifet ime.   The proport ion of 
pat ients predicted to be at  risk of progressing to statutory blindness in both eyes 
within the study was 5.2%, though this figure may be as high as 7.1% (‘worst  case 
scenario’) depending on the reasons behind only test ing single eyes in some 
pat ients.  These results, from the perspect ive of the burden of diagnosed glaucoma, 
seem more opt imist ic than those of previous studies.   For example, Kwon et  al. 
predicted from their study that  the number of pat ients becoming legally blind over 
a follow-up of 22 years could be as high as 19% (Kwon et  al. 2001), whilst  others 
have also predicted higher proport ions (Hat tenhauer et  al. 1998, Chen 2003).   The 
different  methodologies used in these studies conducted more than a decade ago 
are likely to explain the different  results.   For example, the previous studies did not  
use a modelling approach, were based on far fewer pat ients, used different  
definit ions for legal blindness and because they used ‘ret rospect ive chart  review’ 
were very likely subject to select ion bias.   At  the same t ime, it  is tempt ing to 
explain the dif ferences with the idea that  modern therapies are improving pat ient  
prognosis in glaucoma.   Despite small numbers reaching statutory blindness it  
should be noted that  a significant  minority of pat ients (around one in six pat ients) 
in this study were predicted t o develop VF loss that  could affect  their quality of life; 
for example, a level of impairment  that  would likely result  in loss of a driving license 
in the United Kingdom as shown in Chapter 2 (Saunders et  al. 2012a). 
Interest ingly the very wide dist ribut ion of rates of VF loss shown in Figure 3.2 (B) is 
reminiscent  of similar results shown in cont rolled prospect ive studies (Heijl et  al. 
2009, Chauhan et  al. 2010).   However, the proport ion of eyes that  are very rapidly 
progressing appears substant ially smaller than t hose of many other ret rospect ive 
studies.   The 3% of eyes highlighted in this study as progressing at  faster than -
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1.5dB/ year was in cont rast  to the figures from the recent  findings from Heijl et  al.’s 
study in Sweden that  est imated that  15% progressed at  a rate faster than -
1.5dB/ year (Heijl et  al. 2012a) and the New York Progression Study, which 
concurred that  this proport ion was in excess of 9% (De M oraes et  al. 2009b, Prata 
et  al. 2010, Teng et  al. 2010).   There are several possible reasons behind this 
difference.   First , a sizeable proport ion of pseudoexfoliat ion glaucoma (associated 
with faster disease deteriorat ion (Heijl et  al. 2009)) was present  in the Heijl study, 
not  as commonly seen in the UK.   Another possible cause is that  the pat ients in 
these studies were diagnosed with more advanced glaucoma, although it  is not  
really known whether those with advanced defects progress more quickly or  
whether they have reached a stage of more advanced impairment  because they 
presented later.   It  is perhaps worth remembering that  sensit ivit ies below 20dB 
become highly variable, so, as M Ds decrease, they are likely to be subject  to 
increasing noise also.   This in turn could cont ribute to est imates of rate of loss 
more variable too, which may be a factor behind some faster rates of loss 
exhibited.   Nonetheless, this study’s est imates of the ‘fast  progressor’ prevalence 
was more akin to those results from cont rolled clinical cohort  studies (Chauhan et  
al. 2010, M edeiros et  al. 2012, Reis et  al. 2012). 
Remarkably, about  half of all the pat ients sampled experienced an “ improved”  M D 
in at  least  one eye during their follow-up, as can be seen in Figure 3.3.   These 
posit ive slopes can be explained by a combinat ion of high variability associated with 
VF measurements (Heijl et  al. 1987, Turpin & M cKendrick 2011, Russell et  al. 2012a) 
and learning effects, which can persist  over 10 or more tests in some individuals 
(Heijl et  al. 1989, Heijl &  Bengtsson 1996).   The study at tempted to cont rol for the 
lat ter by adopt ing the common pract ice of removing the pat ient ’s first  recorded VF.   
However, there evident ly remains a substant ial difficulty in measuring rates of M D 
change. 
About  90% of those pat ients predicted to be at  risk of statutory blindness in their 
residual expected life t ime already had noteworthy VF damage (M D worse than -
6dB) in at  least  one eye at  baseline (see Figure 3.3).   M ost  of these pat ients had 
advanced impairment  (60% worse than -14dB in at  least  one eye) at  baseline.   
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These stat ist ics st rongly suggest  that  a major cont ributory factor for the risk of 
future visual impairment , or statutory blindness, from glaucoma is late presentat ion 
of the disease.   Other studies support  this important  not ion (Grant  &  Burke 1982, 
Oliver et  al. 2002) and some have explored it  in more detail, highlight ing the real 
threat  to blindness associated with the late detect ion of the disease (Sinclair et  al. 
2004, Henson & Thampy 2005, Kotecha et  al. 2012a).   Indeed, given this was a 
study necessarily limited only to pat ients that  were under clinical care, these results 
suggest  that  it  is the many undiagnosed glaucoma sufferers, who are at  the greatest  
risk of blindness.   This f inding raises an interest ing debate about  how best  to 
balance the use of VF resources in primary and secondary care, especially since it  
was est imated that  only a minority of diagnosed pat ients in clinical care are in 
danger of being severely impacted by their condit ion during their lifet ime.   
Specifically, it  suggests that more resources should be directed towards detect ing 
and case finding glaucoma.   M oreover, whilst  glaucoma is a chronic disease, the 
data here highlights that  those affected are, of course, typically elderly and have 
low residual life expectancy; the results from this study should reinforce the need 
for clinicians to consider life expectancy in their clinical management  of the disease 
(Wesselink et  al. 2011) 
3.4.1 Retrospective Data Analysis 
 
Results from clinical t rials and prospect ive studies primarily inform clinical pract ice 
and decisions about  health service delivery.   St ill, ret rospect ive analysis of very 
large volumes of data collected from the everyday clinical milieu over long periods 
of t ime can provide interest ing material and informat ion to develop new 
hypotheses, as this report  shows.   It  is already known that  volunteers for  
prospect ive studies in glaucoma have bet ter adherence to prescribed therapy than 
those in rout ine medical care (Henson & Shambhu 2006), so prospect ive studies 
and t rials may even misrepresent  the rout ine clinical situat ion.   However, any 
ret rospect ive study, including this one, will have issues with missing or incomplete 
data, although, in this case, this was largely offset  by the sheer volume of data; a 
significant ly larger number of VFs were ut ilised compared to other past  
ret rospect ive studies.   One consequent  limitat ion of the ret rospect ive study was 
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that  a small proport ion of the pat ients studied only had a complete series in one 
eye (431 out  of 3790 pat ients included in the study).   Unfortunately, the reasons 
behind the other eye not  being followed were disparate: the eye may have either 
had extensive damage that  rendered 24-2 VF tests uninformat ive (the pat ient  may 
have been switched to 10-2 test ing for example), or else it  may have been healthy 
and not  tested frequent ly enough t o meet  the inclusion criteria.   It  was at tempted 
to cater for both of these possibilit ies by providing both the ‘worst  case scenario’  
and ‘best  case scenario’ results.   Another issue associated with this ret rospect ive 
analysis concerns the fact  that full pat ient  records were unavailable or not  
considered.   As a result , analyses were just  based on age, gender and VF data.   
Some of the faster progressing pat ients in this sample may have therefore had 
rapidly lowering M Ds as a result  of concomitant  age-related eye disease, principally 
cataract .   It  is possible not  every pat ient  in t he study sample may have had 
glaucoma, but  this possibilit y was minimised through const raining subjects to those 
being followed over at  least  3 years; the majority of subjects that  were monitored 
at  specialist  glaucoma clinics over at  least  3 years are likely to have glaucoma, after 
all.   Furthermore, these findings must  be tempered by the possibilit y that  the 
baseline f ields of the pat ients may not  have been their first  VF assessment ; for 
instance, pat ients may have been t ransferred from a dif ferent  clinical cent re. 
3.4.2 Strengths and Limitations of the Study 
 
One st rength of this study is that  the thresholds chosen for visual impairment  and 
statutory blindness have some evidence-based just ificat ion at t ributed to them.   
Reaching levels of M D worse than -14dB in both eyes has been shown to 
correspond with being legally unfit  to drive in the UK, amongst difficult ies carrying 
out  various other visual tasks (Kooijman et  al. 2004, Kotecha et  al. 2009, Smith et  al. 
2011, Black et  al. 2011, Glen et  al. 2012, Tabret t  &  Lathan 2012).   Furthermore, -
22dB in both eyes is the point  at  which one qualifies for statutory blindness in the 
US, so represents a significant  milestone for pat ients.   However, in spite of the fact  
that  measured sensit ivit ies are weighted towards fixat ion when calculat ing M Ds, it  
is, of course, possible to have preserved visual acuity under these condit ions; 
people who are diagnosed with legal blindness can st ill have some useable vision.   
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In addit ion, it  is important  to emphasise that  using the M D to define visual disability 
does not  appreciate the spat ial dist ribut ion of VF damage, which is important  in a 
pat ient ’s visual funct ion, and ability to carry out  different  tasks (Kooijman et  al. 
2004, Kotecha et  al. 2009, Black et  al. 2011, Tabret t  & Lathan 2012).   For example, 
VF loss close to fixat ion is part icularly important  and eyes with this damage should 
be t reated more aggressively, especially due to the fact  that  the likelihood of  
further damage in the cent ral VF is higher (M embrey et  al. 2000). 
An assumpt ion of this analysis involves the use of a linear rate of progression of M D 
over t ime.   This may not  reflect  the t rue nature of glaucomatous deteriorat ion 
given that  there is some evidence to show pat ient s tend to progress more quickly at  
older ages, although it  is unknown whether this is a result  of older age or more 
advanced VF deteriorat ion (Heijl et  al. 2012a).   Some researchers have also 
advocated the use of exponent ial models for monitoring VF decay for individual test  
sensit ivit ies in part icular (Caprioli et  al. 2011; Azarbod et  al. 2012; Pathak et  al. 
2013).   Nevertheless, linear regression of M Ds is commonly ut ilised in clinical 
pract ice; the Glaucoma Progression Analysis software in the HFA, for instance, 
presents this as “ one method of Tracking Rate of Progression”  (Carl Zeiss M editec 
2003).   Furthermore, studies suggest  that  linear rates of progression for summary 
measures are adequate (Bengtsson et  al. 2009).  In addit ion, previous work has 
shown that  a linear model of VF progression tends to provide more robust  
est imates of future measurements than more complex models (M cNaught  et  al. 
1995, Bryan et  al. 2013).   This demonst rates a simple stat ist ical principle that , 
although more complex models tend to provide bet ter fits of exist ing data, linear 
models tend to be more useful at  predict ing future change.   However, it  is 
important  to be aware that  this M D regression does not  imply a constant  rate of 
sensit ivity loss – a loss of 1dB implies much more damage going from -5dB to -6dB 
than from -25 to -26dB, as a result  of the logarithmic scaling ut ilised for the 
measurement .   It  is further noteworthy that  the ‘future’ forecasts based upon 
current  linear rates of VF loss may make est imates of future prognosis in the 
pat ients studied overly pessimist ic, as t reatment is usually intensified if a pat ient  is 
in danger of progressing to visual disability (Heij l 2013).   On the other hand, the 
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modelling takes no account  of concomitant  eye disease which ult imately might  
precipitate levels of lifet ime visual disability that  are worse than those shown in the 
results.   A technical limitat ion of the calculat ions is that  life expectancies ut ilised 
were periodic and so the study assumes that  the probability of dying at  a given age 
will remain constant  over t ime.   It  was also necessary to assume that  mortality 
rates are independent  of glaucoma as a condit ion, although this seems reasonable 
given results from other studies that  have specifically looked at  this (Grodum et  al. 
2004).   M ortality rates could be affected by other morbidit ies which may be more 
common in individuals with glaucoma; it  is further possible that  fast  progression 
rates may be symptomat ic of poor general healt h or access to medical care, which 
may in turn affect  life expectancy.   However, more research is required to fully 
understand how life expectancy corresponds with rates of VF loss before this can be 
taken into considerat ion. 
It  is important  to reflect  on the generalisability of results.   First ly, the sample was 
only composed of pat ients from hospital care in the UK, and it  should be further 
noted that  the number of pat ients from hospitals in Portsmouth and Cheltenham 
were considerably fewer than those from M oorf ields Eye Hospital in London.   Of 
course, there is no guarantee that  pat ients were t reated equivalent ly across 
hospitals and thus these results most ly reflect  observat ions in M oorfields Eye 
Hospital.   Results are not  direct ly applicable to count ries with dif ferent  
demographics and different  health care systems.   On the other hand, London is a 
cosmopolitan city; the 2011 Census reported that  more than one quarter of the 
populat ion of London did not ident ify themselves as Brit ish (Office of Nat ional 
Stat ist ics 2012), so it  could be postulated that  there is a fair amount  of diversity 
amongst  the pat ients, although the lack of clinical data makes it  impossible t o 
determine this for certain.  Another issue with the study, part icularly when 
focussing on the finding that  worse VF loss at  baseline is associated with a higher 
risk of blindness, is that  it  is assumed that  various factors that  may have an effect  
on end state of disease, such as type of glaucoma and race of pat ient , were 
relat ively uniform throughout  the dist ribut ion.   Unfortunately, it  was not  possible 
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to cont rol for these variables, but  it  is assumed, given the quant ity of the data, that  
the findings overall represent  a reasonable populat ion est imate. 
3.4.3 Conclusions 
 
In conclusion, the main result  from this modelling exercise suggests that  most 
glaucoma pat ients under clinical care are not  in danger of suffering significant  visual 
disability in their lifet ime.  This report  certainly indicates that  the great  majority of 
pat ients that  are followed in glaucoma clinics in t he UK have stable VFs.   There is, 
however, enormous variability in rates of VF loss and also in levels of VF damage at  
presentat ion.   Pat ients that  are in danger of significant  VF impairment  in their 
lifet ime generally present  with more severe VF damage and this may indicate that  
more resources should be concent rated towards detect ing disease before it  
progresses beyond early damage.   It  is hoped that  these results can inform the 
design of bet ter health service delivery and suggest  studies that  should invest igate 
improved allocat ion of VF test ing resources (Heijl 2013).   Furthermore, the results 
from this study illuminate very clearly the importance of reliably detect ing 
significant  VF defects, and other features of glaucoma, in primary care (Henson &  
Thampy 2005). 
No mat ter how quickly glaucoma is diagnosed, however, it  is important  to establish 
rates of loss quickly as there is clearly much variability in the rates of loss and risk of 
blindness from pat ient-to-pat ient  and it  is important  to give higher risk pat ients 
prompt  intervent ion.   However, this takes t ime, mainly due to variability in 
measurements.   This can potent ially be reduced by increasing the number of tests 
used to establish thresholds (thereby increasing the certainty of a measured 
threshold), but  also by reducing the durat ion of t he test , which can prevent  pat ient  
fat igue.   Essent ially, VF test ing algorithms are a compromise between these two 
considerat ions (Turpin &  M cKendrick 2011).   SITA Standard is a current  gold 
standard for measuring threshold in automated perimet ry, but  SITA Fast  is a quicker  
test  to complete (Nordmann et  al. 1998, Wild et  al. 1999, Pierre-Filho et  al. 2006), 
although it  has been suggested that  it  may be less precise (Artes et al. 2002).   The 
next  chapter will therefore look at  the differences in test-retest  variability between 
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SITA Standard and SITA Fast  perimet ric test ing algorithms and at tempts to establish 
whether any difference between the tests is clinically meaningful in the context  of 
t ime to detect  progression in clinical pract ice. 
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Chapter Four: Comparing the relationship between 
variability and sensitivity in SITA Standard and SITA 
Fast visual fields 
 
In the previous chapter it  was established that  a low but  significant  proport ion of 
pat ients in clinical pract ice progress at  a rate that  could lead to visual impairment  
or blindness.   In other words, the majority of pat ients under clinical care are not  
likely to go blind in their predicted remaining lifet ime (Saunders et  al. 2014).   It  is 
important  to be able to different iate between stable and dangerously progressing 
pat ients in order t o ensure appropriate t reatment  can be given to prevent  sight  
loss.   M easuring progression of the VF plays an important  role in finding out  which 
groups require t reatment  intensificat ion.   However, VFs often yield variable 
measurements.   M oreover, measurement  variability increases with declining VF 
sensit ivity (Henson et  al. 2000, Artes, Iwase et  al. 2002, Russell et  al. 2012a).   As a 
result  of this variability, detect ing VF progression is far from st raight-forward, with 
significant  potent ial for detect ing false change or failing to detect  def inite change. 
Visual field test ing algorithms implemented in SAP ought  to generate 
measurements with precision and accuracy that  are sufficient  for monitoring 
progression effect ively.   Accuracy and precision are terms that  are often confused: 
an accurate test  is one that  produces results with as lit t le bias from t rue 
measurements as possible, whereas a precise test  is one with high repeatability in 
the test  results.  The precision of a VF test  can be opt imised by repeated or 
extended test ing, but  this is offset  by the demand for quick examinat ion in a clinical 
environment  and a need to reduce the effect  of fat igue on test  performance 
(Henson & Emuh 2010). 
SITA Standard was developed for the HFA in the 1990s and allows VF test ing to be 
performed in about  half the t ime of that  taken by older ‘Full Threshold’ st rategies 
(Nordmann, Brion et  al. 1998, Bengtsson & Heijl 1998a, Wild et  al. 1999) with no 
significant  decrease in precision (Bengtsson & Heijl 1998a, Artes et  al. 2002).   SITA 
Standard uses prior informat ion based on the sensit ivit ies of the surrounding points 
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and st imulus sequences are interrupted when the measurement  error of the test  
points is small compared to the ERF (Bengtsson et  al. 1997a, Heijl et  al. 2012b).   In 
fact , SITA standard has become a clinical standard for acquiring VF measurements.   
SITA Fast  provides an even quicker test  t ime often taking 5 minutes or less on 
average to administer, through present ing start ing st imuli closer to expected 
thresholds and because st imulus staircases are interrupted at  an earlier stage by 
increasing the ERF cut-off, thereby accept ing lower accuracy of test  results 
(Nordmann et  al. 1998, Bengtsson & Heijl 1998b, Wild et  al. 1999, Pierre-Filho et  al. 
2006).   The shorter durat ion of the SITA Fast  test  means that  it  is an appealing 
method from a pract ical and clinical point  of view.   Yet there remains uncertainty 
about  the precision of measurements from SITA Fast  relat ive to SITA Standard and 
how this impacts on t ime to detect  VF progression.   Choice of test ing algorithm 
therefore presents a dilemma to the clinician. 
The main aim of this chapter is thus to provide some evidence for deciding which 
test should be used in clinical pract ice.   This is carried out  by clarifying the 
difference in precision between SITA Standard and SITA Fast  across the full range of 
VF sensit ivit ies using the large volumes of pat ient  data from clinical pract ice in 
test ing cent res across the UK.   The clinical impact  of choice of VF test  algorithm is 
then est imated by considering average t ime to detect  progression using computer  
simulat ion. 
The work in this chapter has formed a paper that  has been published in the Journal 
of the American M edical Associat ion Ophthalmology (Saunders et  al. 2015).   M y co-
authors for this manuscript  were Richard Russell (RR) and David Crabb (DC).   RR 
cont ributed to the data analysis and the work was directed by RR and DC.   I 
prepared the data, performed all the analysis, wrote the paper and produced all 
results and figures; RR and DC edited and revised the paper.   This research was 
further presented as a read paper at  two internat ional conferences, including the 
North American Perimet ry Society M eet ing in Chapel Hill, NC, USA on the 3rd 
October 2013 and the Associat ion for Research in Vision and Ophthalmology Annual 
M eet ing in Orlando, FL, USA on 6th M ay 2014. 
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4.1 Materials and Methods 
 
This study analysed 473,252 anonymised VFs from 88,954 pat ients from databases 
at  M oorfields Eye Hospital glaucoma clinic in London (320,334 VFs), Cheltenham 
General Hospital Gloucestershire Eye Unit  (50,144 VFs), Queen Alexandra Hospital 
in Portsmouth (31,879 VFs) and the Calderdale and Huddersfield NHS Foundat ion 
Trust  (70,955 VFs).   The study adhered to the Declarat ion of Helsinki, was approved 
by a research governance commit tee of City University London and all anonymised 
data were t ransferred to a secure database.   Only VFs from the HFA using 
Goldmann size III st imuli w ith the 24-2 test  pat tern and either SITA Standard or Fast  
test ing algorithms were included in the study.   Eyes were excluded if they had 
fewer than five VF examinat ions; if both eyes fulfilled these criteria for an individual 
pat ient  then one eye was selected at  random.   In addit ion, pat ients under 35 years 
old were also excluded from the study.   The f irst  VF was removed in order t o 
at tempt  to account  for perimet ric learning effects (Wild et  al. 1989, Heijl et  al. 
1989, Heijl &  Bengtsson 1996) leaving a total of 86,793 VFs from 13,778 pat ients for  
analysis; 66,974 SITA Standard VFs from 10,124 pat ients and 19,819 SITA Fast  VFs 
from 3,654 pat ients. 
4.1.1 Determining the precision of SITA Standard and SITA Fast 
 
The precision of SITA Standard and SITA Fast  was assessed by fit t ing ordinary least  
squares regression to each VF test  locat ion’s sensit ivity series (i.e. PLR).   Fit ted 
values were obtained from the PLR model for each test  locat ion (excluding the blind 
spot  test  locat ions) and raw residuals were then calculated through subt ract ing the 
calculated f it ted values from the observed sensit ivit ies at  each t ime point  in the 
individual series.   The raw residuals were pooled and binned according to fit ted 
sensit ivity (rounded to the nearest  decibel).   Precision was defined to be higher 
where raw residuals were smaller.   This approach, described in more detail by 
Russell et  al. (Russell et  al. 2012a), was carried out  separately for eyes tested using 
SITA Standard and Fast  so that  the precision of the two methods could be 
compared. 
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4.1.2 Evaluating the impact of differences in precision on time to detect 
progression in clinical practice 
 
In order to illust rate the clinical relevance of any addit ional variability associated 
with either of the two algorithms, computer simulat ions were carried out  to 
determine how soon VF progression could be diagnosed.   The methodology ut ilised 
to simulate VF progression is reported in more detail elsewhere (Russell et  al. 
2013).   Ten thousand pointwise VF series were simulated to deteriorate at  three 
different  rates, or speeds, of VF loss over t ime (-0.5, -1 and -2dB per year) from  
three separate start ing sensit ivit ies (30dB, 20dB and 10dB).   Variability was derived 
from the dist ribut ions of PLR residuals ext racted for each algorithm and input  into 
the computer simulat ion.   The t ime taken to detect  deteriorat ion at  the p<0.01 
significance level with two tests per year were recorded and median detect ion 
t imes were compared between SITA Standard and Fast .   All stat ist ical analyses 
were carried out  in the open-source programming language, R (R Development  
Core Team 2014). 
 
4.2 Results 
 
In total, 716,456 PLR models were fit ted across all 52 test  locat ions (blind-spots 
locat ions excluded) of the 13,778 eyes studied, including 526,448 regression lines 
for SITA Standard test  series and 190,008 regression lines for SITA Fast .   As a result , 
4,508,036 residuals were generated.   Characterist ics of the study sample are given 
in Table 4.1.   Baseline M Ds indicated that  the majority of pat ients included in the 
study did not  have severe VF loss, although 1281 SITA Standard eyes (12.7%) and 
321 SITA Fast  eyes (8.8%) had baseline M Ds of -12dB or worse.   Baseline M Ds for 
SITA Fast  tended to be bet ter than those for SITA Standard.   M D and pointwise 
progression rates (dB/ year) in the two groups were very similar.   Interest ingly, 
people followed using SITA Fast  tended to be older than those followed using SITA 
Standard. 
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Table 4.1 – Characteristics of Study Sample 
M easurement SITA Standard (10,124 eyes) SITA Fast (3,654 eyes) 
M edian (Interquartile Range) 
Number of VF tests 6 (4 to 8) 5 (4 to 6) 
Baseline VF sensitivity (dB) 27 (23 to 30) 28 (24 to 30) 
Baseline M ean Deviation (dB) -3.23 (-7.37 to -1.03) -2.20 (-5.42 to -0.38) 
Pointwise progression rate 
(dB/ year) 
-0.13 (-0.55 to 0.17) -0.16 (-0.62 to 0.17) 
M D progression rate (dB/ year) -0.11 (-0.43 to 0.12) -0.14 (-0.49 to 0.09) 
Baseline age (years) 64 (53 to 72) 70 (61 to 78) 
Follow-up period (years) 6.0 (4.0 to 8.5) 5.1 (3.2 to 7.3) 
 
4.2.1 The relative precision of SITA Standard and SITA Fast 
 
Dist ribut ions of residuals for each fit ted-sensit ivity level are shown in Figure 4.1.   
As observed in previous studies, the dist ribut ions of residuals varied according to 
sensit ivity (Artes et  al. 2002, Russell et  al. 2012a).   M ore noteworthy were 
similarit ies between SITA Standard and Fast  results across all sensit ivit ies.   Plot t ing 
the standard deviat ion for each f it ted sensit ivity (Figure 4.2) reveals lit t le difference 
in precision between the two test  algorithms unt il sensit ivity has declined below  
around 20dB.   In fact , the precision of SITA Fast  appears to even be slight ly 
improved over SITA Standard at  higher sensit ivit ies (i.e. the spread of residuals is 
smaller).   The difference in precision between the two tests peaks at  just under 
15dB, where the test  variability is also at  its highest  in both tests.   Even then the 
magnitude of the difference is small: for example, at  14dB the difference in 
standard deviat ions is 0.51dB and this represents a difference of only about  8%. 
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Figure 4.1 - Back-to-back histograms showing distributions of the frequency density of 
raw residuals generated through linear modelling of each test location at rounded fitted 
values of 0, 10, 15, 20 and 30dB for SITA Standard (grey) and SITA Fast (red). 
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Figure 4.2 - Variability across sensitivities for SITA Standard (grey) and Fast (red).   Solid 
lines represent standard deviation (SD) of residuals at each sensitivity and dashed lines 
95% confidence intervals (CI) around those estimates of SD. The solid lines therefore 
represent the variability in SITA Standard and Fast, while the CI simply show these lines 
are not likely to be different due to chance.   It is worth noting the widths of these 
intervals are slightly narrower for SITA Standard because there is more data and thus 
greater certainty about the SD estimates.   The blue background is a smoothed colour 
density representation of the scatterplot for all residuals (approximately 4.5 million). 
 
4.2.2. Simulated time to detect progression using SITA Standard and Fast testing 
algorithms 
 
The results of 10,000 simulat ions of pointwise VF progression demonst rated that  
there was no meaningful difference in detect ion t imes using the two algorithms 
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(Table 4.2).   For example, progression set  at  a speed of -1 dB per year at  init ially 
healthy levels of VF sensit ivity is detected equally well by both the Fast  (median: 4 
years) and Standard algorithms (median: 4 years).   Figure 4.3 shows how this 
difference in precision between the SITA Standard and Fast algorithms might  look in 
real life; in this figure the eye was simulated to progress at a constant rate across all 
points in the VF – variability was then empirically added according to the 
dist ribut ions of residuals for each t rue sensit ivity level.   There is lit t le difference to 
see in the appearance of the greyscales of the VFs.   This figure therefore illust rates 
the not ion that  any moderate addit ional variability associated with SITA Fast is 
barely not iceable. 
Table 4.2 - Time to detect progression at p < 0.01 for SITA Standard and Fast using 
simulations of 100,000 progressing thresholds 
Baseline 
Sensitivity 
(dB) 
Progression 
Rate 
(dB/ year) 
M edian time to detect progression in years 
(Interquartile Range) 
 
 
SITA Standard SITA Fast 
10dB -0.5 14 (3 to 18.5) 14 (3 to 18.5) 
-1 9 (3 to 12) 9.5 (3 to 12) 
-2 6.5 (3 to 9.5) 6.5 (3 to 10) 
20dB -0.5 12.5 (3.5 to 18) 13 (3.5 to 18.5) 
-1 8.5 (3 to 11.5) 8.5 (3 to 12) 
-2 5.5 (2.5 to 7.5) 5.5 (2.5 to 8) 
30dB -0.5 6 (3 to 8.5) 5.5 (2.5 to 7.5) 
-1 4 (2 to 5.5) 4 (2 to 5) 
-2 3 (1.5 to 4) 2.5 (1.5 to 3.5) 
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Figure 4.3 - Simulated greyscales 
produced from a baseline real life 
visual field of the same eye, but the 
variability from SITA Standard and 
Fast using R statistical software (R 
Development Core Team 2014).   
Each test location was simulated to 
progress at 2dB per year with noise 
added from the distributions of 
residuals for each fitted sensitivity. 
 
 
 
 
114 
 
4.3 Discussion 
 
Consistent  with previous studies, the variability of measurements generated using 
both SITA Standard and SITA Fast  algorithms was found to increase with decreasing 
sensit ivity for both tests before declining approaching perimet ric blindness (Artes et  
al. 2002, Russell et  al. 2012a).   One reason why variability does not  cont inually 
increase with VF loss is floor effects result ing from no measurements being possible 
below 0dB; this limitat ion of SAP seems to have some impact  from below 20dB 
(Figure 4.1). 
SITA Fast  has slight ly worse precision overall when compared to SITA Standard, 
though this difference is negligible at  test  locat ions with lit t le or no sensit ivity loss; 
in fact  SITA Fast  seems to be marginally more precise at  this stage (perhaps due to 
init ial presentat ions being closer to t rue thresholds).   The difference in precision 
between methods is more apparent  when thresholds drop to levels closer to 12dB 
and largest  between around 15dB to 10dB, which matches the findings of Artes et 
al (Artes et  al. 2002).   Since variability differences between the two tests are low at  
near-normal thresholds, the shorter test  t imes associated with SITA Fast  may be 
preferable in glaucoma suspects or pat ients with early VF loss.   Furthermore, the 
simulat ion results seem to indicate that  any modest  sacrifice in precision from using 
SITA Fast makes lit t le difference to the t ime to detect  pointwise progression with 
linear regression (Table 4.2).   It  is important  to note that  research suggests that  a 
30-60% drop in variability is required in SAP in order to make a signif icant  
difference to the speed at  which deteriorat ion is diagnosed (Turpin & M cKendrick 
2011); this level of difference was certainly not  apparent  in this study.   On the 
other hand, the reduced test  t ime of SITA Fast  relat ive to SITA Standard (roughly 
two to three minutes according to the literature [Nordmann et  al. 1998, Wild et  al. 
1999, Pierre-Filho et  al. 2006]) may not  be sufficient  to make using this test  
worthwhile in the clinic. 
Analysis of average t imes to detect  dif ferent  rates of VF deteriorat ion, using a 
published model for simulat ing VF progression (Russell et  al. 2013), was very 
informat ive (Table 4.2).   When the level of pointwise VF damage drops below  
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20dB, the precision of the two algorithms are poor, perhaps too poor for detect ing 
significant  pointwise VF progression in a reasonable t ime period.   For example, at  
that  level of VF damage the model suggests it  would take more than 8 years to 
detect  a rate of -1dB per year with an examinat ion every six months, whether using 
SITA Standard or Fast .   This limitat ion about  SAP has been well reported (Gardiner 
&  Crabb 2002b, Chauhan et  al. 2008b, Crabb & Garway-Heath 2012) and recent ly 
published data indicates that  recording at  these sensit ivit ies, regardless of test ing 
algorithm, may simply be unreliable; an apparent  change in sensit ivity within this 
range may not  be informat ive of disease progression at  all and should therefore be 
eliminated or counted as 0dB (Gardiner et  al. 2014).   If  this is the case then 
differences in precision around this part  of the measurement  scale would be 
meaningless and it  would be reasonable to conclude that  SITA Fast  could be as 
effect ive as SITA standard for follow-up. 
4.3.1 Study Strengths and Limitations 
 
This study did not  consider the accuracy of the two test ing algorithms.   Evidence 
from computer simulat ion and real pat ient  data suggest  that  both SITA st rategies 
(although SITA Fast  more so) tend to produce threshold values that  are 
systemat ically higher than the original HFA Full-Threshold algorithm (Nordmann et  
al. 1998, Bengtsson & Heijl 1998b, Wild et  al. 1999, Artes et  al. 2002).   
Furthermore, given the reduct ion in number of tests required to calculate a 
threshold that , in each case, there is possibly a lower number of thresholds that  
SITA Fast  can take.   However, SITA Standard and Fast  may not  necessarily be less 
accurate than Full-Threshold test ing, as this assumes that  Full-Threshold is a gold-
standard.   Herein lies the issue: there is no gold-standard to evaluate the accuracy 
of these test algorithms; repeated test ing of point s to generate frequency of seeing 
curves (Gardiner et  al. 2014) could be considered as one potent ial approach to 
calculate thresholds more accurately, but  this could st ill be subject  to non-constant  
variability across sensit ivit ies, inter-pat ient  variability and fat igue.   M ost  
important ly, VF total deviat ion measurements are age-corrected, so should not  be 
affected by bias and given the similar scale of the rival methods, the relat ive 
accuracy of the tests should not  affect  ut ilit y in monitoring progression.   In fact , 
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smaller variability in the SITA normat ive database has been shown to result  in these 
algorithms actually being more sensit ive to change than Full Threshold test ing 
(Bengtsson & Heijl 1999).   It  is somet imes thought  that , because both methods 
ut ilise surrounding thresholds to help derive sensit ivity values and that  SITA Fast  
tolerates a lower threshold of measurement  certainty to reduce the number of 
st imulus presentat ions (Bengtsson & Heijl 1998b), VF damage has a higher 
likelihood of being missed or wrongly recorded in SITA Fast  compared with 
Standard.   This phenomenon was not  tested in this study and can only be 
invest igated in a prospect ive study. 
One st rength of the study was the fact  that the precision est imates are based on 
millions of points from real clinical data rather t han data from a small number of 
people taking part  in a more cont rolled experiment .   The sheer size of this dataset  
means that , whilst  there are bound to be anomalies and out liers, the results are 
overall probably a good reflect ion of the precision of perimet ric test ing found in 
day-to-day clinical pract ice.   A drawback with this approach is the lack of definit ive 
clinical knowledge about  the individual pat ients included in the study.   For 
instance, pat ients may have had co-morbidit ies that  affect  the VF, like cataract , that 
could well affect  est imates.   In addit ion, even the type of diagnosis of glaucoma 
was not  available – it  is only known that  pat ients were in glaucoma clinics.   No 
exclusion criteria based upon reliability criteria (FPs, FNs and FLs) were applied to 
the datasets because much of these data was unavailable for this study.   This is a 
limitat ion from the perspect ive that  VFs with values for these indices above an 
arbit rary determined criterion are often excluded in clinical pract ice.   However, it  
could be argued that  these measurements are integral to the threshold est imates 
themselves.   Further, one could also take the view that  the reliability indices are 
possibly the most  unreliable measures on the print-out  (Shao et  al. 2011) and this 
study makes the simplifying assumpt ion that  ‘unreliable’ VFs would have existed in 
equal measure in the Fast  and Standard VFs, and this would not  impact  these 
findings.   It  is also important  to acknowledge that  these est imates of precision only 
represent  an average rather than a measure that  can be applied to different  
individuals; pat ients perform different ly at  perimet ry and some produce 
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measurements with higher variability than others (Heijl et  al. 1987, Russell et  al. 
2013).   It  was not  possible to separate out  variability caused by residual learning 
effects, technician experience, seasonal and t ime-of-day effects or any other  
sources of variability that  may all have an effect  on any given test .   Without  more 
detailed informat ion on pat ient  series there was no at tempt  to remove measured 
sensit ivity out liers, as it  was important  not  to int roduce bias into the study with 
overly select ive criteria with insuff icient  evidence.   Furthermore, the dist ribut ion of 
cases is likely dominated by those with smaller amounts of VF loss and tests that  
are within normal limits, as the higher density of points in the bot tom right  corner  
of Figure 2 suggests.   In addit ion it  is important  t o note that  these results est imate 
precision based upon following pat ients longitudinally rather than through 
obtaining test -retest  data, so are probably more relevant  in the context  of looking 
at  follow-up than the diagnosis of a single VF. 
There are other aspects of the study that  demand greater scrut iny.   For instance, as 
a group, pat ients tested with SITA Fast  were, on average, older than those tested 
using SITA Standard.   It  may be speculated that  this ref lects the preconcept ion that  
older people are thought  to be worse at  perimet ry (Ball et  al. 1990, Chauhan &  
House 1991, Birt  et  al. 1997), which could lead to these pat ients being offered the 
quicker test  in the belief that  it  is more suited to them.   Also, the baseline M Ds for 
SITA Fast  tended to be higher than those for SITA Standard.   This again may be 
explained by select ion bias because the clinic databases would include people being 
followed without  VF defects (pat ients at  r isk of developing glaucoma and ocular 
hypertensives) who may have been more likely to be assigned to the ‘quicker’ test .   
One assumpt ion made in the study was that  the model-f it ted VF sensit ivit ies were 
akin to pat ients’ “ t rue”  sensit ivit ies, which is reliant  on assuming a linear 
relat ionship between change in VF thresholds and t ime.   Alternat ive t rend analyses 
modelling sensit ivity changes over t ime have been proposed (Pathak et  al. 2013, 
Azarbod et  al. 2012, Caprioli et  al. 2011, Russell &  Crabb 2011), yet  pointwise linear  
regression, as ut ilised here, is commonly used and, in pract ice, likely to be as 
effect ive (if not  more) at  predict ing future loss as these other methods (M cNaught  
et  al. 1995, Bryan et  al. 2013).   In any case, for t his study the regression is simply 
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used to ext ract  an est imate of precision via the residuals.   It  is further worth not ing 
that  pointwise VF variability was analysed without  regard for locat ion in the VF 
even though it  is already known that  variability tends to differ according to test 
locat ion (Heijl et  al. 1987).   However, this is confounded by the fact  that  sensit ivity, 
which is not  independent of variability, also varies according to test  locat ion 
(Henson et  al. 2000, Artes et  al. 2002, Russell et  al. 2012a).   As of yet , there is no 
clear evidence to suggest  that  there is a clinically significant  difference in variability 
in test  locat ions that  is independent  of sensit ivity.   It  is worth not ing that  both SITA 
algorithms ut ilise ‘smoothing’, that  is adjust ing measured sensit ivit ies according to 
adjacent  locat ions and st imulus response t imes, at  the end of test ing (Bengtsson et  
al. 1997a); the ‘noise’ added to simulated progression could not  include or take into 
account  this addit ional source of variability, so the simulat ions are subject  to slight  
oversimplificat ion.   It  would perhaps also be interest ing to look at  the comparat ive 
performance of the test ing algorithms using other criteria for defining loss in 
further work through simulat ions such as Glaucoma Change Probability Analysis 
(Bengtsson et  al. 1997b, Heijl et  al. 2003). 
4.3.2 Further thoughts and Conclusions 
 
Finally, it  is most  important  to ref lect  on pat ient  preference for different  types of 
perimet ry; it  is imperat ive to account  for this when choosing a test ing algorithm.   
For example, some pat ients may feel fat igue more acutely than others and benefit  
from the shorter test ing t ime of SITA Fast , whilst , for other pat ients it  may be 
valuable to make use of the addit ional precision that  comes with SITA Standard, 
part icularly if the disease has progressed beyond an early stage.   In the experience 
of clinical colleagues, some pat ients complain of having to delineate a high number 
of barely percept ible st imuli w ith SITA Fast  because the algorithm presents st imuli 
closer to thresholds in order to reduce test  t ime.   Therefore, it  is wrong to assume 
that  SITA Fast  is an ‘easier’ test .   In pract ice it  seems important  to select  the 
algorithm most  suited to the pat ient  and then, most  essent ial of all, use this 
consistent ly throughout  their follow-up (M usch et  al. 2005), as clinical 
recommendat ions already st ipulate (Chauhan et  al. 2008b, European Glaucoma 
Society 2008). 
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Overall, this study suggests that  there is some reduct ion in measurement  precision 
associated with using SITA Fast  instead of SITA Standard.   However, this difference 
is unlikely to have a significant  clinical impact  on t he t ime to detect  VF progression.   
This study does not  allow  for any conclusion to be drawn about  comparat ive 
accuracy of the measurements from SITA Standard and SITA Fast .   However, 
regardless of which test ing algorithm is used, it  is clear that  the t ime it  takes to 
detect  progression is perhaps too long to ensure that  pat ients at risk of progressing 
to blindness are given t imely intervent ion.   As a result , it  may be important  to 
assess whether it  is possible to ant icipate future rapid progressors from any 
baseline characterist ics.   Invest igat ion of the use of these risk factors in the context  
of ant icipat ing future rates of loss will therefore be the subject  of the next  chapter. 
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Chapter Five: Using r isk factors for fast glaucomatous 
progression to identify groups at r isk of blindness 
 
The ability to discriminate between fast  and slow  progressors of glaucoma would be 
clinically useful in ensuring that  the appropriate level of t reatment  is given (Caprioli 
2008).   Determining the rate of progression as quickly as possible is therefore of 
high importance in glaucoma care.   There is even evidence t o suggest  that  rate of 
loss itself may impact  on pat ient  QoL (Lisboa et  al. 2013), so it  is essent ial these 
rates are cont rolled effect ively.   However, in the previous chapter, it  was 
established that  regardless of the test ing algorithm ut ilised, detect ing 
glaucomatous progression with any certainty using VFs alone can take a long t ime, 
perhaps too long to react  in t ime to preserve pat ient  visual funct ion.   This is 
obviously an important  issue in determining VF deteriorat ion.   As a result , finding 
ways of singling out  pat ients that  are more at  risk of rapid progression than others 
at  baseline could potent ially be clinically useful.   Pat ients at  risk of severe rates of 
progression could have their t reatment  intensity increased w ithout  need for the 
extensive follow-up as would be required if following pat ients solely ut ilising VFs.   
This chapter will therefore review the literature to determine whether pat ients at  
risk of fast  progression can be ident if ied more quickly by using other measurements 
taken in clinical pract ice, looking specif ically at  the ut ilit y of a risk calculator  
developed for this purpose by De M oraes et  al. (De M oraes et  al. 2012).   This 
chapter ends with a study that  demonst rates the limitat ions of this risk calculator. 
5.1 Risk factors for fast disease progression 
 
Risk factors associated with developing glaucoma, have already been looked at  in 
Chapter 1.   M any of these same risk factors have been linked to rate of VF 
progression.   This sect ion will hence proceed to go through the various risk factors 
found or thought  to be associated w ith rates of funct ional loss. 
 
5.1.1 Intraocular pressure 
 
There exists a sizeable body of evidence that  has linked the magnitude of measured 
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IOP to progression rate, observed in both ret rospect ive analysis of clinical data 
(Teng et  al. 2010, Heijl et  al. 2012a, Chauhan et  al. 2014) and in cont rolled clinical 
study (The Advanced Glaucoma Intervent ion Study Invest igators 2000, Heijl &  
Bengtsson et  al. 2009, M edeiros et  al. 2012, Chauhan et  al. 2014).   There are a 
couple of instances where the relat ionship between IOP and progression rate is 
more ambiguous however.   For instance, the Collaborat ive Normal Tension 
Glaucoma Study (CNTGS) looking at  NTG pat ients found no signif icant  relat ionship 
between progression rate and unt reated IOP (Drance et  al. 2001).   However, this 
may be due to the fact  that  this study exclusively comprised of NTG pat ients, so, by 
definit ion, no subjects had notably high pressures. 
There is some debate as to what  IOP measures are most  important  in determining 
VF progression.   M ost  of the t ime, average IOP over follow-up is ut ilised (The 
Advanced Glaucoma Intervent ion Study Invest igators 2000, De M oraes et  al. 2011a, 
Heijl et  al. 2012a, M edeiros et  al. 2012), although the peak IOP measurement  over 
follow-up (De M oraes et  al. 2011a) in addit ion to measurement  of IOP at  baseline 
(Heijl et  al. 2009, Teng et  al. 2010) have also been mooted as potent ially useful.   
IOP variability measures such as the range (Heijl et  al. 2012a, Chauhan et  al. 2014) 
however, do not  necessarily give a sense of the magnitude of IOP, which is 
generally important  in determining risk.   Regardless of how it  is expressed, IOP has 
been consistent ly shown to have a profound effect  on VF loss and a major 
predict ive factor for progressing at  rates that  could lead t o blindness. 
 
5.1.2 Baseline Visual Field loss 
 
As demonst rated in Chapter 3 (Saunders et  al. 2014), init ial VF damage at  diagnosis 
is also likely to be linked to fast  rates of progression thereafter.   This is supported 
by Lee and colleagues, who found that  those categorised as rapid progressors had 
significant ly lower M Ds than slower progressors (Lee et al. 2014).   Further, in a 
cohort  of pat ients with DH, Prata et  al. est imated that  eyes with a baseline M D 
worse than -4dB were over 200% more likely to be faster progressors (rate of loss 
worse than -1.5dB/ year) (Prata et  al. 2010).   However, it  is unclear whether the 
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correlat ion between VF damage at  baseline and progression rate is because faster 
progressors are inevitably diagnosed at  a later stage of disease, that  rate of loss 
may change over the course of disease or whether this is a result  of higher 
measurement  accuracy at  later disease stages due to staircasing effects (M alik et al. 
2006).   Cont radict ing these findings, Heijl et  al., looking at  pat ient  records of  
Scandinavian pat ients, actually found that  pat ients with a start ing M D of bet ter 
than -10.03dB had worse progression than those with earlier loss (Heijl et  al. 
2012a).   It  is, however, likely that  ceiling effects were a large factor in this result  
given that  a sizeable number of pat ients in the study had M Ds worse than -20dB.   
To further confuse mat ters, Forchheimer et  al. found, once IOP had been corrected 
for, no signif icant  difference in progression rates between groups st rat ified 
according to baseline damage; the authors speculated that  more intensive 
t reatment  with more advanced disease may have been a cont ribut ing factor in 
these findings (Forchheimer et  al. 2011).   Regardless, the fact  that  presentat ion 
t ime is likely to suggest  something about  how quickly pat ients are progressing 
should be given considerat ion. 
5.1.3 Patient characteristics 
 
M any studies have found significant  relat ionships between age and progression 
rates.   One study modelling progression rates est imated that  the rate of VF 
deteriorat ion increased by -0.019dB/ year for each year lived (Heijl et  al. 2012).   
Further, in the cont rol arm of the EM GT, pat ients older than 68 progressed 
significant ly more quickly than younger pat ients (Heijl et  al. 2009), whilst  the CGS 
also found increasing age was associated with worse rates of M D loss (Chauhan et  
al. 2010).   Older pat ients have also been noted to progress more quickly than 
younger pat ients in ret rospect ive data analysis (Prata et  al. 2010, Heijl et  al. 2012, 
Chauhan et  al. 2014).   Faster progressors furthermore tend to be older than slower 
progressing pat ients (Lee et  al. 2014).   However, not  all studies have found a 
significant  link between age and rate of VF loss.   Ut ilising informat ion from nine 
different  populat ion surveys and est imat ing rates of loss from prevalence rates and 
baseline WEM D Broman et  al. could not  find consistent  evidence of age affect ing 
rates of loss in OAG pat ients (Broman et  al. 2008), while Drance et  al. also could not  
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find evidence of age affect ing progression rate in their CNTGS cohort  (Drance et  al. 
2001).   Overall, evidence seems to suggest  that age is important  to consider when 
analysing risk of fast  progression, although this is perhaps offset  by the fact  that 
fast  progression may not  be as large an issue if residual life expectancy is lower. 
Ethnicity is another factor that  has been linked to rate of progression.   Drance and 
colleagues found that  Asians in the CNGTS had slower rates of progression than 
Caucasian pat ients, whilst  the few enrolled black pat ients also tended to progress 
quickly (Drance et  al. 2001).   Similarly, Lee et  al. found a higher proport ion of black 
pat ients than Caucasian pat ients were faster progressors (Lee et  al. 2014).   In fact , 
Lee et  al. found that  African Americans had a 54% greater likelihood of being rapid 
progressors than Caucasians, although this was only after account ing for glaucoma 
severity at  baseline.   Finally, Broman et  al. est imated that  African pat ients tended 
to progress more quickly than Hispanic and White pat ients (Broman et  al. 2008).   
Broman et  al.’s results further suggest that  Chinese pat ients are actually the fastest  
progressing group, seemingly cont radict ing the findings of the CNGTS, although t his 
is potent ially a result  of far fewer pat ients being surveyed from this demographic 
than the others.  
The CNGTS also found evidence that  women tend to progress more quickly than 
men (Drance et  al. 2001), but  this has not  been found consistent ly by a lot  of other  
researchers (Broman et  al. 2008, Prata et  al. 2010, Chauhan et  al. 2010, Heijl et  al. 
2012). 
 
5.1.4 Structural factors 
 
There are various st ructural indicators that  have been linked to subsequent  fast 
progression also.   For instance, longitudinal opt ic disc change has been shown to 
precede measurable VF deteriorat ion (Chauhan et  al. 2009) and Lee et  al. linked 
larger vert ical cup-disc rat ios to faster rates of VF loss (Lee et al. 2014).   In addit ion, 
pat ients with focal opt ic disc damage have been seen to be faster progressors to 
pat ients with more diffuse damage (Reis et  al. 2012).   Given that  st ructural damage 
will inevitably impact  on funct ional loss it  is perhaps not  surprising that  opt ic nerve 
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damage coincides with faster funct ional deteriorat ion.   As a result , many studies 
have at tempted to use st ructural measurements to improve est imates of VF loss 
(Zhu et  al. 2010, M edeiros et  al. 2011, Russell et  al. 2012b, Zhu et  al. 2014) although 
this has often challenging due to the inherent  variability in both sets of 
measurements (Gardiner &  Johnson 2012). 
Another characterist ic linked to faster progression rates is thin CCT.   M edeiros et 
al. found a signif icant  link between CCT and rate of progression with each addit ional 
100µm being associated with an improvement  in prognosis of 0.21dB/ year M D 
(M edeiros et  al. 2012). 
M yopia has also been linked to increased rate of VF loss in diagnosed glaucoma 
pat ients (Perdicchi et  al. 2007), although myopia was not  even observed as a risk 
factor for disease in one study looking at  NTG pat ients (Sohn et  al. 2010) leaving its 
status more ambiguous.   The presence of Beta-zone parapapillary at rophy (Beta-
PPA) has also been suggested to have some influence on rate of VF loss (Teng et  al. 
2010).   This refers to degenerat ion of ret inal pigment  epithelial cells adjacent  to 
the opt ic disc nerve head in addit ion to thinning of the choroidal or ret inal cells in 
this area (see Figure 5.1), which is occasionally a feature of myopic eyes, but  occurs 
more often (and tends to be larger) in eyes with glaucomatous opt ic-nerve damage 
(Jonas et  al. 1989).   Furthermore, in some studies, the development  of this 
condit ion in ocular hypertensives and glaucoma pat ients seems to mirror the 
development  of disease progression (Kono et  al. 1999, Tezel et  al. 2000).   Speed of 
progression was not  only found to be faster in eyes with Beta-PPA by Teng et  al., 
but  more eyes with MDs progressing at  a faster rate than -0.5dB/ year, had this 
opt ic disc characterist ic (Teng et  al. 2010). 
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Figure 5.1 – An optic nerve – the solid and dashed lines show the locations of the alpha 
and Beta-zones respectively.   Damage to retinal pigment epithelial cells in this area is 
defined as Beta-zone parapapillary atrophy.   This image has been taken from Teng et al. 
2010. 
Other studies have found that  specif ic features of glaucomatous loss may be linked 
to more rapid VF deteriorat ion.   For instance, Heijl et  al. observed in the unt reated 
arm of the EM GT that  pat ients with pseudoexfoliat ion syndrome tended to have 
faster rates of loss than those that  did not  (Heijl et  al. 2009).   Pseudoexoliat ion 
glaucoma, however, was not  found to be significant ly faster when looking at  data 
from clinical pract ice (Heijl et  al. 2012).   One big difference between the cohorts is 
the fact  that  pat ients in clinical pract ice are receiving t reatment , so this could be 
one mechanism by which these cont rast ing results may have been observed.   
Alternat ively, many pseudoexfoliat ive pat ients had higher levels of damage at  
baseline in the lat ter study, which may indicate that  ceiling effects may have played 
some role in affect ing the results. 
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Opt ic disc haemorrhages (DH) have also previously been linked to greater likelihood 
of VF deteriorat ion (Drance et  al. 1977, Siegner &  Net land 1996, Leske et al. 2007, 
Kim 2014).   These burst  blood capillaries usually around the opt ic disc are often 
hard to f ind in an exam (no imaging devices can yet  ident ify these automat ically), 
but  are a visible indicator that  the opt ic disc is being damaged and that  the disease 
is act ive (Radclif fe et  al. 2014).   Having long been recognised as a risk-factor for 
future VF damage or progression, there is evidence to suggest that it  can have a 
profound effect  on rate of progression also with one study showing that 
progression rates increased follow ing DH (De M oraes et  al. 2009a). 
 
5.1.5 Other factors 
 
In addit ion to the other potent ial r isk factors for fast  disease progression discussed 
above there are some circumstant ial characterist ics associated with faster disease 
progression worth ment ioning.   Surgery, be it  laser or t rabeculectomy, is one such 
factor.   Heijl et  al. found that  more intensive t reatment  was associated with 
greater rates of progression, probably due to the fact  that  surgery is only 
performed when progression is not  being cont rolled adequately.   By definit ion, 
pat ients requiring surgery are therefore likely to be faster progressors (Heijl et  al. 
2012). 
Drance et  al. found some evidence that  presence of migraine may be linked to rate 
of VF loss in pat ients with NTG, though it  is worth not ing that  t he majority of  
migrainous pat ients in their study were female.   However, migraine was not  found 
to be an important  risk factor in a study invest igat ing clinical data from pat ients 
with DH in clinical pract ice (Prata et  al. 2010). 
 
5.2 The De Moraes Risk Calculator 
 
The ability to ut ilise these risk factors to ant icipate which pat ients are at  greatest  
risk of fast  progression at  diagnosis would be ext remely useful clinically; potent ially 
beneficial t o both clinicians and pat ients in saving resources and t ime, whilst  st ill  
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ensuring that  pat ients receive the care they require and saving sight  years.   
However, in spite of this, there have been few at tempts to actually design a risk 
calculator for glaucoma pat ients. 
The OHTS at tempted to design a calculator for purposes of determining which 
pat ients with OHT are at  greatest  risk of progressing to glaucoma (Ocular 
Hypertension Treatment  Study Group & European Glaucoma Prevent ion Study 
Group 2007).   The use of the calculator developed has further been shown to be an 
improvement  over clinical judgement  in determining future development  of 
glaucomatous disease (M ansberger &  Cioff i 2006).   However, this is of lim ited use 
for glaucoma pat ients given it  was only designed for glaucoma suspects.   
Addit ionally, this calculator cannot  give any informat ion about  whether the pat ient  
is at  risk of progressing at  a rate that  may lead to blindness. 
However, a group from New York recent ly developed two models using the 
ret rospect ive New York Glaucoma Progression Study (NY-GAPS) to assess the 
probability of pat ient  progression and the expected rate of this progression, 
validat ing their model ut ilising pat ient  data from the Advanced Imaging in 
Glaucoma Study (AIGS) (De M oraes et  al. 2012).   The result  of this is the first  risk 
calculator developed for use in glaucoma. 
5.2.1. Formulated model 
 
There were two calculators developed: one for assessing risk of progression and 
another (of main interest  in this sect ion) focussing on predict ing rate of M D loss per 
year, which will be hereafter referred to as the ‘De M oraes model’.   The variables 
obtained ut ilised the same variables derived from a previous study from the same 
group and included a number of cont inuous variables such as Age, CCT, peak IOP 
and mean IOP, some binary variables such as the presence of DH, Beta-PPA, 
exfoliat ion syndrome and whether the pat ient  has had glaucoma surgery (De 
M oraes et  al. 2011a).   The De M oraes model developed using 587 eyes from 587 
pat ients can be at  the t op of the following page: 
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ܴܽݐ݁	݋݂	ܸܨ	ܿℎܽ݊݃݁	(݀ܤ ݕ݁ܽݎ⁄ ) = 	−0.5343 + (ܣ݃݁) ∗ −0.005227 + (ܥܥܶ) ∗
0.002212 + (ܦܪ) ∗ −0.16 + (ܲ݁ܽ݇	ܫܱܲ) ∗ −0.0259 + (݉݁ܽ݊	ܫܱܲ) ∗−0.008372 + (ܾ݁ݐܽ − ܲܲܣ) ∗ −0.04003 + (ܧݔ݂݋݈݅ܽݐ݅݋݊) ∗ −0.07813 +
(ܩ݈ܽݑܿ݋݉ܽ	ݏݑݎ݃݁ݎݕ) ∗ 0.4521 + (ܩ݈ܽݑܿ݋݉ܽ	ݏݑݎ݃݁ݎݕ ∗ ݉݁ܽ݊	ܫܱܲ) ∗−0.04704	  
This model implies that  faster rates of change are associated with higher age, lower 
CCT and higher peak and mean IOP, as one might  expect .   Considering the rough 
scales of the variables concerned CCT seems to be the most  important  variable with 
peak IOP and age significant ly less important .   M ean IOP is about  a third as 
important  as peak IOP.   In addit ion, the presence of DH, Beta-PPA and exfoliat ion 
syndrome account  for an ext ra -0.278 dB/ year combined with DH the largest  
cont ributor.   Glaucoma surgery, once the interact ion term in the model is taken 
into account  (considering the IOP will be over 10mm Hg), seems to suggest  faster 
rates of loss, in agreement  with previous studies (Heijl et  al. 2012).   As 
aforement ioned, this is likely due to the fact  that pat ients that require surgery are 
often the fastest  progressors who most  require the t reatment  in the first  place.    
5.2.2 Model evaluation methods 
 
De M oraes et  al. developed their model using the NY-GAPS database and evaluated 
it  using VFs from AIGS.   Their model was assessed using two methods: through 
comparing the f it ted and observed rates of change in the validat ion dataset  (AIGS), 
in addit ion to looking at  the predicted and observed final M D values ext rapolated 
from the calculated rates of progression (De M oraes et  al. 2012).   Observed rates 
of change were calculated from ut ilising linear regression of a whole series of 
points. 
The performance of the model was then assessed using Bland-Altman plots (Bland 
& Altman 1986) comparing predicted against  observed rates of M D change.   These 
plots display the average and difference between two measurements, which is 
highly useful in assessing their agreement .   In addit ion, the coefficient  of  
determinat ion (R2), which measures the f it  of the model, for a model predict ing 
observed rates of loss was calculated. 
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5.2.3 The coefficient of determination – the R2 and adjusted R2 statistics 
 
The well-known R2 stat ist ic, or the (mult iple) coefficient  of determinat ion, pertains 
to the proport ion of variance in the response variable explained by a fit ted model 
relat ive to simply taking the mean of the response.   In other words, it  describes 
how well the model f its the data.   An R2 close to 1 implies an almost  perfect  
relat ionship between the model and data, whereas an R2 close to 0 implies that  just  
fit t ing the mean is equivalent  to the model fit ted.   Often, more than one variable is 
available t o explain an outcome (mult ivariate model); in this situat ion, as variables 
are added, the R2 will increase even if the variable is not  important .   The adjusted 
R2 at tempts to correct  for this by penalising for increasing the number of variables, 
so is often preferred in comparing models.   This stat ist ic is often used in comparing 
models, but , unfortunately, there are no set  criteria as to what  universally 
represents a “ good”  adjusted R2 value, so the only way of assessing such a stat ist ic 
is via comparison with another predict ive model. 
5.2.4 Model evaluation results 
 
The model comparing observed and predicted global rates of progression yielded 
an R2 stat ist ic of 0.14 and an adjusted R2 of 0.13.   The Bland Altman plot  in Figure 
5.2 suggests that , on average, rate of loss est imates in the model tend to err 
towards being slight ly pessimist ic; predicted rates of loss average at  0.13dB/ year 
worse than actual rates.   The model tends to become more opt imist ic as observed 
progression rates worsen.   The authors suggested, with these findings, that  their 
risk calculator had “ moderate accuracy” .   However, this assert ion is, at  best , 
baseless, and likely ext remely misleading as the findings of the next  sect ion w ill 
suggest . 
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Figure 5.2 – This Bland-Altman plot displays the differences between observed and 
predicted rates of loss in the validation dataset taken from De M oraes et al. 2012     
5.3 Evaluation of the model utility 
 
It  is difficult  to calculate the ut ilit y of this calculator without  comparison with a 
compet itor model.   For instance, it  is uncertain whether this model, containing a 
whole bat tery of variables, has any more ut ilit y than simply making a predict ion 
based upon, for example, the first  two VFs.   Although, it  is not  possible to use the 
same data as De M oraes et  al. and direct  comparison of R2s is ill-advised, the work 
of the next  sect ion suggests that  the usefulness of this model is not  as high as the 
authors suggest .   This work was published as a short  art icle (let ter) by Invest igat ive 
Ophthalmology and Visual Science (Saunders et  al. 2012b).   Richard Russell (RR) 
and David Crabb (DC) were joint  co-authors of this work and directed the project .   
RR further cont ributed to the data analysis, but  I completed everything else 
described in the remainder of this chapter.   All data ut ilised was collected from 
M oorf ields Eye Hospital. 
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5.3.1 Methods 
 
In order to illust rate that  a model with an adjusted R2 of 0.13 is inappropriate for  
use as a predict ive tool, an alternat ive, purely illust rat ive rate calculator using only 
the pat ient  age (which has been shown to be related to rate of VF loss [Heijl et  al. 
2003]) and the pat ient ’s first  two VFs was designed.   This small number of variables 
cont rasts to the De M oraes calculator, which used nine dif ferent  variables. 
To const ruct  this model 68,099 anonymised VFs collected from 8,252 anonymised 
pat ients visit ing the Glaucoma service at  M oorfields Eye Hospital between 1997 and 
2009 using the HFA (24-2 test  pat tern, Goldmann size III st imulus and SITA Standard 
test ing algorithm) were ut ilised.   Data were examined in accordance w ith the 
Declarat ion of Helsinki.   Pat ients with fewer than 4 VFs (per eye) once the first  VF 
was removed to account  for learning effects were excluded.   Furthermore, the 
interval between the f irst  and second VFs was rest ricted to the range 3 to 13 
months and this interval was not  allowed to exceed 40% of the overall follow-up 
t ime.   VF tests with FP or FN rates above 30% or FLs greater than 20% were 
discarded.   Where both eyes of a pat ient  were eligible, an eye was selected at 
random, leaving 875 pat ients (875 eyes) for invest igat ion.   The demographics of 
the study were comparable to the reference dataset  in the De M oraes study, but  
their validat ion dataset  contained pat ients with lower magnitude and variability of 
damage, as can be seen in Table 5.1. 
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Table 5.1 - A comparison of the demographics of datasets utilised in the De M oraes study 
(De M oraes et al. 2012) and the sample used for this project 
 New York 
Glaucoma 
Progression Study 
Advanced Imaging 
for Glaucoma 
Study 
M oorfields 
Glaucoma 
service data 
Number of Patients 587 62 875 
Age at baseline 
(yrs) 
64.9 ± 13.0 67.4 ± 8.3 62.7 ± 13.0 
Baseline mean 
deviation (M D) (dB) 
-7.1 ± 5.1 -3.7 ± 4.4 -7.0 ± 5.3 
Follow-up time (yrs) 6.4 ± 1.7 4.0 ± 0.9 5.8 ± 1.7 
 
The “ t rue”  rates of progression for each pat ient  were calculated using ordinary 
least  squares regression of the M D over t ime; the same method as that  ut ilised in 
the De M oraes paper (De M oraes et  al. 2012).   In this model the difference 
between M Ds in the second and first  VFs divided by the t ime interval separat ing 
them was included to est imate an “ init ial rate of loss” .   The “ t rue”  rates of 
progression were then regressed against  the baseline age of pat ients and their VF 
status across two visits as a basic model from which adjusted R2 values were 
generated.   All models fit ted were of the form: ܴܽݐ݁	݋݂	ܸܨ	ܿℎܽ݊݃݁	(݀ܤ)
= ߚ଴ ∗ ܲܽݐ݅݁݊ݐ	ܽ݃݁	(ݕ݁ܽݎݏ) + ߚଵ ∗ ܫ݊݅ݐ݈݅ܽ	ܴܽݐ݁	݋݂	ܸܨ	݈݋ݏݏ	 ൬ ݀ܤݕ݁ܽݎ൰ 
In order to facilitate comparisons, the study sample was split  into a reference 
dataset  and a validat ion dataset  comprising exact ly the same numbers of pat ients 
as included in the De M oraes study (i.e., 587 pat ients in the reference dataset  and 
62 pat ients in the validat ion dataset ).   To gain a dist ribut ion of values for the 
adjusted R2 stat ist ic, the 875 pat ients were randomly sampled without  replacement  
100,000 t imes into reference and validat ion datasets in order to at tain 100,000 
adjusted R2s for each model (i.e., for the reference dataset , 587 pat ients were 
selected at  random from the 875 pat ients in the complete dataset , and 62 pat ients 
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were sampled from the remaining 288 pat ients, and this was repeated 100,000 
t imes).   R2 stat ist ics were therefore obtained for both the reference datasets and 
models derived from the reference datasets applied to the validat ion datasets. 
 
5.3.2 Results 
 
The dist ribut ion of adjusted R2s for the 100,000 reference models can be seen in 
Figure 5.3.   The median adjusted R2 is 0.10, whilst  the reported R2 for the De 
M oraes calculator lies at  the 87th percent ile (0.13).   However, given that  the 
reported R2 could actually take any value between 0.125 and 0.135, the possibilit y 
of get t ing this stat ist ic by chance in the M oorfields dataset  could, in fact , be as high 
as 20%. 
 
Figure 5.3 - A histogram showing the distribution of adjusted R2 values from 100,000 
simulated reference models.   The black bars represent the potential range of R2 values 
found by De M oraes et al. 2012. 
Figure 5.4 shows the adjusted R2 stat ist ic yielded when the reference model is fit ted 
to the validat ion dataset .   The median adjusted stat ist ic here is 0.08, but  the 
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spread of this dist ribut ion should be noted; it  was possible to simulate an adjusted 
R2 stat ist ic as high as 0.59 (due to the small sample size).   The probability of gaining 
a bet ter stat ist ic than that  of the De M oraes model was close to 35%. 
 
 
Figure 5.4 – A histogram showing the distribution of adjusted R2 values from 100,000 
simulated reference models fitted to simulated validation datasets.   The black bars 
represent the potential range of R2 values found by De M oraes et al. 2012. 
One reference model was selected from the dist ribut ion in Figure 5.3 with an R2 
similar in magnitude to that  of the De M oraes rate calculator.   The fit  of this model 
can be seen in Figure 5.5, whilst  Figure 5.6 shows the effect  of applying this model 
to a sample validat ion dataset  (once again sampled to match the R2 in De M oraes et 
al.’s paper); the 95% limits of agreement  are shown by the dot ted lines in Figure 
5.6, and are more reflect ive of the likely range of differences between the 
est imated and actual rates of progression than the 95% CI for the average 
difference (indicated by the dashed lines) report ed in the De M oraes et  al. paper 
abst ract .   Figure 5.5 and Figure 5.6 clearly demonst rate the inadequacy of this 
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model, designed to mirror that  of the De M oraes paper, for predict ing rates of VF 
loss in spite of stat ist ical signif icance. 
 
Figure 5.5 - A plot of the estimated progression rate of patients in the selected reference 
dataset against their “true” rate of progression.   The solid line represents exact 
correspondence between the estimated and actual rates of progression (i.e. the line of 
unity).   The R2 is equal to 0.14 for this model. 
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Figure 5.6 - A Bland-Altman plot  comparing the progression rates of a selected validation 
dataset to the rates estimated in the model shown in figure 5.5 (R2=0.12).   The 95% 
M ean Confidence Interval (dashed lines) is 0.14 to -0.11dB per year.   However, the more 
informative 95% limits of agreement (dotted lines) range from -1.0 to 1.02.   As in De 
M oraes et al.’s model, the fit is worse at larger rates of progression. 
 
5.3.3 Discussion 
 
The “ risk”  model developed here would be poor in pract ice, and it  is intuit ively a 
bad idea to est imate a pat ient ’s rate of loss from their baseline damage and age 
alone.   It  does, nonetheless, give a sense of how poorly the De M oraes calculator 
predicts rate of loss.   Though it  is t rue that , st rict ly, the sets of R2 values from this 
model are not  direct ly comparable due to the fact  that  the data are different , the 
purpose of this exercise was to give some perspect ive to how the R2 values 
presented by De M oraes et  al. corresponded with a much more basic modelling 
method.   It  can be said that this very basic model performed almost  as well w ith 
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modelling the progression rates of pat ients in the M oorfields dataset  as the more 
complex De M oraes calculator did with data from the NY-GAPS and AIGS t rials. 
 
This study at tempted to create a context  for the De M oraes calculator’s ability to 
est imate rate of VF loss, but  it  is important  to note there are several limitat ions in 
the approach used in this study.   For a start , the “ validat ion”  dataset  ut ilised was 
not  a different  dataset  from a different  clinical cent re and these pat ients had worse 
average M D than those used in validat ing the De M oraes calculator.   Further, M Ds 
of greater severit ies have been shown to be more variable than healthy ones 
(Russell et  al. 2013), which suggests that  rates of loss will be predicted less 
accurately in pat ients with more advanced VF damage.   Thus, the characterist ics of 
the De M oraes validat ion dataset  may lead to more favourable results, as in the 
simpler model shown (see Figure 5.6), their calculator more accurately models 
pat ients with slower rates of VF loss. 
 
There is another important  message in this short  study.   R2 stat ist ics are often well 
understood and correct ly interpreted, but  can also be misleading, as the precision 
of the stat ist ic is dependent  on sample size (Wishart  et  al. 1931, Olkin &  Finn 1995) 
and the coeff icient  is commonly presented without  CIs or lim its of tolerance.   
Without  a sense of comparison the adjusted R2 stat ist ic is limited in its usefulness 
and it  is apparent  that  there is, as yet , no reference standard for test ing rate 
calculators such as this.   The compet itor model const ructed in this study is very 
sensit ive to the sample that  was chosen, which is apparent  from both Figure 5.3 
and Figure 5.4; the interquart ile range of adjusted R2s for the model just  through 
select ing different  field series could be as much as 10%.   It  is worth not ing that  the 
similar data characterist ics and propert ies of the De M oraes dataset  make it  likely 
that  their model is likely subject  to similar sampling error, which suggests its ut ilit y 
is highly uncertain.   Figure 5.5 and Figure 5.6 suggest  that  rate calculators with 
small R2 values are inadequate for accurately predict ing rates of loss especially in 
pat ients with fast  progression, who are the most  at  risk of visual impairment . 
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Finally, it  is important  to emphasise that  this illust rat ive rate calculator is not  a 
serious at tempt  at  int roducing an alternat ive modelling st rategy and should not  be 
used to est imate rate of VF loss, yet  it  st ill seemed to provide similar predict ive 
accuracy to the De M oraes calculator.   The De M oraes calculator employed 
measurements that  can be taken at  the first  visit , alt hough the inclusion of 
glaucoma surgery as a baseline predict ive variable is cont roversial in this context.   
In fact , given the substant ial model coefficient  associated with surgery, it  would be 
interest ing to see how their rate calculator would perform without  this informat ion.   
De M oraes et al. should be commended for their novel at tempt  at  developing a 
stat ist ical model for predict ing progression in pat ients with t reated glaucoma and 
especially for at tempt ing to validate it  using independent  pat ient  data.   However, it  
would  appear that  the conclusion that  must  be drawn is that  the limitat ions and 
low accuracy of their model make it  completely unsuitable for clinical pract ice. 
 
5.4 Conclusions 
 
Although it  would be incredibly helpful to be able to ant icipate which pat ients are 
at  greatest  risk of fast  progression, current  risk calculators may not  have the 
capability of sufficient ly st rat ifying pat ients in this manner to be useful in clinical 
pract ice.   Clearly the variables included in t he De M oraes calculator are all 
associated with the rate of loss and the methods used to select  them were correct , 
but  this does not  necessarily t ranslate to development  of a model w ith great  ut ilit y.   
It  is possible that  some of the variables in the model could be linearly dependent  
(part icularly the IOP peak and mean measurements) and that  possibly a simpler 
model with less variables than the one proposed in the paper would have yielded 
similar results.   Ult imately, unt il more is understood about  how risk factors relate 
to progression and the mechanisms underlying disease, any risk calculator 
developed is inevitably going to suffer from issues of this nature. 
 
As a result , it  is st ill seems sensible to establish rate as quickly as possible.   It  has 
previously been suggested that  test ing six t imes within an init ial interval of two 
years would part icularly help establish this (Chauhan et  al. 2008b).   Accuracy of 
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measurements can be further opt imised by grouping measurements at  the 
beginning and end of the init ial two year follow-up period (De M oraes et  al. 2011b, 
Crabb & Garway-Heath 2012).   However, the fact  remains that  this is not  pract iced 
clinically (Fung et  al. 2013, M alik et  al. 2013) and many clinicians judge that  it  is too 
large burden to place on t ime and resources (M alik et  al. 2013).   One potent ial 
solut ion, which would potent ially help relieve this burden would be to use adapt ive 
test ing, adjust ing intervals between tests and t reatment  according to change or  
variability in pat ient  VFs (Jansonius 2006).   Perhaps combining clinical informat ion 
(such as IOP, CCT and presence of disc haemorrhage etc.) with VF measurements in 
a modelling context  could further aid in the ability to assess the risk of pat ient  
progression (M edeiros et  al. 2012).   Overall, although baseline measurements are 
useful, for the moment , only t ime w ill tell whether a pat ient  is one of the few that  is 
in danger of progressing at  a rate that  could lead t o visual impairment . 
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Chapter Six: Conclusions and Further Work 
 
Though much research has been directed towards monitoring glaucomatous VF loss 
and, to an increasing extent , the impact  of glaucoma on vision-related QoL (Glen et  
al. 2011), there are st ill many unanswered quest ions concerning what  severity of 
disease impacts on QoL, how it  can be best monitored and which pat ients are most  
at  risk of progressing to visual impairment  or blindness.   The masses of VF data 
acquired in clinical pract ice are a useful resource in helping answer these quest ions 
and generat ing hypotheses for future studies.   This thesis and the studies it  
contains has sought  to ut ilise this UK clinical data for precisely this purpose.   Below, 
I summarise the findings of the previous four chapters and the conclusions drawn 
from them before summarising the novel cont ribut ions of the thesis and describing 
further quest ions arising from this research. 
6.1 Summary  
 
The study described in Chapter 2 invest igated what  levels of VF severity are 
associated with loss of legal f itness to drive; an important  landmark for pat ients in 
terms of independence (Fonda, Wallace et  al. 2001).   The IVF was used as a 
surrogate of a binocular test  and legal VF requirements were used to categorise 
pat ients as individuals who would “ pass”  or “ fail”  the legal VF component  of fitness 
to drive in the same manner set  out  by Crabb et  al. (Crabb et  al. 2004).   Expected 
driving status was then compared against M Ds recorded in clinical pract ice.   The 
bet ter eye M D was more useful at  predict ing whether pat ients would pass these 
criteria than the worse eye M D.   Unsurprisingly, t here was no ut ilit y from using the 
worse eye in predict ing est imated legal f itness to drive.   It  was established that  a 
criterion of worse than -14dB in the bet ter eye was related to a probability of 
around 90% of failing the driving test .   Clinical measurements in glaucoma have 
often been diff icult  to align with real life funct ion and are therefore not  relatable to 
pat ients.   This research was novel because it  was the first  to at tempt to devise a 
general M D threshold relat ing to legal f itness to drive to aid clinicians in evaluat ing 
VF measurements in the context  of how it  may impact  on QoL. 
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The study in Chapter 3 ut ilised one of the landmarks to visual disability found in the 
previous chapter, in addit ion to clinical def init ions of statutory blindness (US Social 
Security Administ rat ion 2011).   Using these landmarks, this study sought  to 
est imate how many individuals were est imated to be in danger of progressing to 
these damage levels within their predicted remaining lifet ime.   M Ds in each eye at  
death were ext rapolated from global rates of loss est imated from linear regression 
of M D in both eyes and ONS life expectancies (Office of Nat ional Stat ist ics 2011).   
The f indings were that  a small, but  signif icant  minority of pat ients are progressing 
at  a rate that  would lead to statutory blindness (around 1 in 20) although a further  
10% of pat ients progressed to a point  where there was a 9 in 10 chance in 
becoming legally unfit  to drive.   Furthermore, this study found that  around 70% of 
pat ients that  were expected to progress to blindness actually had an M D worse 
than -6dB (or at  least  a “ moderate defect ”  on the H-P-A scale [Hodapp et  al. 1993]) 
at  baseline.   Only 1% progressed to this stage when diagnosed earlier suggest ing 
that  lateness of presentat ion is a big factor in future prognosis.   There are plenty of 
studies that  have looked at  rates of loss for glaucoma pat ients (Heijl et  al. 2012) and 
many that  have est imated numbers of pat ients that  have progressed to clinically 
diagnosed blindness (Hat tenhauer et  al. 1998, Oliver et  al. 2002, Chen 2003).   
Addit ionally, ut ilising life expectancy in clinical decision making has also been 
suggested previously (Wesselink et  al. 2011).   However, this is the first  study to 
pract ically consider pat ient  progression rates in the context  of their expected 
remaining lifet ime to ext rapolate future VF status in both eyes of the pat ient  to 
est imate their future visual funct ion. 
The study in Chapter 4 sought  to compare SITA Standard and SITA Fast  test ing 
algorithms to determine the difference in precision in measurements using the two 
methods and whether such differences could have an impact  on the t ime to detect  
progression evaluated using simulat ions.   Ult imately, a small dif ference in precision 
between the SITA Standard and Fast  test ing algorithms was observed, but  this did 
not  t ranslate to any meaningful dif ference between the algorithms.   As a result , it  
was concluded that  it  probably did not  mat ter which algorithm was used.   On one 
hand, it  would perhaps bet ter to use the faster test , yet , in real terms, this is only 
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likely to save 2 t o 3 minutes per eye based on past  studies (Nordmann et al.  1998, 
Wild et  al. 1999, Pierre-Filho et  al. 2006) and it  is yet  possible there is an 
unsubstant iated reduct ion in accuracy using SITA Fast.   Overall, it  is perhaps best  to 
choose the easiest test  for the pat ient , but  it  is hard to know which test this is; 
although SITA Fast  is quicker, some clinical colleagues have suggested that  it  may 
be more diff icult  to do, although, as far as I am aware, there is not  yet  evidence to 
show this.   Ult imately, it  was apparent  that  both tests have precisions that  mean 
that  it  could st ill take too long to diagnose progression in the context  of pat ient  
vision loss.   Although, relat ive precision of SITA Standard and Fast  has been looked 
at  once previously (Artes et  al. 2002) this analysis was performed in comparison to 
Full Threshold test ing, which itself is not  a perfect  gold standard.   This study by 
cont rast  est imated each algorithm’s precision individually in the context  of its own 
measurements and is the first  to at tempt  to est imate the clinical impact  of any 
est imated differences in precision. 
In the context  of the fact  that  the previous chapter demonst rated the t ime to 
detect  progression may be too long, Chapter 5 explored the ut ilit y of a current  risk-
calculator to est imate rates of loss based on baseline clinical characterist ics 
proposed by De M oraes et  al (De M oraes et  al. 2012), through formulat ing a simple 
(and not  clinically useful) model with similar stat ist ical propert ies.   The study 
demonst rated that  the ut ilit y of models with as low an R2 stat ist ic as the De M oraes 
model is likely to be low in clinical pract ice.   Due to the nature of their study and 
the fact  that  coefficients of determinat ion for different  data cannot  be direct ly 
compared, it  is not  even certain whether their method has ut ilit y over simple 
models using just  age and init ial M Ds.   It  is clear that  there is st ill a lot  of progress 
st ill to be made on at tempt ing to establish which pat ients are at  risk of fast  
progression at  baseline. 
6.2 Thesis contributions 
 
Overall, t here are various cont ribut ions to the field that  have come out  of this 
thesis: 
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- In the absence of any reference standard for clinical measurements, it  has 
established evidence-based landmarks for visual impairment  (Chapter 2). 
- It  has supported, using clinical data, est imates for proport ions of pat ients 
classified as “ fast  progressors”  for glaucoma (Chapter 3). 
- It  has looked at  pat ient  progression rates in the context  of their predicted 
remaining lifet ime (Chapter 3). 
- It  has established a modern est imate, albeit  based on modelling, of how  
many pat ients with glaucoma are likely to go blind from their condit ion 
(Chapter 3). 
- It  has supported previous findings that  baseline damage is important  to 
future prognosis (Chapter 3). 
- It  has established precision est imates for sensit ivit ies for SITA Standard and 
Fast  using longitudinal data (Chapter 4). 
- In the debate of whether to use SITA Standard or Fast , it  is the first  to ut ilise 
simulat ions to evaluate pract ical clinical impact  on t ime to detect  
progression (Chapter 4). 
- It  has supported previous f indings that  it  takes a long t ime to detect  
progression w ith any degree of certainty (Chapter 4). 
- It  has contextualised current  risk calculators and established that  it  is st ill  
insuff icient  for ant icipat ing risk of progression wit hout  VF data (Chapter 5). 
6.3 Further work 
 
What  follows is a short  descript ion of some studies and hypotheses that  could be 
future work arising from the results described in t his thesis. 
6.3.1 Topics from Chapter 2 
 
In Chapter 2, the severity of pat ient  VF loss, measured using BEM D, was related to 
legal fitness to drive in the UK.   However, this does not  necessarily relate to actual 
fitness to drive and there has been much crit icism and demand for more research 
relat ing to this (West lake 2000).   Some pat ients that  fall short  of driving standards 
can feel as though they are safe drivers; in other words they do not  perceive a loss 
in visual funct ion, apart  from in the applicat ion of VF standards.   The evidence 
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relat ing driving safety to VF loss is often spurious and inconsistent  and more 
evidence of the link between motor collisions in the context  of mileage and VF 
damage is required.   One potent ially interest ing avenue to explore would be to 
calculate the relat ionship between observed and expected numbers of motor  
vehicle collisions at  different  levels of VF loss.   One could do this using a cont rol 
populat ion, but  alternat ively a model developed to incorporate various risk factors 
could be ut ilised (M aycock & Lockwood 1993).   Init ial analysis conducted using 
pat ient  quest ionnaire data on accident  frequency in the United Kingdom Glaucoma 
Treatment  Study (UKGTS) has not  revealed a significant  relat ionship between IVF 
mean sensit ivity once other mit igat ing factors including mileage have been 
accounted for. 
It  would perhaps also be useful to similarly relat e clinical measurements to other 
important  visual funct ion landmarks such as difficulty reading and danger of falls, 
both of which could have a massive impact  on a pat ient ’s overall QoL (Aspinall et  al. 
2008).   As QoL is an under-invest igated topic in glaucoma research (Glen et  al. 
2011) it  could also be of interest  to invest igate the relat ionship between t rial 
progression status (i.e. the point  at  which glaucomatous progression is flagged in a 
clinical t r ial) and reported QoL or even rates of loss and QoL given the findings of 
Lisboa et  al. (Lisboa et  al. 2013).   In this respect , future targets in glaucoma 
t reatment  could be aligned to a measureable reduct ion in visual disability rather 
than potent ially arbit rary changes in VF measurements. 
A topic that  has been the subject  of much invest igat ion is impact  of VF loss on 
reading speed (Crossland et  al. 2005, Ramulu et  al. 2009a, Burton et  al. 2012, 
Ramulu et  al. 2012).   Subject  to a good deal of work so far has been a project  that 
at tempted to discover which areas of the VF were most  correlated with impaired 
silent  reading speed.   This study ut ilised 92 part icipants (54 bilateral glaucoma 
pat ients from M oorfields Eye Hospital and 38 visually healthy age-related cont rols) 
with good corrected binocular acuity and at tempted to determine whether silent  
reading speed was impacted by different  levels of VF loss.   Overall, no clear 
relat ionship between damage and reading speed could be found, either between 
cont rols and pat ients or relat ing to level of VF loss, mainly ow ing to the low  
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numbers of pat ients it  was possible to recruit  for the study and also due to a low  
range of VF loss.   However, there was a slight  suggest ion that the inferior-left  
corner of the paracent ral binocular VF, thought  to be used in the return-sweep, 
may be more related than other parts.   This work, undertaken with Robyn Burton 
and David Crabb has been submit ted for publicat ion in the Japanese Journal of 
Ophthalmology and, at  t ime of writ ing, is current ly under review. 
 
Figure 6.1 - A map displaying each test location in the binocular IVF ranked by R2 statistics 
in the Reading study discussed in section 6.3.1.   Black squares correspond with ranks 1 to 
5, whilst grey squares represent ranks 6 to 10.   The area bordered by red lines indicates a 
region that is likely to be of greater importance than other sections of the VF when 
considering reading speed for patients in this study.   Figure taken from Burton et al. 
2015. 
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6.3.2 Topics from Chapter 3 
 
There were a number of interest ing findings from Chapter 3, but  there are plenty of 
quest ions arising from this research that  merit  ext ra invest igat ion.   For instance, 
although it  was interest ing to invest igate the number of individuals in danger of 
progressing to a VF status where risk of visual impairment  is high, there was no 
indicat ion in this study of the number of sight-years lost  due to the condit ion.   It  is 
obvious that  being blind for one year is less devastat ing to a pat ient  than being 
blind for ten, so it  would be interest ing to perform some further analysis to 
invest igate how many years pat ients would be est imated to have to deal with 
impaired vision as a result  of their glaucoma. 
Further, though the study in Chapter 3 established that  pat ients diagnosed with 
worse field loss at  baseline are at  greater risk of progressing to statutory blindness, 
it  is not  clear whether this was due to the fact  that  dangerously fast  progressors are 
more likely to be diagnosed late or whether pat ients with advanced field loss at  
diagnosis progress similarly to those detected early, but  are simply referred at  too 
late a stage.   The evidence for which scenario is the case is cont rast ing.   Lee et  al. 
reported that  pat ients categorised as faster progressors had lower baseline M Ds 
(Lee et  al. 2014), yet  Heijl et  al., separat ing out  their cohort  using a median level of 
baseline damage, found that  pat ients with an earlier stage of disease tended to 
progress more quickly than those with an M D over worse than -10dB at  baseline 
(Heijl et  al. 2012).   However, due to the fact  the study was not  specifically tailored 
to invest igate this, their results may have been affected by ceiling effects; an 
analysis st rat ifying start ing levels of damage would be much more illuminat ing in 
answering this quest ion.   It  would also perhaps be interest ing to invest igate 
whether rates of loss increase during the disease, although it  would be diff icult  to 
do this without  following a large cohort  of pat ient s for a very long period of t ime. 
A recent  study has suggested, reassuringly based on the results of this chapter, that  
pat ients, on average, are being diagnosed with less severe VF loss than 15 years 
ago, with NICE guidelines in part icular thought  to make a difference (Boodhna et  al. 
2014).   One other opportunity this data affords is the ability to assess whether 
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rates of loss in glaucoma are changing over t ime.  Potent ially, if rates of loss are 
slower than in the past , this could change the out look on pat ient  prognosis 
forecasted. 
Finally, it  was notable in the study of Chapter 3 that  there were many pat ients who 
progressed in one eye, but  not  the other.   It  would be interest ing to invest igate 
using large-scale clinical data how common this is in clinical pract ice. 
6.3.3 Topics from Chapter 4 
 
Chapter 4 seemingly established that  using SITA Standard or Fast  in pat ient  follow-
up made lit t le dif ference, but  one issue with this conclusion is that  the study did not  
invest igate the accuracy of the two tests.   One possible consequence of the likely 
lower number of steps in the staircase algorithm as a consequence of requiring a 
lower level of certainty of the threshold before est imat ing it  is that  there is actually 
a lower range of measurements that  a threshold can take using SITA Fast.   An 
implicat ion of this would be that  potent ially SITA Fast  could have a tendency to fail 
to detect  early, small VF scotomas.   This has never been explicit ly tested, although 
other studies seem to suggest  the sensit ivity of both algorithms of detect ing early 
loss in pract ice is similar (Bengtsson & Heijl 1999, Pierre-Filho et  al. 2006).   
Unfortunately, this could only really be assessed using a prospect ive study of test-
retest  data in a similar study design to that  ut ilised by Artes et  al. t o measure the 
relat ive precision of the algorithms (Artes et  al. 2002). 
Another interest ing quest ion, given recommendat ions to give pat ients a test  most  
suitable to them would be t o have glaucoma pat ients of varying severity take the 
test and feedback which test is easier.   This could be assessed ut ilising 
quest ionnaires or even through monitoring pupil act ivity direct ly as Henson et  al. 
have done previously (Henson & Emuh 2010).   This too would require a prospect ive 
cohort  to invest igate. 
In the study of Chapter 4, simulat ions to evaluate t ime-to-detect  progression, using 
noise from SITA Standard and Fast , were reliant  on the assumpt ion of VF 
progression being linear.   It  may therefore be interest ing to ut ilise simulat ions of 
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other theoret ical types of VF loss, including exponent ial regression and event-based 
analyses such as Glaucoma Change Probability Analysis.  
Gardiner et  al. suggest  that  there is so lit t le ut ilit y in measuring thresholds below  
19dB that  these should be disregarded in analysis (Gardiner et  al. 2014).   In the 
study of Chapter 4, differences between SITA Standard and Fast  were even less 
significant  than they were in the current  study.   It  would interest ing to invest igate 
whether findings from other studies would change through insert ing a f loor effect  
at  this sensit ivity threshold (i.e. rounding up thresholds below this cut-off to 19dB). 
 
6.3.4 Topics from Chapter 5 
 
Chapter 5 suggested that  the only published risk calculator for predict ing 
glaucomatous progression at  baseline has an R2 stat ist ic that  is likely not  adequate 
in ant icipat ing which pat ients are in danger of suffering long-term visual 
impairment .   However, it  would be useful to f irmly establish this through direct  
comparison between the methods.   The biggest  flaw in the work by De M oraes et  
al. was the fact that  they used an R2 in isolat ion rather than through comparing 
their method with another current  gold standard (which could have been as simple 
as simply ut ilising the init ial two VFs).   Ideally, it  would be interest ing to set up a 
study to find out  the t rue efficacy of the De M oraes risk calculator against  other 
standards for predict ing future VF progression (for instance a simple model 
containing age and MD, or a short-term calculat ion of progression rate).   What  may 
be even more worth invest igat ing would be developing a calculator incorporat ing 
pat ient  age and baseline M D in calculat ing risk of progression to visual impairment .   
In the meant ime, it  is worth considering the use of a tool developed by Wesselink 
et  al. (Figure 6.2), which at tempts graphically to categorise the risk of an eye 
suffering severe impairment  in a pat ient ’s lifet ime from their M D, age and gender 
without  knowing their rate of loss (Wesselink et  al. 2011, Wesselink &  Jansonius 
2014).   Est imates of risk have large uncertaint y at t ributed to them, but  this is 
sensible at  present  as it  reflects the lack of informat ion available at  baseline.   
However, once there is sufficient  follow-up to est imate rates of VF loss these can be 
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used to refine est imates of the risk of progressing to VF impairment  (Wesselink et  
al. 2011). 
 
Figure 6.2 – A tool developed by Wesselink et al. 2011 to illustrate the risk of patients 
progressing to blindness from baseline for men (women have longer life-expectancies).   
The colours represent risk of becoming visually impaired (M D worse than -20dB) during a 
patient’s predicted remaining lifetime.   In the red zone, the probability of becoming 
visually impaired exceeds 2.5% even with treatment.   In the amber zone, the probability 
of becoming visually impaired is below 2.5% with treatment, but greater than 2.5% 
without.   Patients in the green zone have a lower than 2.5% chance of progressing to 
visual impairment even foregoing treatment.   The white dots represent male patients 
from the Groningen Longitudinal Eye Study (Heeg et al. 2005).   This figure was taken 
from Wesselink & Jansonius 2014.  
 
6.3.5 Other questions 
 
Using large amounts of ret rospect ive data from clinical pract ice can potent ially lend 
itself to a variety of other potent ial studies.   For instance, it  would be ext remely 
useful from the perspect ive of many QoL studies to know the relat ive prevalence of 
superior and inferior VF loss.   This would lend it self to being able to quant ify how 
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many pat ients are likely to be in danger of suffering forms of visual impairment  
associated with losing vision in specif ic areas of the VF.   For example, though Black 
et  al. have established pat ients with inferior defects are at  greater risk of falls (Black 
et  al. 2011), it  is unclear how many pat ients have predominant ly inferior VF loss in 
glaucoma.   In addit ion, it  has been suggested that  gender may be related to 
lateness of presentat ion for other diseases.   So far in glaucoma, whether this is the 
case or not  is ambiguous (Fraser et  al. 1999, Fraser et  al. 2001), so it  would be 
interest ing to use large-scale data to invest igate this quest ion. 
Visual f ields are an unusual measurement  with many sources of variability, which 
means that  there are plenty of pit falls in their use in evaluat ing VF deteriorat ion.   
However, massive amounts of clinical data can be used to learn more about  the 
progression of glaucoma.   Hopefully, in the near future, new methods could yet  
allow for earlier and more accurate glaucoma diagnosis and monitoring.   For 
example, novel research aims to determine how st ructural defects can be better 
linked t o funct ional ones to aid diagnoses with promising results thus far (Boland et  
al. 2008, Zhu et  al. 2010).   Incorporat ing Bayesian stat ist ics into monitoring VF 
progression, using prior knowledge of pat ients with glaucoma or st ructural 
informat ion, is another interest ing research topic (M edeiros et  al. 2011, Russell et  
al. 2012b), although this has only made a small difference so far.   Another method 
has ut ilised the pat ient ’s own variability to define the likelihood of progression 
more clearly (O'Leary et  al. 2012).   Furthermore, various new modelling methods 
that  overcome the difficult ies of the assumpt ions of commonly-used linear 
regression methods being violated have been suggested (Caprioli et  al. 2011, 
Russell &  Crabb 2011, Pathak et  al. 2013)   However, one of the most  promising 
methods of all t hus far, called Analysis with Non-Stat ionary Weibull Error  
Regression with spat ial enhancement  (ANSWERS), has used pat ient  test -retest  data 
to model variability at  different  fit ted sensit ivit ies to inform modelling methods 
more accurately, increasing the speed of diagnosis and categorising eyes more 
effect ively (Zhu et  al. 2014).   This Bayesian approach also incorporates st ructural 
informat ion into its modelling st ructure.   In summary, there are many new 
methods being developed to bet ter monitor and predict  future glaucomatous loss 
151 
 
and this large-scale clinical data is an excellent  t raining-ground for test ing new 
methods. 
Finally, although not  used in any studies in this thesis, the use of large-scale VF data 
could also potent ially be useful for monit oring and audit ing service delivery for  
glaucoma across clinical cent res.   This is already pract iced in other ocular disease 
and VF data lends itself well to this endeavour.   Further analysis of data collected 
from clinical pract ice may help suggest  ways of improving the eff iciency with which 
glaucoma is detected and managed in primary and secondary care and prevent  
avoidable sight  loss.  
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